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Abstract 
Stage conversion is a hallmark of parasites in general and permits unprecedented vaccine 
strategies. In the case of malaria, experimental immunizations with live genetically attenuated 
parasites (GAPs) preventing the development beyond the clinically silent liver stage have proven 
safe and efficacious against challenge infections in mice, primates, and humans. A number of 
GAPs have been engineered in Plasmodium berghei, P. yoelii and P. falciparum with varying 
safety and efficacy, however, a superior vaccine candidate providing both safety and efficacy and 
the underlying immune effector mechanisms against pre-erythrocytic stages remain elusive.  
One GAP vaccine candidate, SLARP, provides the most robust life cycle arrest in vivo and in 
vitro. However, immunizations with ΔSLARP sporozoites do not elicit long-lasting immunity, 
most likely as a result of early liver stage arrest. In contrast, ΔP36p/P36 sporozoites elicit long-
lasting immunity, but lead to breakthrough infections during immunizations. This study gives a 
systematic pre-clinical evaluation of a triple knockout (tKO) GAP by combining ΔSLARP and 
ΔP36p/P36, which is a crucial step before translation to human clinical trials. Complete arrest of 
tKO parasites in cultured hepatoma cells and sporozoite-infected mice was confirmed. Animals 
immunized with tKO sporozoites elicit high antibody titers. Parasite load in the liver and the 
time to blood infection after a sporozoite challenge revealed reduced efficacy of the tKO vaccine.  
While superior immunity can be achieved by a late developmental arrest at liver-to-blood stage 
conversion, the underlying molecular mechanisms remain elusive. An important question is 
whether parasite antigens are exposed to the hepatocyte cytoplasm. Protein translocation into 
the host cell cytoplasm mediated by PTEX, a protein translocon, is considered essential for blood 
stages. Strikingly, during liver stage maturation Heat-shock-protein 101 (HSP101), a core 
component of PTEX, is not expressed, suggesting that immune recognition of infected cells is 
severely reduced due to the lack of parasite-derived epitopes presented by MHCI.  
To clarify the role of HSP101 in liver stage protein export and potential concomitant enhanced 
host immune responses, transgenic P. berghei parasites were generated expressing an extra copy 
of HSP101 to commence parasite protein export in early liver stages. Parasites expressing 
elevated levels of HSP101 show severe liver stage growth defects in vitro and in vivo and in good 
agreement, inferior protection was observed in immunized animals. Surprisingly, parasites 
expressing low levels of HSP101 are able to complete the life cycle, but lack early liver stage 
protein export. Our results suggest that HSP101 expression is tightly controlled and PTEX-
dependent early liver stage export cannot be restored solely by HSP101 overexpression. 
Overall, pre-clinical analysis and improvement of GAP-based vaccine candidates can inform 
ongoing human vaccine trials and boost malaria vaccine development.  
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Zusammenfassung 
Der Stadienwechsel ist ein Merkmal von Parasiten, welcher einen Angriffsbereich für potentielle 
Impfstoffkandidaten bildet. Im Fall von Malaria haben experimentelle Immunisierungsstudien 
mit genetisch attenuierten Leberstadien Parasiten (GAP), welche die Entwicklung über das 
klinisch asymptomatische Leberstadium hinaus verhindern, erwiesen, dass eine sichere und 
effiziente Immunisierung in Mäusen, Primaten und Menschen gewährleistet ist. Eine Reihe von 
GAPs mit unterschiedlicher Sicherheit und Wirksamkeit wurden in Plasmodium berghei, P. 
yoelii und P. falciparum generiert. Ein Impfstoffkandidat, der sowohl Sicherheit und 
Wirksamkeit als auch die zugrunde liegenden Prozesse der Immunerkennung und -antworten 
gegen prä-erythrozytische Stadien bietet, ist nach wie vor weitestgehend nicht in Sicht. 
Zum jetzigen Zeitpunkt existiert nur ein GAP-basierter Kandidat ∆SLARP, welcher vollständig 
in der Leber arretiert. Jedoch haben Langzeitstudien gezeigt, dass der Kandidat keinen 
vollständigen und langanhaltenden Schutz bieten kann, höchstwahrscheinlich als Folge eines 
frühen Entwicklungsstillstandes in der Leber. Im Gegensatz dazu bieten Immunisierungen mit 
ΔP36p/P36 Sporozoiten einen langanhaltenden Schutz führen jedoch während des 
Immunisierungsprozesses gelegentlich zu Blutstadieninfektionen. Diese Studie liefert eine 
systematische vorklinische Bewertung eines dreifachen KO (tKO) GAP-Parasiten, durch die 
Kombination zweier Knockouts ΔSLARP und ΔP36p/P36. Dies ist ein entscheidender Schritt vor 
der Durchführung von humanen klinischen Studien. Die vollständige Arretierung von tKO 
Parasiten in kultivierten Hepatomzellen und mit Sporozoiten infizierten Mäusen konnte 
bestätigt werden. Mit tKO Sporozoiten immunisierte Tiere entwickeln ähnliche Antikörpertiter 
wie die Tiere, welche mit den ursprünglichen KOs immunisiert wurden. Die Parasitenlast in der 
Leber und die Zeit bis zur Blutinfektion nach einer Sporozoiteninfektion zeigten jedoch eine 
verminderte Wirksamkeit des tKO-GAP-Impfstoffs. 
Während ein besserer Schutz durch einen späten Entwicklungsstillstand bei dem 
Parasitenstadienwechsel von Leber zu Blut erreicht werden kann, bleiben die zugrunde liegenden 
molekularen Mechanismen unklar. Eine weitere wichtige Frage ist, ob parasitäre Antigene im 
hepatozyten Zytoplasma sichtbar sind, eine Vorrausetzung für die Antigenpräsentation durch 
infizierten Leberzellen. Die Modifizierung der erythrozytären Wirtszelle ist ein 
überlebenswichtiger Mechanismus, der von dem Export von parasitären Proteinen durch PTEX, 
ein Proteintranslocon, in das Zytoplasma der Wirtszelle ermöglicht wird. Erste Studien konnten 
zeigen, dass der Proteinexportkomplex in Leberstadien nicht vollständig funktionstüchtig ist, da 
ein essentielles Protein, das Hitzeschockprotein 101 (HSP101), eine Kernkomponente von 
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PTEX, nicht exprimiert wird. Es lässt vermuten, dass die Immunerkennung infizierter Zellen, 
aufgrund der limitierten Präsentation von parasitären Epitopen über MHCI, stark reduziert ist. 
Um die Rolle von HSP101 für den Export von Leberproteinen und die damit einhergehenden 
verstärkten Immunantworten des Wirts zu klären, wurden transgene P. berghei Parasiten 
erzeugt, die eine zusätzliche Kopie des HSP101 Proteins tragen, um den Parasitenproteinexport 
in frühen Leberstadien anzustoßen. Transgene Parasiten weisen in vitro und in vivo schwere 
Wachstumsstörungen im Leberstadium auf. Mäuse, die mit transgenen Parasiten immunisiert 
wurden, sind nicht gut gegen Neuinfektionen geschützt. Überraschenderweise können Parasiten, 
die geringe Mengen an HSP101 exprimieren, den Lebenszyklus abschließen, dabei konnte der 
frühe Export von Leberstadienproteinen nicht nachgewiesen werden. Die Ergebnisse legen nahe, 
dass die Expression von HSP101 streng kontrolliert wird und der PTEX-abhängige Export im 
frühen Leberstadien nicht durch die Überexpression von HSP101 wiederhergestellt werden 
kann, was auf ein multifaktorielles-System schließen lässt. 
Insgesamt können prä-klinische Studien und die Weiterentwicklung von GAP-basierten 
Impfstoffkandidaten die laufenden humanen Impfstoffstudien beeinflussen und die Entwicklung 
von Malariaimpfstoffen vorantreiben. 
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kg    kilogram 
KO    knockout 
L    liter 
LB    Lysogeny Broth 
LISP    Liver specific protein 
LS    Liver stage 
M    molar 
m    meter 
MΦ   macrophage 
mCh   mCherry 
MgCl2    magnesium chloride 
MHC    major histocompatibility complex 
ml   milliliter 
min    minutes 
mm    millimeter 
mRNA   messenger ribonucleic acid 
n    number 
NaCl   sodium chloride 
N-terminal   amino-terminal 
NF-κB    nuclear factor kappa-light-chain-enhancer of activated B cells 
n.d.    not determinable 
ng   nanogram 
nm    nanometer 
NMRI    Naval Medical Research Institute 
ORF    open reading frame 
P.    Plasmodium 
p    p-value 
   
p.i.   post infection 
P36p   6-cysteine protein 
P36   6-cysteine protein 
PALM  Plasmodium-specific apicoplast protein important for liver merozoites 
formation 
P. berghei/ P.b.  Plasmodium berghei 
P. chabaudi   Plasmodium chabaudi 
P. falciparum/ P.f.  Plasmodium falciparum 
P. vivax   Plasmodium vivax 
P. yoelii   Plasmodium yoelii 
PBS    phosphate buffered saline 
PCR    Polymerase chain reaction 
PEXEL   Plasmodium export element 
PFA    Paraformaldehyde 
PM    Plasmepsin 
PNEP    PEXEL-negative exported proteins 
PPM    Parasite plasma membrane 
PRR    pattern recognition receptor 
PTEX    Plasmodium translocon of export proteins 
PV    Parasitophorous vacuole 
PVM    parasitophorous vacuole membrane 
RAS    Radiation attenuated sporozoites 
RBC    Red blood cells 
rev    reverse 
RFP    red fluorescent protein 
RNA    Ribonucleic acid 
rpm    revolutions per minute 
RPMI    Roswell Park Memorial Institute medium 
RT   room temperature   
qRT-PCR   Real-time quantitative PCR  
SLARP   Sporozoite and liver stage asparagine-rich protein 
s    second/s 
s. ch.   see chapter 
SD    standard deviation 
Taq    Thermus aquaticus 
tKO   triple knockout 
TMD    transmembrane domain 
TNF-α    Tumor necrosis factor alpha 
TRX   thioredoxin 
TRAP    Thrombospondin-related anonymous protein 
TVN    tubovesicular network 
UIS    upregulated in infective sporozoites 
UTR    untranslated region 
WHO    World Health Organization 
WT   wildtype
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1 Introduction  
1.1 Malaria: An introduction to the disease 
Malaria remains the most important vector-borne infectious disease, affecting half of the world’s 
population. Globally, >200 million infected individuals develop clinical symptoms, and >400,000 
die because of severe malaria, primarily children in Sub-Saharan Africa (WHO, 2018). New 
strategies for malaria prevention and eradication are thus urgently required. The current malaria 
control programs target the causative agents, Plasmodium falciparum, P. vivax, and three other 
human-infecting Plasmodium parasites, at different life cycle stages, which together reduces 
morbidity and mortality in endemic regions. Attacking the parasite at its vector stage with long-
lasting insecticide treated bed nets and insecticide-indoor residual spraying combined with 
access to rapid diagnosis and artemisinin-based combination therapy for clinical malaria 
episodes are recommended by the WHO (WHO, 2018) 
Protozoan Plasmodium parasites belonging to the phylum of Apicomplexa, infect a diverse range 
of mammalian hosts. Five Plasmodium species are known to infect humans with Plasmodium 
falciparum, claiming most of the deadly cases. In contrast, P. vivax the most wide spread 
Plasmodium species forms dormant liver stages, so called hypnozoites, that can cause relapsing 
Plasmodium infections, thereby underestimating the impact of P. vivax on global malaria burden 
(Mueller et al., 2009). Two other strains P. ovale (split in curtisi and wallikeri) and P. malariae 
contribute only to a small proportion of mild malaria infections, which are relatively short lived 
for P. ovale but can last a decade P. malariae (Faye et al., 1998, Sutherland et al., 2010, Ansari et 
al., 2016). More recently, P. knowlesi, primarily a zoonosis, has been attributed to several human 
deaths in Southeast Asia. Human to human transmission has not been observed and its impact 
on the global malaria burden remains elusive (Ahmed & Cox-Singh, 2015).  
Malaria burden in endemic regions is dependent on vector prevalence, transmission efficiency, 
asymptomatic carrier reservoirs, and Plasmodium strain and treatment availability. Primarily at 
risk are children under five years and pregnant women, since naturally acquired and placental 
immunity are absent in young patients and mothers carrying their first child, respectively. 
Symptomatic infections are caused by the blood stage of the parasites with symptoms including 
fever, headache and nausea. Complicated or severe malaria cases are described as cases causing 
hypoxia, anemia and cerebral malaria, which can lead to death in patients. Infections in adults 
are often asymptomatic, with mild symptomatic periods, and as a consequence fail to be treated. 
This reservoir of untreated infections propagates the cycle of malaria infections (Chen et al., 
2016).  
Introduction 
  2 
Repeated exposure to Plasmodium transmission in malaria-endemic countries leads only to very 
slow acquisition of naturally acquired immunity that rapidly wanes. Development of protective 
immunity is likely hindered by blood infection, the exclusive cause of malaria-related morbidity 
and mortality. Therefore, the pre-erythrocytic phase of the Plasmodium life cycle in the 
mammalian host is particularly attractive as immunization agent since no clinical symptoms are 
associated with this first replication phase (Prudencio et al., 2006, Silvie et al., 2008, 
Matuschewski et al., 2011). Prevention of disease by vaccination is an ideal addition to the 
portfolio of malaria intervention tools; however, it remains one of the greatest challenges in 
medical research. 
1.2 Plasmodium: Shining a light on the parasite life cycle 
Continuous stage conversion while evading the human immune system requires a constant 
change in parasitic protein repertoire. Determined by its life cycle parasites switch between intra- 
and extracellular stages leading to perpetual change in parasite morphology.  
Upon an infectious mosquito bite, the parasite is injected into the dermis of the host with the 
saliva of the mosquito. The active parasite stage, termed sporozoite, travels in a gliding 
movement to the nearest blood vessel (Fig. 1). Hereby TRAP-like protein (TLP) plays a major 
role in parasite gliding ability and infectivity (Sultan et al., 1997, Heiss et al., 2008, Moreira et al., 
2008). Sporozoites remaining in the dermis contribute to antibody development against 
sporozoite surface antigens in the draining lymph nodes of the skin (Amino et al., 2008). 
Particularly CSP (circumsporozoite protein) and TRAP (thrombospondin-related anonymous 
protein) are recognized as sporozoite antigens; however, many other surface proteins might play 
a role in this process (Yoshida et al., 1980, Trieu et al., 2011).  
Once in the blood stream, parasites actively invade the liver through the sinusoidal barrier in a 
process termed traversal. Sporozoites traverse several hepatocytes before infecting a final one to 
mature into infective merozoites for red blood cell (RBC) infection (Fig. 1). Traversal requires 
expression of SPECT (Sporozoite microneme protein essential for traversal), SPECT2 (perforin-
like protein 1, PLP1), CelTOS (cell traversal protein for ookinetes and sporozoites) and several 
other parasite proteins (Ishino et al., 2004, Bhanot et al., 2005, Risco-Castillo et al., 2015), 
however, precise protein function in traversal remains to be elucidated. Infection of hepatocytes 
is mediated by sporozoites binding to hepatocyte surface proteins CD81 and scavenger receptor 
B1, inducing sporozoite invasion and formation of a parasitophorous vacuole (PV) (Rodrigues et 
al., 2008, Manzoni et al., 2017). PV establishment, remodeling and maintenance are vital for 
intra-hepatocytic development and rely on, amongst other processes, interaction of hepatocyte 
receptor EphA2 with parasite proteins P36p (P52) and P36 (Kaushansky et al., 2015). During 
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sporozoite maturation liver stage gene expression is tightly controlled by various mechanisms 
among them proteins e.g. SLARP and PUF2 controlling mRNA translation or internal sequences 
in ORFs of liver specific genes (Silvie et al., 2008, Muller et al., 2011). Incorporation of 
transcriptionally and translationally regulated sporozoite genes such as UIS3 and UIS4 
(upregulated in infective sporozoites gene 3 and 4) remodel the PVM (Mueller et al., 2005). 
Parasites eventually develop into liver stage trophozoites. Further maturation to liver stage 
schizonts induces elevated protein export facilitating PVM destruction and subsequent 
merosome release (Burda et al., 2015, Burda et al., 2017). Mature merosomes harboring 
thousands of merozoites bud off and attach to the host’s lung blood capillaries from where they 
are released after 44 hours in the liver for P. berghei and 7-10 days in P. falciparum (Sturm et al., 
2006).  
Within seconds, merozoites invade RBCs using a complex interplay of multiple parasite and host 
proteins to induce a patent blood stage infection. The parasite then rapidly matures in a PV from 
ring stages into trophozoites (Fig. 1). However, blood cells are deprived of most living cell 
components including a mechanism to acquire nutrients for cell growth or recognize non-self 
proteins to be displayed to cytotoxic T cells via the major histocompatibility complex (MHCI). 
Hence, the parasite uses a protein translocon termed PTEX to export parasitic proteins beyond 
the PV to remodel its host cell (Boddey & Cowman, 2013). Remodeling phases enable the 
parasite to acquire nutrients, dispose waste and establish knob like structures on the iRBC 
surface to sequester in the blood vessels to avoid splenic killing (Langreth & Peterson, 1985, 
Miller et al., 2012). However, PfEMP1 (erythrocyte membrane protein 1), the mediator of 
vascular sequestration, is also a target for the host immune system to recognize and eventually 
attack the otherwise hiding parasite. To avoid clearance parasite by the host’s immune system use 
a system of 60 sequentially expressed var genes encoding EMP1 to undergo antigenic changes 
(Guizetti & Scherf, 2013).  
After completing schizogony, schizonts rupture and release 16-32 mature merozoites to infect 
other RBCs (Cowman & Crabb, 2006). A few of the parasites are programmed to follow a 
different path in the next maturation phase developing into mature sexual stages, termed female 
or male gametocytes, in the bone marrow. During the next blood meal, mosquitoes take up 
mature gametocytes with the ingested blood into the midgut of the mosquito (Fig. 1). 
Exflagellating male gametocytes form zygotes with female gametocytes and sexually replicate into 
ookinetes, which travel across the midgut barrier to mature into oocysts. During oocyst 
maturation thousands of sporozoites are formed which are released after 17 days and travel to the 
salivary glands of the mosquito where they are then transmitted to the human host during the 
next infectious bite of a mosquito (Guttery et al., 2015, Sinden, 2015). 
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Figure 1 Plasmodium life cycle 
Upon a bite of an infected mosquito, sporozoites glide through the dermis to reach the next blood vessel. 
When reaching the liver, sporozoites traverse across the sinusoidal barrier and several hepatocytes before 
infecting the one to asexually mature into mature merosomes. Merosomes harboring thousands of 
merozoites bud into the lung lumen where they release the merozoites. Free merozoites invade red blood 
cells where they mature from ring stages over trophozoites to merozoites, which break free to infect new 
red blood cells and complete the asexual cycle. Each cycle, a small proportion of parasites develop into 
sexual stage gametocytes. During the mosquito’s next blood meal gametocytes are ingested to complete the 
life cycle in the mosquito by developing via ookinetes and oocyst to sporozoites (Portugal et al., 2011). 
1.3 The murine Plasmodium vaccine model  
Rodent Plasmodium parasites were first discovered in the Democratic Republic of Congo in 1984 
(Vincke & Lips, 1948). Studies of infected African thicket rats led to the discovery of four rodent 
species P. berghei, P. yoelii, P. chabaudi and P. vinckei, which were all transferred to rodent 
laboratory models. In the early 2000s, genome sequencing for P. falciparum and P. berghei 
opened up new possibilities for genetic manipulation of Plasmodium parasites. Conventional 
double homologous crossover of haploid asexual Plasmodium blood stages allowed investigation 
of the parasite’s unique maturation. CRISPR-Cas9 and DiCre conditional knockout systems 
revolutionized indepth exploration of P. falciparum blood stage’s genome and proteome (Collins 
et al., 2013, Ghorbal et al., 2014). However, the mosquito stages and the clinically silent liver 
stage remained poorly studied. Larger screens for sporozoites and liver stage-specific genes 
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identified essential stage-specific proteins. Established murine malaria models employing the 
rodent malaria parasites P. berghei and P. yoelii enable the exploration of stage-specific proteins 
and their importance for parasite survival. In recent years more than 120 candidate genes have 
been analyzed by reverse genetics (Janse et al., 2011), data that is valuable for non-blood stage 
drug and vaccine studies. 
To evaluate immunological host-parasite interactions and induce robust long-term immunity 
against challenge infections, it is important to identify the correct parasite/host combination 
from which to draw valid conclusions following pre-clinical immunization experiments 
(Matuschewski, 2013). The P. berghei-C57BL/6 combination remains the most robust vaccine 
model to date, whereas immunizations using P. yoelii mutants in BALB/c mice are only of 
modest predictive value, since protection is easily achieved in this model. Other combinations, 
such as P. berghei and BALB/c mice, are invalid because of refractoriness of particular 
combinations of mouse strains and infections with certain murine malaria sporozoites (Scheller 
et al., 1994). One important immunological difference is that protection in the P. yoelii-BALB/c 
model largely depends on the immunodominant CD8+ T cell epitope of CSP. In marked contrast, 
T cell responses in the P. berghei-C57BL/6 model are likely multifactorial (Hafalla et al., 2011, 
Hafalla et al., 2013), which closely mimics infections in human populations with a large range of 
MHCI haplotypes and only infrequent CSP–specific CD8+ T cell responses (Offeddu et al., 2012). 
This observation raises the general questions as to which mouse model best mimics the potential 
outcome of an orthologous knockout vaccine in humans and how transferable data generated in 
a mouse model are for human application. Transferring these findings to the human malaria 
agent P. falciparum is a challenge since studies on human liver stages are difficult. Humanized 
mouse models and primary human hepatocytes give the first indication on liver developmental 
abortion and safety of vaccine candidates. Only very few vaccine candidates have been tested for 
their safety and protection in human volunteers, however an ultimate study is inevitable. 
In conclusion, comparative studies on vaccine efficacy should include the P. berghei-C57BL/6 
model (Friesen & Matuschewski, 2011), to better define long-term protection against re-
challenges. The recent evaluation of Grammomys dolichurus, an Afrotropical arboreal rodent, 
which naturally harbors rodent Plasmodium infections, as a model to study pre-erythrocytic 
vaccine strategies will be an important addition for preclinical evaluation of safety and 
immunogenicity of GAP vaccines (Conteh et al., 2017). In concordance with the data from 
murine Plasmodium models, the natural host is highly susceptible to P. berghei sporozoite 
induced infections and multiple high immunization doses are required for robust protection 
(Conteh et al., 2017). Vaccines should be evaluated for vaccine safety and immunogenicity in a 
two-step preclinical process before advancing to human trials. First, comparative evaluation of 
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the candidate P. berghei and P. yoelii GAP lines in the respective mouse strains, C57BL/6 and 
BALB/c, will pre-select GAPs that are completely arrested upon high dose sporozoite 
inoculations and elicit long-lasting (>30 days) sterile immunity. Second, confirmation of safety 
and immunogenicity of the P. berghei GAP line in G. dolichurus immunization and challenge 
study provides an evidence-based rationale for translation to P. falciparum GAP trials. 
1.4 Genetically attenuated parasites as vaccine candidates 
Approaches to design a protective long-lasting malaria vaccine are wide-ranging, and some of 
them have already reached phase III clinical trials (WHO, 2016). Among these candidates is 
RTS,S/AS01, which is the first malaria vaccine to achieve licensure for administration in malaria 
endemic areas. RTS,S/AS01 is a hepatitis B-based subunit vaccine and contains a fragment of 
CSP (Stoute et al., 1997). Recent phase III clinical trial results revealed an unfavorable protection 
level casting doubt on the impact of RTS,S/AS01 in malaria control efforts (Rts et al., 2011, Olotu 
et al., 2016).  
A benchmark for a malaria vaccine has existed already for several decades, and this experimental 
vaccine with proven long-term protection is a whole sporozoite vaccine. Small immunization 
studies in mice, non-human primates, and humans demonstrated that radiation attenuated 
sporozoites (RAS) elicit sterile protection against Plasmodium challenge infections (Nussenzweig 
et al., 1967, Nussenzweig et al., 1969, Clyde et al., 1973, Gwadz et al., 1979) (Hoffman et al., 
2002). Irradiation induces DNA breakage in the parasites, which reduces the numbers of nuclear 
divisions and limits liver stage expansion to early schizonts (Fig. 2, Silvie et al., 2002). Timing 
and radiation dosage are critical since over-irradiated sporozoites arrest early at the unicellular 
stage, thus decreasing protection in experimental cohorts (Friesen & Matuschewski, 2011). 
Successful hepatocyte invasion and initial intra-hepatic development of live, metabolically active 
sporozoites are required to elicit strong immunity, and, therefore, pose a substantial hurdle 
toward an affordable and undemanding sporozoite vaccine. The central importance of live and 
metabolically active sporozoites has been corroborated with heat-killed sporozoites, which elicit 
only very weak and short-term, antibody-mediated protection against subsequent Plasmodium 
sporozoite challenge infections (Hafalla et al., 2006). On the other hand, suboptimal irradiation 
harbors the risk of breakthrough infections during vaccination — a considerable drawback 
concerning safety. RAS arrest early during liver stage development and express primarily 
sporozoite-derived antigens, including CSP and TRAP, which likely contribute to priming of T 
cell-mediated immunity. 
Liver stage developmental arrest can also be achieved by an alternative approach, termed 
chemical attenuation of sporozoites (CAS), which is based on simultaneous administration of 
Introduction 
  7 
normal sporozoites and anti-malarial drugs e.g. chloroquine, azithromycin (AZ) or 
pyrimethamine (Fig. 2, Belnoue et al., 2004, Putrianti et al., 2009, Roestenberg et al., 2009, 
Friesen et al., 2010, Bijker et al., 2013). While these approaches offer interesting evaluations in 
small-scale exploratory clinical studies, they are critically reliant on continuous clinical 
supervision during drug administration and currently bear no translational perspective. 
 
Figure 2 Malaria preventive vaccine strategies 
The different pre-erythrocytic vaccine approaches tackle the parasite during its asymptomatic asexual 
replication in the liver. Immunizations with heat-killed sporozoites don not allow therefore, lack 
protection against follow-up infection. Irradiated sporozoites lead to early arrest of the parasite in the liver 
and therefore induce intermediate protection. Genetically attenuated parasites (GAPs) arrest, depending 
on the gene knockout, at early to late liver stage. Immunizations with GAPs elicit potent protection, but 
occasionally lead to breakthrough infections during immunization. Parasites under drug cover develop 
until early liver stages (PQ) or until the first replication cycle in blood stages (AZ or CQ) and 
immunizations elicit potent protection against follow-up infections (Matuschewski et al., 2011). 
The potential to induce lasting protection by live attenuated, metabolically active parasites led to 
the engineering of genetically attenuated parasites (GAPs) as tailored whole parasite vaccines 
against malaria infections (Fig. 2, Mueller et al., 2005). Murine malaria models employing the 
rodent malaria parasites P. berghei and P. yoelii enable the exploration of liver stage-specific 
proteins function and their importance for parasite survival. In the past, over 120 genes have 
been targeted by experimental genetics and analyzed for defects during the Plasmodium life cycle 
in both vector and mammalian host (Janse et al., 2011). Many gene knockouts resulted in normal 
parasite life cycle progression or refractoriness to targeted deletion, indicative of redundant 
functions during life cycle progression or vital roles for blood infection, respectively. 
Additionally, arrest of the parasite development in the mosquito midgut, prior to salivary gland 
colonization, or ahead of hepatocyte invasion was frequently observed. Accordingly, only very 
few candidate genes fulfill the criteria of potential GAP vaccine candidate lines.  
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1.4.1 First generation GAPs: Proof of principle studies 
The first preclinical studies that showed successful generation of GAP lines and tested their 
efficacy in immunization protocols targeted Plasmodium berghei genes that represent members 
of the early transcribed membrane protein (ETRAMP) family (Mueller et al., 2005, Mueller et al., 
2005). The selected genes, i.e., upregulated in infective sporozoites gene 3 (UIS3) and UIS4, 
fulfilled three principal criteria: (i) stage-specific gene expression in pre-erythrocytic stages, 
thereby allowing recombinant knockout strains to be selected during blood stage transfection; 
(ii) abundant expression in pre-erythrocytic stages, indicating likely vital roles during this phase 
of the life cycle; and (iii) genes that are unique to Plasmodium and related haemosporidian 
parasites, which all share the hallmark of the first obligate population expansion phase in the 
host liver (Matuschewski et al., 2002). In vitro studies in cultured hepatoma cells revealed that P. 
berghei as well as P. yoelii ∆UIS3 and ∆UIS4 parasite lines arrest early during liver stage 
development after completion of sporozoite transformation to liver stages, but before onset of 
parasite replication (Fig. 3, Mueller et al., 2005, Mueller et al., 2005, Tarun et al., 2007). 
Immunization studies with one prime and two booster vaccinations showed complete long-term 
protection with P. berghei and P. yoelii ∆UIS3 and ∆UIS4 GAPs in C57BL/6 and BALB/cJ mice, 
respectively (Mueller et al., 2005, Mueller et al., 2005, Tarun et al., 2007). The study on P. berghei 
∆UIS4 GAPs established frequent occurrence of breakthrough infections, i.e., a proportion of 
animals developed blood infections during the immunization procedure (Mueller et al., 2005). 
This safety concern needs careful examination before progression of P. falciparum GAPs to 
human testing can take place (Matuschewski, 2013). Notably, the identification of orthologous 
genes for UIS3 and UIS4 in P. falciparum has so far remained elusive, although various 
ETRAMPs emerge as potential candidates (Spielmann et al., 2012).  
Another first generation GAP line in P. berghei and P. yoelii are parasites that lack P36p (also 
termed P52), a member of the Plasmodium-specific 6-Cysteine protein family (van Dijk et al., 
2005). Parasites lacking P36p (P52) or its paralogue, P36, arrest again early during liver stage 
development after completion of sporozoite transformation (Fig. 3, Ishino et al., 2005, van Dijk 
et al., 2005). ∆P36p sporozoites transmigrate and invade hepatocytes, wherein they initiate the 
formation of a parasitophorous vacuole (PV). Although they start to mature into liver stage 
trophozoites, ∆P36p parasites suddenly abort this development, most likely because maintenance 
and maturation of the PVM are critically impaired (van Dijk et al., 2005). 
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Figure 3 Precision developmental arrests during Plasmodium liver stage maturation by genetically 
arrested parasites (GAPs) 
A sporozoite (green) invades a suitable hepatocyte under simultaneous formation of a replication-
competent intracellular organelle, termed parasitophorous vacuole (orange). After intracellular 
transformation to round early liver stages, the parasite expands to a single-cell liver stage trophozoite. 
Early arresting GAPs, e.g., ∆UIS3, ∆SLARP,∆P36p, stop cell division at this stage. Next, the trophozoite 
grows in size and replicates and eventually forms a schizont that exceeds the size of the original host cell. 
Many GAP lines, such as deletions of the FASII biosynthesis pathway or other apicoplast functions, e.g., 
∆PALM, arrest after full liver stage maturation. In the last phase of pre-erythrocytic development, the first 
generation of erythrocyte-invading stages, termed merozoites are formed and released from the infected 
hepatocytes into the blood stream. This step marks the transition from the clinically and diagnostically 
silent liver phase to the blood infection, which is responsible for all malaria-related symptoms and 
pathology. GAPs (right) are listed next to the phase of liver stage development (left) according to their life 
cycle arrest. Safe and unsafe GAPs are depicted in black and gray, respectively. Knockouts of the murine 
and human Plasmodium species are shown on the left and right side, respectively (Kreutzfeld et al., 2017). 
Once more, occasional breakthrough infections in mice inoculated with ∆P36p sporozoites were 
observed (van Dijk et al., 2005). Interestingly, in the ∆P36p/P36 double knockout, parasite 
expression of the signature merozoite surface protein 1 (MSP1) could not be detected, and the 
mechanism of breakthrough infections remains unsolved (Ploemen et al., 2012). Targeted gene 
deletion of a second member of the 6-Cys family, termed B9, led to a similar early arrest and 
occasional breakthrough infections (Annoura et al., 2014). 
Together, the first generation GAPs established that precise developmental arrests during the 
first clinically silent, intrahepatic Plasmodium expansion phase can be engineered by tailored 
removal of individual vital genes from the entire Plasmodium genome. These uniform, 
genetically defined parasites consistently elicit lasting protection against sporozoite challenge 
infections in vaccination protocols with three consecutive GAP sporozoite inoculations. 
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1.4.2 GAPs targeting liver stage differentiation: Safety first 
The observations of breakthrough blood infections during the immunization protocol in a 
proportion of animals (Mueller et al., 2005b; van Dijk et al., 2005) initiated the search for 
candidate Plasmodium genes that are key developmental factors, for instance transcription 
factors at the nexus of sporozoite to liver stage transformation. Such a factor was identified 
during the analysis of sporozoite-specific (S) genes (Kaiser et al., 2004). Targeted gene deletion of 
this factor, termed S22 or sporozoite and liver stage asparagine-rich protein (SLARP or SAP1) 
(Aly et al., 2008, Silvie et al., 2008), resulted in a complete arrest of the parasite at early liver 
stage development prior to nuclear division (Fig. 3). A novel hallmark of ∆SLARP parasites was 
the differential down-regulation of many liver stage-specific mRNAs and their corresponding 
proteins, including PVM resident proteins such as UIS3 and UIS4 (Aly et al., 2008, Silvie et al., 
2008), suggesting pleiotropic defects as a result of the absence of a major transcriptional or post-
transcriptional regulator of liver stage differentiation.  
Most importantly, ∆SLARP parasites are the first and only GAPs reported to fulfill all criteria of 
safe arrest (Aly et al., 2008, Silvie et al., 2008). Accordingly, after the safety failure of PfP52/P36, 
all PfGAPs developed for clinical testing in humans include the corresponding PfSLARP 
knockout (Mikolajczak et al., 2014, van Schaijk et al., 2014, Kublin et al., 2017). However, 
immunization studies showed a reduction in long-term protection in animals immunized with P. 
berghei ∆SLARP parasites, where only 40% of all animals were protected 3.5 months after 
immunization (Silvie et al., 2008). It is conceivable that ∆SLARP parasites display a smaller array 
of antigens, but this has to be experimentally tested employing systems immunology approaches. 
In conclusion, immunization data together with the demonstration of a very early, complete 
arrest indicate that ∆SLARP parasites are comparable to RAS, with the important distinctions of 
a precision life cycle arrest in humans (Kublin et al., 2017) and safe handling of ∆SLARP. 
1.4.3 Late arresting GAPs: Improved immunogenicity but lack of safety 
Studies employing co-administration of normal sporozoites and anti-malarial drugs have 
consistently shown superior immunity of late liver stage and/or early blood cycle arrest in 
murine malaria models (Belnoue et al., 2004, Friesen et al., 2010, Friesen & Matuschewski, 2011) 
and small scale human trials (Roestenberg et al., 2009, Bijker et al., 2013), suggesting that a late 
liver stage arrest offers multiple advantages, perhaps including broader antigen presentation 
(Borrmann & Matuschewski, 2011). Unexpectedly, antibiotic-induced arrest at the transition 
from late liver stages to blood infection leads to better protection than a later arrest, after a few 
rounds of blood stage replication, induced by chloroquine treatment (Friesen and Matuschewski, 
2011). This indicates an immune-modulatory effect by infected red blood cells and potential 
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benefits of a complete arrest at the liver stage. 
Therefore, tailored arrest toward the end of liver stage maturation was an important third step in 
GAP vaccine design. A CAS-based arrest using the antibiotic azithromycin showed that 
specifically targeting the Plasmodium apicoplast, a relict non-photosynthetic plastid organelle, 
resulted in late arrest after complete liver stage maturation (Friesen et al., 2010). Accordingly, 
two complementary approaches targeting key factors in the Plasmodium apicoplast led to 
generation of late-arrested GAPs and their testing in vaccine studies (Fig. 3), namely deletion of 
a fatty acid biosynthesis enzyme (Butler et al., 2011) and a Plasmodium-specific protein of 
unknown function (Haussig et al., 2011). In both cases potent protection against reinfection was 
reported and superior protection correlated with extended liver stage maturation. However, 
safety concerns were reported for ∆PALM whereas safety of fatty acid synthesis II (FASII) 
enzyme knockout was promising in P. yoelii (Vaughan et al., 2009, Pei et al., 2010, Butler et al., 
2011, Haussig et al., 2011, Lindner et al., 2014) but failed to be confirmed in P. berghei, thereby 
limiting the use of these vaccines candidates (Yu et al., 2008, Annoura et al., 2012, Shears et al., 
2017). The additional, unexpected finding of aborted parasite development in mosquitos infected 
with the corresponding P. falciparum knockouts (Cobbold et al., 2013, van Schaijk et al., 2014) 
essentially eliminated the possibility to develop GAP vaccines by targeted deletion of the FASII 
pathway. Together, these results also raise the important question of which prerequisites have to 
be fulfilled to transfer discoveries from murine models to PfGAP vaccines However, these 
examples illustrate that a tight late liver stage arrested parasite might be achieved once a suitable 
P. falciparum liver stage-specific gene at the nexus of stage conversion is identified. 
1.5 Immune mechanisms in Plasmodium infections and immunizations 
1.5.1 Fighting the disease: Host immune responses and parasite’s hiding mechanism 
Natural immunity is only slowly acquired after several rounds of infection and wanes quickly 
upon lack of constant exposure to parasites.  Immunity is most likely a consequence of antigenic 
responses to erythrocytic stages either by exposure to a vast amount of P. falciparum isolates or 
cross-protection by shared antigenic targets. However, full immunity is never achieved as 
residents of malaria endemic countries only acquire immunity against symptomatic infections; 
yearly reinfections with asymptomatic outcome are seen on a regular basis. This serves as a 
constant reservoir for circulation of malaria infections. Studies on host-parasite interaction in 
particular on host immune responses to the parasite and Plasmodium’s mechanism of hiding are 
essential for development of a safe and efficacious vaccine.  
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Figure 4 Host immune responses to malaria infections 
Sporozoites, injected by a bite of an infected mosquito, elicit the first host immune responses during a 
Plasmodium infection. Primarily antibodies are generated against sporozoite surface antigens in the skin 
and skin-draining lymph nodes. During liver stage development an interplay of parasite peptide 
presentation by MHCI of hepatocytes and by MHCII of antigen presenting cells (APCs) prime CD8+ T 
cells for reinfections. Innate immune responses tackle the parasite via nitric oxide (NO), which is 
triggered by a cascade of cytokine release by immune cells. Certainly, the spleen and draining lymph nodes 
play a major role in forming an adaptive immune response against reinfections. In blood stages antibodies 
are primed against parasitic proteins sitting on the remodeled erythrocyte (Riley & Stewart, 2013). 
Once sporozoites enter the host they are detected by the host’s immune system. Thus, 
sporozoites move quickly to the next stage and limit protein discharge to avoid recognition by 
the host. However, motility is based on an actomyosin motor mediated by TRAP-like proteins, 
which enable parasites to glide and transmigrate through the dermis, blood stream and 
sinusoidal barrier (Sultan et al., 1997, Menard, 2001). Sporozoites defective for gliding are 
rapidly targeted and removed by CD11b+ phagocytic cells. A percentage of parasites remains in 
the dermis and can be taken up by the lymphatic system where they are eventually targeted by 
CD11c+ dendritic cells (Fig. 4). Furthermore, a subset of sporozoites that escaped the first wave 
of host immune response manage to form exo-erythrocytic forms (EEF), potentially displaying 
an unknown set of additional parasite antigens (Amino et al., 2008). Sporozoite specific 
antibodies, generated during sporozoite migration, help to block sporozoite gliding and 
hepatocyte infection in subsequent infections. Although TRAP has been demonstrated to be the 
major ligand for hepatocyte entry, antibody-mediated blockage of TRAP led to normal infection 
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rates (Gantt et al., 2000). CSP is most likely the pre-dominant contributor to antibody responses, 
but other antigens might also play a role since whole sporozoite antibody responses have been 
reported.  
Pre-erythrocytic contribution to natural acquired immunity is only limited and most likely 
dampened by blood stage infections as parasite/DC interaction mediates cytokine secretion 
suppressing liver stage protective effector CD8+ T cells (Ocana-Morgner et al., 2003, Ocana-
Morgner et al., 2007). Parasites crossing the sinusoidal barrier encounter Kupfer cells, specialized 
liver MΦ (Frevert et al., 2006, Frevert et al., 2008). KCs might act as an actual “barrier” as 
depletion of KCs led to an enhanced infection rate in P. yoelii parasites (Baer et al., 2007). 
Subsequent parasite migration through hepatocytes induces MyD88 (Torgler et al., 2008), which 
leads to NF-κB activation and in return to expression of the inducible nitric oxide synthase 
(iNOS) interfering with EEF development (Fig. 4, Nussler et al., 1993, Seguin et al., 1994). Pre-
dominant responses to parasitic CSP are seen at early stages, as it is highly expressed in 
sporozoites and very early liver stage development. Discharge of CSP might redirect NF-κB 
responses to traversed and not infected cells (Singh et al., 2007). Upon liver infection, parasites 
develop in a PV to shield themselves from host recognition. In contrast to blood stage infections, 
parasites keep host cell remodeling to a minimum as antigen discharge and protein export can 
lead to antigen presentation via MHCI for priming of naïve CD8+ T cells. Other antigen 
presenting cells (APCs) play a minor role however, it is believed that long persisting parasites 
induce further responses by DC opsonization and secondary MHCII presentation (Plebanski et 
al., 2005). However, damaging inflammation in this vital organ is kept to a minimum (Crispe et 
al., 2006), thereby limiting priming and recruitment of immune cells. Interestingly, merosomes 
are directly released into the lung circulation where they attach to release merozoites, evading 
discharge of merozoites close to phagocytic KCs. This notion was confirmed in vitro where MΦs 
failed to phagocytose merosomes (Sturm et al., 2006, Baer et al., 2007).  
Natural acquired immunity is predominantly based on B-cell mediated antibody responses to 
parasite blood stage infection, corroborated by a study reporting that gamma globulins from 
adults in highly endemic areas where able to protect children against high parasitic infections 
(Cohen et al., 1961). Two mechanisms are most likely contributing to blood stage protection i) 
inhibition of merozoites invasion and ii) antibody response to infected RBCs ( Fig. 4, Langhorne 
et al., 2008). The latter is an interplay between parasite hiding and efficient replication. Upon 
RBC infection the parasite replicates in a PV avoiding recognition by the host immune system. 
Moreover, erythrocytes lack the MHCI presentation pathway and are therefore not targeted by 
conventional T cells. However, the parasite needs to remodel its “empty” host cell to provide 
nutrients and dispose waste for maturation. It exports a vast amount of proteins to establish a 
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well-structured network for cell function. A drawback is recognition by the spleen, as iRBCs, 
deformed by parasite infections, are cleared. To avoid splenic killing trophozoites and schizonts 
expose a protein termed EMP1 at the RBC surface to mediate vascular endothelial cell adhesion. 
Sequestration of trophozoites and schizonts is a major contributor to mortality and morbidity; 
particularly, cerebral malaria is associated with parasite sequestration to microcapillaries in the 
brain causing vascular occlusion leading to local hypoxia and inflammation (Cunnington et al., 
2013). Sequestration is enhanced in a feedback loop by pathogenic immune responses. 
Upregulation of major EMP1 binding receptors such as ICAM-1 (cell-adhesion molecule-1) and 
VCAM-1 (vascular cell adhesion molecule-1) and many more is triggered by overproduction of 
TNF-α and IFN-γ (Berendt et al., 1989, Lennartz et al., 2017, Mahamar et al., 2017). Blocking 
cytoadhesion enhances splenic killing of iRBCs, as demonstrated in a study, where severe malaria 
outcome was avoided by antibody responses to iRBCs surface. EMP1 was verified to be the major 
target for protective antibodies in individuals from high transmission areas (Bull et al., 1998). To 
avoid population limiting immune responses the parasite harbors a family of 60 var genes 
encoding different EMP1 surface proteins, a major factor for slow acquisition of immunity. Thus, 
humoral responses to Plasmodium infection are critically timed and determine disease outcome. 
Additionally, overwhelming the reticuloendothelial system with parasite biomass in the form of 
hemozoin can hamper macrophage and dendritic cell antigen presentation and lead to the release 
of large amounts of cytokines such as TNF-α, IL-1 and IFN-γ. Cytokine storms are a major factor 
of malaria pathology (Clark & Vissel, 2017). Expression of anti-inflammatory cytokines as TGFβ 
and IL-10 counterbalances cytokine storms and has a major impact on disease outcome 
(Stevenson & Riley, 2004). Subsets of CD4+ T cells, Th1, have been shown to control blood stage 
infection in humans and rodents by expression of IFN-γ and IL-10 (Su & Stevenson, 2000, 
Jagannathan et al., 2014). 
1.5.2 Primary immune responses: The role of IgG-antibody in sporozoite infections 
Natural infection with sporozoites induces little inflammation, as pattern recognition receptors 
(PRRs) are unable to detect sporozoite innate immune ligands e.g. CSP. This notion was 
corroborated with P. yoelii irradiated sporozoites inducing inflammation whereas viable P. yoelii 
sporozoites reduced inflammation in BALB/c mice (Khan & Vanderberg, 1992, Vanderberg et al., 
1993). However, the major antigen CSP seems to be immunogenic as long as it is presented in an 
inflammatory context, as RTS,S vaccine induces a 20-fold higher antibody expression compared 
to natural infections (Polhemus et al., 2009). Immunization with irradiated sporozoites in 
rodents revealed presence of anti-CSP antibodies (Kumar et al., 2006), which was confirmed in 
naturally P. vivax exposed individuals carrying detectable levels of anti-CSP antibodies (Wipasa 
et al., 2010). High antibody titers are essential for impeding hepatocyte entry and neutralizing 
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sporozoites, as low antibody-titers are associated with enhanced infection (Nudelman et al., 
1989). However, an array of studies raised the question whether CSP-mediated antibodies are 
dispensable for sporozoite-induced protection (Kumar et al., 2006, Gruner et al., 2007, Mauduit 
et al., 2009). Sporozoite immunization enabled exposure to the whole parasite surface antigenic 
repertoire, which led to the discovery of two other sporozoite surface antigens TRAP and LSA-1 
(liver stage antigen type 1) (Guerin-Marchand et al., 1987, Robson et al., 1988).  
Induction of high antibody titers is also dependent on an interplay between B cells with CD4+ 
cells triggered by MHCII antigen presentation (Fig. 4). IFN-γ producing CD4+ T cells from RAS-
immunized individuals lyse B-cells pulsed with CSP epitopes in vitro (Frevert et al., 2009). 
Similarly, IFN-γ producing CD4+ T cells have been linked to reinfection resistance (Reece et al., 
2004). CD4+ T cells are essential for development of CSP-specific CD8+ T cells, which are primed 
by DCs in the draining lymph node (Carvalho et al., 2002, Morrot et al., 2005, Chakravarty et al., 
2007). CSP-specific CD8+ T cells make their way to the liver to recognize parasite antigens 
presented by infected liver cells via MHCI and eliminate them (Chakravarty et al., 2008). 
1.5.3 Immune mechanisms of GAPs: The central role of effector memory CD8+ T 
cells in liver stage immunity 
IFN-γ producing CD8+ T cells were identified to be the key mediator of pre-erythrocytic induced 
protection in RAS immunized rodents (Schofield et al., 1987, Weiss et al., 1988, Romero et al., 
1989). Immunizations with low dose P. yoelii RAS led to immunity in mice (Chattopadhyay et al., 
2009), whereas in endemic areas repeated exposure failed to induce a robust CD8+ T cell response 
(Overstreet et al., 2008). It remains to be determined which factors contribute to robust sterile 
protection, but patent blood stage infections seem to play a central role in efficiency of pre-
erythrocytic immunity (White et al., 2015).  
CD8+ T cells remain the primary target cells for induced immunity as immunization in β2-
microglobulin knockout mice, deficient of CD8+ T cell responses, failed to induce sterile 
immunity after wildtype (WT) challenge (White et al., 1996). Infected hepatocytes display 
parasite antigens via MHCI to cytolytic CD8+ T cells, which leads in return to hepatocyte 
destruction (Fig. 5, Schofield (Mellouk et al., 1987, Schofield et al., 1987, Malik et al., 1991, Sano 
et al., 2001). This was confirmed by CSP-T cell clones recognizing hepatocytes expressing the 
matching haplotype on their cell surface (Balam et al., 2012). Destruction of hepatocytes is 
mediated mainly by IFN-γ, as neutralizing studies revealed (Ferreira et al., 1986, Schofield et al., 
1987, Hafalla et al., 2006). IFN-γ production is upregulated in a positive feedback loop by 
subsequent IL-12 release, which in turn triggers NK-cells to release IFN-γ (Fig. 5, Tsuji et al., 
1995, Hafalla et al., 2011).  
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CD4+ T cells are generally a major contributor to mount an effective T cell response whether this 
is true for liver stage immunity still needs to be determined. Importance of CD8+ T cells in 
immunity to infections, but neither of CD4+ T cells nor antibodies, was confirmed by 
immunization studies with P. berghei ∆UIS3 parasites in B-cell deficient mice or C57BL/6 mice 
depleted of an additional adoptive transfer with CD4+ or CD8+ cells (Mueller et al., 2007). These 
findings were supported in another study where immunization with P. yoelii ∆UIS3 and ∆UIS4 of 
CD8+ T cell deficient mice abrogated vaccine efficacy (Tarun et al., 2007). 
 
Figure 5 CD8+ T cell priming and effector mechanisms 
Once sporozoites reached the liver they cross the sinusoidal barrier (1) and traverse through several 
hepatocytes (2) before infecting a final one to mature into exo-eryhtrocytic forms (EEF) (3). Mature liver 
stages, merosomes, bud into the lung microcapillaries and release merozoites directly into the blood 
stream – the onset of symptomatic Plasmodium infections. Parasitic material derived from sporozoite 
traversal, EEF material and autophagy of EEF primes CD8+ by MHCI presentation of infected hepatocytes 
and CD8+ and CD4+ T cells through cross presentation by DCs. Upon reinfection adaptive immune 
responses can eliminate EEF by cytolysis or indirectly by IFN-γ secretion inducing a signaling cascade and 
EEF elimination by NO (Hafalla et al., 2011). 
Long-term protection is based on persistence of intra-hepatic metabolically active parasites 
(Scheller & Azad, 1995). Comparison studies with GAP-based and RAS vaccines corroborated 
this notion as GAP immunized animals revealed higher levels of IFN-γ producing T cells (Jobe et 
al., 2007). Furthermore, increased CD8+ T cell responses were detected in mice immunized with 
late arresting GAPs (Butler et al., 2011). Expansion of short-lived CD11ahi, CD62lo, CD44hi 
CD8b+ cells was observed in late arresting GAP immunized mice. Upon restimulation of infected 
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hepatocytes these effector cells release IFN-γ, TNF-α and IL-2 for subsequent hepatocyte 
destruction (Cooney et al., 2013). 
CD8+ T cell priming is still poorly understood and is probably based on a large set of target 
antigens that are displayed by infected hepatocytes (Hafalla et al., 2013). An interplay of cross-
presentation by DCs in different organs e.g. spleen, liver and skin-draining lymph nodes is 
certainly required for sufficient immunity (Sano et al., 2001, Chakravarty et al., 2007, Balam et 
al., 2012). Whether late arresting GAPs present an array of additional antigens leading to the 
observed superior immunity remains elusive.  
1.6 Advanced GAP research: An approach to enhanced immunity and safety 
1.6.1 GAPs with multiple gene deletion: Synergetic or antagonistic 
Development of parasite lines that harbor multiple gene deletions is likely to increase safety; 
however, whether synergistic or antagonistic effects modulate immunogenicity is less 
straightforward to predict and likely depends on the selected knockout combination. Soon after 
the first proof-of-principle studies, a GAP parasite line that harbors two consecutive gene 
deletions, namely ∆UIS3 and ∆UIS4, was engineered in P. berghei (Jobe et al., 2007). As expected, 
∆UIS3/UIS4 parasites displayed a complete arrest in early liver stages, indicating that vaccine 
strains harboring multiple independent gene deletions perform safer than single knockout GAPs. 
Importantly, long-term protection against a high-dose sporozoite challenge infection was 
induced. 
In marked contrast, when a double knockout was performed for the P. berghei paralogs P36p 
(P52) and P36, which are neighboring genes and likely arose through gene duplication, safety was 
not improved (Annoura et al., 2012), strongly suggesting that independent genes need to be 
targeted in multiple gene knockout strategies. Since ∆SLARP GAPs lead to a complete 
termination of liver stage development (Aly et al., 2008, Silvie et al., 2008), they constituted the 
obvious platform for combinations with other arresting single knockouts of the 6-Cys gene 
family (Fig. 3)(Mikolajczak et al., 2014, van Schaijk et al., 2014, Kublin et al., 2017). However, it 
remains to be shown whether addition of B9, P36, and/or P36p (P52) knockout provides any 
additional benefit beyond perception of additional gene deletions. An important investigation 
with combinatorial knockouts will be the systematic expression profiling of liver stage-specific 
genes, as was previously done for ∆SLARP parasites (Silvie et al., 2008). Such an analysis will 
provide first insights into the expected antigenic repertoire displayed by the respective GAPs. 
Instead of adding additional gene deletions, which might not add significantly to vaccine efficacy, 
the combination of a gene deletion with transgene expression of additional factors could amplify 
antigen presentation during pre-erythrocytic development. However, a principal concern in 
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gain-of-function mutants is that parasites containing mutations in the transgene promoter and 
other regulatory elements, which lead to a reduced transgene expression, will be swiftly selected. 
Therefore, GAPs that express additional Plasmodium antigens in order to broaden the 
immunogenic repertoire without further reducing parasite fitness might be a particularly 
rewarding research direction. 
1.6.2 Immunogenicity vs. safety: Taking a closer look at two promising vaccine 
candidates 
Promising induction of immune responses by GAP vaccines were first received with ∆P36p, the 
paralogue gene ∆P36 immunization or a combined ∆P36p/P36 parasite line (van Dijk et al., 
2005). These two genes belong to the Plasmodium-specific-6-Cys gene family and are likely 
contributing to the selective CD81-independent hepatoma cell entry in P. berghei (Manzoni et 
al., 2017). A potential, albeit untested, advantage of 6-Cysteine protein based GAPs is enhanced 
antigen presentation via MHCI on infected hepatocytes, since maintenance of the 
parasitophorous vacuole is impaired (Table 1). Perhaps even more importantly, the propensity to 
increase apoptosis in ∆P36p-infected hepatocytes (van Dijk et al., 2005) might enhance cross 
priming by dendritic cells (DCs) that phagocytose apoptotic bodies (Leiriao et al., 2005), 
although this conjecture remains controversial (Renia et al., 2006).  
Unfortunately, despite favorable immune responses, as seen in ∆UIS4/UIS3 parasites, occasional 
breakthrough infections limit the vaccine potential of this parasite line (Table 1, van Dijk et al., 
2005). However, only the knockout of one candidate transcript of the sporozoites containing a 
targeted deletion of a master regulator of liver stage development SLARP, Sporozoite and liver 
stage Asparagine-Rich Protein, has so far been proven to arrest fully in liver stages in both 
animal models and humans (Aly et al., 2008, Silvie et al., 2008). The drawback of the early arrest 
of ∆SLARP parasites lies within a decreased potent immunity against follow-up infections (Table 
1, Silvie et al., 2008). To improve GAP safety and efficacy, several double and triple knockout 
GAPs have been engineered in P. yoelii and P. falciparum (Mikolajczak et al., 2014, van Schaijk et 
al., 2014, Kublin et al., 2017).  
Table 1 Features of ∆SLARP and ∆P36p vaccine candidates 
 ∆SLARP ∆P36p 
Attenuation (safety) complete breakthrough 
infections 
PVM (establishment, remodeling 
and maintenance) 
establishment but no 
remodeling 
no PVM 
Protection after immunization partial  sterile  
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The first human clinical phase I trial was recently conducted with a P. falciparum 3KO GAPs 
missing the paralog genes P52 (P36p) and P36 and in addition SLARP (Kublin et al., 2017). The 
study showed complete arrest of the 3KO GAP in humans (<10) and mice in the CSP-response 
dominated BALB/c P. yoelii model (<30). Immunization/challenge studies in BALB/cJ mice 
revealed complete protection after 7, 30 and 180 days post immunization (Kublin et al., 2017). 
However, sufficient pre-clinical data of this 3KO GAP remains elusive. In particular, studies 
using the P. berghei C57BL/6 model that mimics the human MHCI epitope situation of a 
combination of epitope specific CD8+ T cell responses for protection. GAPs are not only eliciting 
antibody responses against sporozoites and intra-hepatic stages but also contribute to CD8+ T 
cell mediated protection against liver stages (Kreutzfeld et al., 2017). It is critical for a sufficient 
long-term potent immunity to take the CD8+ T cell mediated response into consideration. 
Studies of CD8+ T cells responses in humans are difficult; therefore, to study CD8+ T cells 
responses, pre-clinical studies in mice are unavoidable. By generating a triple genetically 
attenuated parasite line in P. berghei potent immunity mediated by antibody and CD8+ T cell 
responses as well as safety could be studied. 
1.7 Protein export in Plasmodium: Remodeling the host cell from inside out 
1.7.1 Plasmodium's export machinery 
Asexual development inside a parasitophorous vacuole in intra-erythrocytic as well as intra-
hepatic stages requires the parasite to remodel its host cell for survival and rapid replication. 
Insertion of pores into the PVM to uptake nutrients and dispose waste is key for parasite 
survival, especially in intra-erythrocytic development where the parasite is required to remodel 
its host cell as essential cell mechanisms in nucleated cells are missing. Therefore, the parasite 
exports a large set of proteins to remodel the host cell for its purposes. The exportome of 
Plasmodium is believed to be 10% of its whole proteome (Spielmann & Gilberger, 2015).  
To export proteins across two membranes, plasma membrane and parasitophorous vacuole 
membrane, a tight processing pathway is required. Proteins destined for export travel from the 
endoplasmic reticulum (ER) to the PV in a poorly understood manner (Fig. 6). Plasmodium 
export element (PEXEL) comprising of a RxLxE/Q/D sequence located downstream of the ER 
signal sequence, was determined to be the key export label in proteins sequences (Hiller et al., 
2004, Marti et al., 2004). Early studies with PfKHARP (knob-associated histidine-rich protein) 
GFP chimaeras confirmed the notion that an amino-terminal signal sequence is required for ER 
entry, suggesting that a further downstream sequence is required for PVM translocation 
(Wickham et al., 2001). Interestingly, studies revealed that a change in amino acid residues from 
arginine or leucine to alanine trapped the export protein in the ER or PV (Marti et al., 2004). 
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Upon ER entry the PEXEL motif is cleaved downstream of the leucine residue by Plasmepsin V, 
an aspartyl protease, as the new N-terminus is acetylated (Chang et al., 2008, Boddey et al., 2009, 
Boddey et al., 2010, Russo et al., 2010, Marapana et al., 2018). Recently, Marpana et al. reported 
that Plasmepsin V binds several proteins forming a unique complex to enable ER entry of cargo 
proteins destined for export, which is distinct from secretory pathway (Marapana et al., 2018). It 
remains unclear how exported proteins can thereafter be recognized as distinct export signals are 
missing after cleavage. However, a class of exported proteins does not harbor a PEXEL motif, 
termed PEXEL independent export proteins (PNEPs), but rather uses an internal transmembrane 
segment as ER entry signal (Spielmann & Gilberger, 2010, Kulzer et al., 2012, Boddey et al., 
2013). Surprisingly, REX2 (ring export protein 2), a PNEP protein, was shown to be N-terminally 
processed independent of Plasmepsin V, suggesting that the sequence right downstream of 
PEXEL might also play an important role in targeted export (Haase et al., 2009, Gruring et al., 
2012). Processed proteins are believed to be loaded into secretory vesicles to be transported and 
released into the PV. 
 
Figure 6 PTEX-dependent export in blood stages and the PTEX export machinery 
Host cell remodeling requires export of parasite proteins eg. knob-associated proteins for knob assembly 
and cell adherence via the PfEMP1 complex. Proteins destined for export are processed in the ER, 
deposited in export zones in the PV and translocated into the host cell cytoplasm by a protein translocon 
termed PTEX. Refolding of proteins is possibly taking place in parasitic compartments of the iRBC (J 
dots). PTEX is composed of three core components EXP2, PTEX150 and HSP101. EXP2 is the membrane 
spanning protein, PTEX150 has a structural component linking EXP2 and HSP101 and HSP101 is a AAA+ 
ATPase unfolding and translocating proteins across the PVM. Two other auxiliary proteins TRX2 and 
PTEX88 are involved in protein unfolding and help to transport specialized subsets of cargo, respectively 
(modified from Desai & Miller, 2014, de Koning-Ward et al., 2016). 
Once in the PV, proteins need to cross the PVM to reach the host’s cells cytoplasm. As 
erythrocytes are deficient of translocons and can therefore not be scavenged by the parasites, a 
parasitic PVM translocon (PTEX) was identified (Fig. 6, de Koning-Ward et al., 2009). Studies in 
human and rodent Plasmodium revealed that the complex is comprised of five proteins of which 
three are core proteins (EXP2, HSP101, PTEX150) and two are non-essential (PTEX88, TRX2) 
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(de Koning-Ward et al., 2009, Matthews et al., 2013, Matz et al., 2013). These proteins seem to be 
Plasmodium specific with very little structural evidence of orthologs in other Apicomplexa (Ho et 
al., 2018). HSP101, the motor of the complex, is a Cl1 AAA+-ATPase harboring a cargo-binding 
pore loop at the N-terminal end and is most likely responsible for protein unfolding and active 
translocation through the complex (Fig. 6, de Koning-Ward et al., 2009, Beck et al., 2014, Ho et 
al., 2018). In contrast, EXP2 plays a central role as a membrane-spanning component, but 
simultaneously acts as nutrient channel in a PTEX-independent manner (Fig. 6, Garten et al., 
2018). There is little evidence of functional domain in PTEX150, however, recent studies 
confirmed early assumptions that PTEX150 plays a structural role linking EXP2 and HSP101 
(Fig. 6, Bullen et al., 2012, Elsworth et al., 2014, Garten et al., 2018). Knockout studies of all core 
components in human and rodent Plasmodium species corroborated the importance of these 
proteins for parasite blood stage survival (Matthews et al., 2013, Matz et al., 2013, Beck et al., 
2014, Elsworth et al., 2014). The roles of Trx2 and PTEX88 in protein translocation are poorly 
understood, however, knockout of Trx2 led to a prolonged cell cycle and reduced parasitic 
surface proteins on iRBCs indicating that Trx2 might help unfolding cargo proteins by reduction 
and oxidation of disulfide bonds (Matthews et al., 2013, Matz et al., 2013, Elsworth et al., 2014). 
PTEX88 knockout resulted in normal life cycle progression but reduced experimental cerebral 
malaria cases and cytoadherens was observed in knockout parasites, thus possibly helping 
HSP101 in specific protein translocation important for virulence of the parasite (Matz et al., 
2015, Chisholm et al., 2016, Chisholm et al., 2018). Protein translocation seems to be an interplay 
of many proteins, further transient protein involvement has been predicted for PV1 
(parasitophorous vacuolar protein 1) as a dense granule protein facilitating export of specific 
cargos and Pf113 to define export zones in the PV. Whether HSP70-x a heat-shock-protein helps 
to pull proteins through the PTEX complex remains controversial (Elsworth et al., 2016, Cobb et 
al., 2017, Matz & Matuschewski, 2018, Morita et al., 2018). 
1.7.2 Export in blood stages 
Plasmodium is among very few parasites which have evolved to replicate in a non-nucleated cell. 
To modulate the cell to its purposes specific exported proteins are required which are particularly 
important for cell rigidity and virulence. It is believed that 25% of the exportome are essential for 
parasite survival in blood stages (Maier et al., 2008). 
PTEX components are stored in granules, which are released upon merozoite invasion of RBCs 
and immediately initiate PTEX formation. Exported proteins have three distinct destinations in 
the host cell i) the Maurer’s clefts ii) soluble proteins the cytoplasm or iii) the membrane 
cytoskeleton. Upon translocation proteins might be transported in a vesicle-independent manner 
through the erythrocytes’ cytoplasm as chaperon-associated transport complexes (Knuepfer et 
Introduction 
  22 
al., 2005, Knuepfer et al., 2005). How exported proteins are refolded still remains elusive, 
however, there is strong evidence that parasitic chaperons in cytoplasmic J-dot structures, with 
the help of host chaperons, mediate this process (Kulzer et al., 2010). Of particular interest are 
the so-called knob structures at the erythrocytic membrane, which mediate sequestration of the 
parasite to vascular endothelial cells to avoid splenic macrophage killing (Fig. 6). These knob-
like protrusions are assemblies of the KAHRP protein linked to the host cell cytoskeleton 
(Watermeyer et al., 2016) where EMP1, a PEXEL-independently exported protein, is inserted 
into the blood cell membrane to mediate cell adherence (Kriek et al., 2003). Parasites deficient of 
knobs reveal a decreased cytoadherence, which can be potentially mediated by blocking PEXEL-
dependent KHARP export (Crabb et al., 1997, Glenister et al., 2002).  
1.7.3 Export in liver stages 
Most of our knowledge on protein export is derived from the intra-erythrocytic stage and liver 
stage export remains largely elusive. As metabolically active cells, hepatocytes enable the parasite 
to exploit the host cell limiting the need for intensive remodeling and thus directing energy into 
extensive growth (Prudencio et al., 2006). Moreover, hepatocytes harbor an active MHCI 
pathway with the potential to present parasitic antigens to the host’s immune cells (Chakravarty 
et al., 2007). To avoid recognition by the host, the parasite might keep protein translocation 
during early to mid liver stage development to a minimum. To date only peptides of sporozoite 
origin could be identified on MHCI expressing cells (Bongfen et al., 2007, Hafalla et al., 2013, 
Muller et al., 2017). Recently the first liver stage specific peptide Kb-17 was identified but its 
influence on protection remains to be determined (Pichugin et al., 2018).  
Only two proteins are reported to translocate during liver stage growth: CSP and LISP2 (Singh et 
al., 2007, Orito et al., 2013). CSP export remains controversial, while Singh et al. suggested that 
CSP is localizing to and around the host nucleus 2-6 hours post infection (p.i.) (Singh et al., 
2007), Cockburn et al. could not confirm these observations 6 hours p. i. (Cockburn et al., 2011). 
As a major surface antigen of sporozoites, CSP might be already released into the host’s 
cytoplasm during sporozoite entry. Corroborating this notion, studies demonstrated that CSP is 
constantly shed during sporozoite transmigration and released into traversed cells where it 
localizes to the host’s nucleus to redirect host immune responses to traversed but not infected 
cells. In contrast, LISP2 is the only liver stage protein exported during liver stage development. 
Immunofluorescence assays with LISP2 antibodies demonstrated onset of export at 24 hours post 
infection. However, parasites harboring a C-terminal mCherry tagged LISP2 failed to export the 
tagged protein to the hepatocyte cytoplasm (Orito et al., 2013), possibly due to C-terminal 
processing of LISP2. Sequence analysis revealed that LISP2 harbors a PEXEL motive and is 
additionally cleaved on both sides, confirming the observations made by Orito et al. (personal 
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communication Melanie Shears, John Hopkins School of Medicine). It will be of great interest 
whether the potential liver stage exportome is processed differently to blood stages exported 
proteins. 
Further experimental genetics revealed similar restrictions in liver stage export. Fusion of the 
CSP PEXEL motif to truncated OVA (ovalbumin) and infection with these transgenic parasites 
increased CD8+ T cell proliferation but failed to induce export (Montagna et al., 2014). Similarly, 
mCherry fused to CS-PEXEL or IBIS-PEXEL under the control of liver stage promoters IBIS or 
UIS4 remained in the PV during liver stage development in vitro (Josephine Grützke, MPIIB, 
PhD thesis 2015). 
Strikingly, during liver stage maturation, HSP101 is not expressed until 48 hours post infection, 
whereas all other PTEX components are present (Matz et al., 2015), offering a potential 
explanation why liver stage export seems to be restricted or is limited to yet unidentified 
proteins. Unraveling processes involved in pre-erythrocytic protein translocation or potential 
substitution of HSP101 would significantly impact our current knowledge of liver stage export. 
Of interest would be whether increasing export in early liver stages would lead to increased 
parasite-recognition by presentation of parasite-derived epitopes via MHCI and consequently 
upscaling immune responses. 
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1.8 Aim of the study 
Immunity against malaria infections can be achieved by various whole sporozoite vaccine 
approaches, which have previously been shown to be effective in non-human primates, humans 
and rodents. Targeted deletion of liver stage genes enables specific liver stage arrest of parasites, 
which can serve as metabolic active live attenuated vaccines. These genetically attenuated 
parasite (GAP) vaccines enable development of pre-erythrocytic immunity and therefore hinder 
the onset of symptomatic blood stage infections after sporozoite challenge. Considerable 
numbers of GAP-based candidates have been successfully tested, however, drawbacks in safety or 
efficacy kept the search going for the “one” perfect GAP-based vaccine candidate.  
Two GAPs displaying different required vaccine features are of particular interest. ∆SLARP 
parasites were the first and remain the only GAPs to induce complete arrest of liver stages, 
probably induced by down regulation of important liver stage genes, making it a perfect vaccine 
candidate. However, sterile protection was absent in immunized mice a sign of inferior vaccine 
efficacy. On the other side of the spectrum are ∆P36p/P36 parasites, a double knockout of two 
neighboring paralog genes required for PVM establishment, which elicit sterile protection, but 
occasional blood stage breakthrough infections limit the use as potential vaccine candidate. By 
combining these two knockouts, I hoped to increase safety and efficacy of GAP-based vaccine 
candidates. To determines whether triple knockout (tKO) GAPs are superior to other GAP 
candidates, the following questions were asked, whether: 
i) safety requirements are fulfilled in tKO GAPs 
ii) immunizations with tKO GAPs confer sterile protection against Plasmodium  
challenge 
iii) underlying immune mechanism can be deciphered and correlated with  
protection 
It still needs to be determined, whether late arresting parasites confer better protection. It is 
hypothesized that better induction of immune responses in later liver stages is among other 
factors realized by an increased parasitic antigenic display via MHCI to the host’s immune 
system. Parasites harbor an export complex, termed PTEX, responsible for targeted protein 
export in blood and late liver stages. Expression of a core component; HSP101, is absent in early 
liver stages, perhaps limiting protein export during this stage of the life cycle. Whether this is a 
way for the parasite to hide from the host’s immune system remains elusive. The prospect of 
restoring protein export in early liver stages by overexpressing HSP101, might lead to increased 
protein export and in consequence antigen presentation by infected liver cells, which in turn 
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could promote immune cell priming and subsequent protection against sporozoite challenge 
(Fig. 7). The aim of the study was to determine whether HSP101: 
i) overexpression interferes with Plasmodium life cycle 
ii) is the limiting factor for liver stage protein export 
iii) liver stage overexpression and concomitant PTEX reconstruction leads to 
increased immunity against re-infections 
 
 
Exploring two different approaches on increasing pre-erythrocytic immunity by GAP-based 
vaccination might give a novel insight into pre-erythrocytic host-parasite interplay and 
underlying immune mechanisms to sterile protection. 
Figure 7 Hypothesis of early liver stage 
export 
Protein export in early liver stages is 
absent in P. berghei parasites (red). 
Proteins destined for export (red dots) 
cannot cross the PVM. A transgenic 
parasite overexpressing HSP101 (green) 
could restore the complex and onset 
protein export (green dots). Parasitic 
protein could be processed and peptide 
presented to CD8+ T cells in an MHCI 
dependent manner. This could potentially 
lead to increased protection against 
follow-up infections. 
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2 Material and Methods 
2.1 Materials 
The laboratory work was conducted at the Max Planck Institute of Infection Biology, Berlin and 
Humboldt University, Berlin. The following is a combined collection of materials used in both 
laboratories. 
2.1.1 Biological resources 
Animals / cells  Source 
Mus musculus Naval Medical Research 
Institute (NMRI) mice 
Charles River Laboratories, Germany 
Mus musculus C57BL/6  Charles River Laboratories, Germany 
Janvier LABS, Germany 
Anopheles stephensi Nijmegen, Netherlands (Janse et al., 
2006) 
Plasmodium berghei ANKA-GFP507 cl  Nijmegen, Netherlands (Janse et al., 
2006a) 
Plasmodium berghei ANKA  Nijmegen, Netherlands (Janse et al., 
2006a) 
Plasmodium berghei ANKA bergreen  Nijmegen, Netherlands (Janse et al., 
2006a, Kooij et al., 2012) 
Huh7 human hepatoma cells  
Escherichia coli XL-1 Blue  Stratagene, Germany 
Escherichia coli XL-10-Gold Stratagene, Germany 
2.1.2 Laboratory equipment 
Instruments Company 
Agarose Gel Casting System Horizon 11-14 Biometra, Germany 
Owe Scientific Inc. 
Electrophoresis power supply  Amersham Pharmacia Biotech, UK 
Agarose gel EPS 200, power supply Pharmacia Biotech 
Gel documentation system Gel Doc 2000 Bio-Rad, Germany 
Magnetic stirrer, Yellow MAG MS7  IKA laboratory equipment, Germany 
Amaxa Electroporator  Amaxa, Germany 
Bench top centrifuge 5424  Eppendorf, Germany 
5415R Refirgerated Centrifuge Eppendorf, Germany 
Megafuge 1.OR, Thermo Scientific  Heraeus, Germany 
Multifuge X1, Thermo Scientific  Heraeus, Germany 
Mini centrifuge Heathrow Scientific 
Fridge 4°C  Liebherr, Germany 
Freezer -20°C  Liebherr, Germany 
Freezer -80°C  Heraeus, Germany 
Ice machine AF 200  Scotsman ICe Systems, USA 
Nitrogen cavitation chamber  Parr Instrument Company, USA 
Heating Block, Thermo Scientific  Eppendorf, Germany 
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Incubator for cell culture  Heraeus, Germany 
Incubator P. berghei cultures  Mytrom, Germany 
Incubator E.coli  Heraeus, Germany 
Incubator and shaker for liquid E.coli 
cultures (Innova 4000) 
New Brunswick Scientific 
Mice facility incubator Ehret, Germany 
Vortex-Genie2  Scientific Industries, USA 
Rocking platform, Rotamax 120  Heidolph Instruments, Germany 
Shaker DRS-12 Heraeus, Germany 
Micropipettes (Gilson)  Abimed, Germany 
Pipetus®  Hirschmann Laborgeräte, Germany 
Mosquito cages  BioQuip Products Inc, USA 
Mice cages Ehret, Germany 
Nanodrop ND 1000  peQLab, Germany 
Hemocytometer  Marienfeld, Germany 
PCR Thermocycler, MJ-mini  Bio-Rad, Germany 
pH-meter  Mettler Toledo, Germany 
Sterile bench, Herasafe KS12  Heraeus, Germany 
Scale MXX-212 and SI-64  Denver Instrument, USA 
Balances Sartorius, Germany 
Binocular, M80, MZ10F  Leica, Germany 
BX50 fluorescence microscope Olympus, Germany 
DM LS microscope Leica, Germany 
EOS700D camera Canon, Japan 
Leica DM2500 brightfield microscope Leica, Germany 
Axio Observer Z1 inverted fluorescence 
microscope with AxioCam MRm  
Zeiss, Germany 
AnxiioCam MRm Zeiss, Germany 
Axio Observer Z2 Zeiss, Germany 
Microscope (cell culture) DMIL LED  Leica, Germany 
Vortex-Genie 2  Scientific industries 
HERAsafe KS12 KS Sterile hood  Thermo Scientific 
Water bath  GFL, Germany 
PCR machine, MJ Mini™  Bio-Rad, Germany 
Thermal cycler, MJ Mini, Gradient Bio-Rad, Germany 
MACSQuant® benchtop Flowcytometer Miltenyi Biotec, Germany 
BD FACS –CantoII Flowcytometer BD Bioscience, Germany 
BD FACS – Aria cell sorter BD Bioscience, Germany 
2.1.3 Laboratory materials 
Consumables Company 
6-well plate  Greiner Bio-One, Germany 
Sarstedt, Germany 
24-well plate  Greiner Bio-One, Germany 
Sarstedt, Germany 
48-well plate  Greiner Bio-One, Germany 
Sarstedt, Germany 
Cell culture flask (T-25 and T-75)  Greiner Bio-One, Germany 
Microplate 96-well, μ-clear (U-bottom)  Greiner Bio-One, Germany 
Microplate 96-well, μ-clear (V-bottom)  Greiner Bio-One, Germany 
8-well glas bottom chamber slides, LabTek  Nunc, Thermo Fischer, Germany 
8-well plastic bottom chamber slides, Nunc, Thermo Fischer, Germany 
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LabTek  
μ-slide, 8-well  ibidi Germany 
Round glas cover slips  Roth, Germany 
Petri dishes Greiner Bio-One, Germany 
Cover slips  Roth, Germany 
Corning BioCoat Cellware, USA 
Cryo-freezing tubes  Greiner Bio-One, Germany 
Electroporation cuvettes  Amaxa, Germany 
Eppendorf tubes, 1.5 ml  Eppendorf, Germany 
Sarstedt, Germany 
Eppendorf tubes, 2 ml  Eppendorf, Germany 
Sarstedt, Germany 
PCR tubes  Greiner Bio-One, Germany 
Sarstedt, Germany 
FACS tube Sarstedt, Germany 
Falcon blue cap tubes (50 mL and 15 mL)  Greiner Bio-One, Germany 
Forceps  Neolab, Germany 
FST by DUMONT 
Glass slides, clear  Menzel, Germany 
Microscope oil  Zeiss, Germany 
Needles, sterile (0,4 x 20 mm) Braun, Germany 
Needles, sterile (0,6 x 25 mm) Henke-Sass Wolf, Germany 
Omnifix ®-F Syringes 1ml  Braun, Germany 
Inject ® Syringes 5 ml Braun, Germany 
Syringes, insulin Braun, Germany 
Serological pipettes (5, 10 and 25 mL)  Greiner Bio-One, Germany 
Sterile filter (0.2 and 0.4 mm)  Millipore, Ireland 
Sterile filtration units (500 mL)  NALGENE®, USA 
Filtration bottle Rapid Flow Thermo Scientific, USA 
Pipette tips  Brand GMBH, Germany 
Sarstedt, Germany 
Pasteur pipettes  Roth, Germany 
Cell strainer  BD Bioscience, USA 
Bel Nature cotton Hartmann, Germany 
2.1.4 Chemicals 
Reagents Company 
1 kb DNA-Ladder MBI Fermentas, Thermo Fischer, USA 
GeneRuler 1kb Plus DNA Ladder  MBI Fermentas, Thermo Fischer, USA 
6 x DNA loading dye  MBI Fermentas, Thermo Fischer, USA 
Agarose  Invitrogen, Germany 
Alsever’s solution  Sigma-Aldrich, Germany 
Ammonium persulfate (APS) Roth, Germany 
Albumin fraction  Roth, Germany 
Ampicillin  Roth, Germany 
LB-Agar powder (Lennox L Agar)  Invitrogen, Germany 
Cellulose (Carboxymethyl)  Sigma-Aldrich, Germany 
Cutsmart Restriction Enzyme Buffer New England BioLabs, USA 
SYBR Safe DNA Gel stain  Invitrogen, Germany 
Dulbecco's modifiec Eagle Medium (DMEM) GibcoBRL, Germany 
DMSO (Dimethyl sulphoxide)  Merck, Germany 
dNTP-mix  MBI Fermentas, Germany 
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FCS (Fetal Calf Serum), certified (USA)  Gibco Invitrogen, Germany 
FCS Gibco  Invitrogen, Germany 
PAN-biotech, Germany 
Fluoromount G  Southern Biotec, USA 
Fibrous Cellulose Powder  Whatman, United Kingdom 
Sigma-Aldrich Germany 
Formaldehyde  Merck, Darmstadt Germany 
Formaldehyde 16%, MeOH-free  Polyscience Germany 
Gentamycin  Invitrogen, Germany 
Gibco, Life Technologies Germany 
Giemsa stain  VWR Germany 
Glass beads, unwashed  Sigma-Aldrich, Germany 
Glucose  Merck, Germany 
Glycerol  Roth, Germany 
Heparin  Ratiopharm, Germany 
HEPES  Merck/Calbiochem, Germany 
HCl Roth, Germany 
Immersion oil Roth, Germany 
Isoflurane  Baxter, Germany 
Methanol Thermo Scientific 
NaOH Merck, Germany 
Nycodenz density gradient medium Axis Shield, Norway 
Phalloidin 1:50 Molecular Probes, Netherlands 
Paraformaldehyde powder Merck, Germany 
Percoll GE Healthcare, USA 
PBS, sterile solution  Gibco Invitrogen, Germany 
PBS, tablets  Gibco Invitrogen, Germany 
Penicillin-Streptomycin, liquid  Invitrogen, Germany 
Pyrimethame  Sigma, Germany 
RPMI 1640-medium  GibcoBRL, Germany 
Saponin  Sigma, Germany 
Sodium chloride  Roth, Germany 
Sodium acetate  Roth, Germany 
Ambion, Germany 
Sodium hydrogencabonate  Roth, Germany 
SYBR Safe DNA Gel stain  Invitrogen, Germany 
SOC Outgrowth Medium New England Biolabs 
Tris (hydoxymethyl)aminomethane (TRIS)  Roth, Germany 
Trypsin-EDTA  Invitrogen, Germany 
Triton X-100  Roth, Germany 
Tween 20  Roth, Germany 
ß-Mercaptoethanol Sigma-Aldrich, Germany 
L-Glutamine  Gibco, Life technologies, Germany 
Anti-Anti  Gibco, Life technologies, Germany 
Glycine  Roth, Germany 
Ethanol, absolute AppliChem, Germany 
Hoechst 33342  Invitrogen, Germany 
Nocodazole  Calbiochem, Merck, Germany 
Brefeldin A (1:1,000) AppliChem, Germany 
Glutaraldehyde  Sigma-Aldrich, Germany 
2-Propanol Rotipuran  Roth, Germany 
BD Wash  BD Bioscience, Germany 
Trizol  Invitrogen, Germany 
Perm-Wash Buffer BD Bioscience, Germany 
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2.1.5 Commercial kits 
Kits Company 
Human T Cell Nucleofector Kit  Lonza, Germany 
QIAprep Spin Miniprep Kit  QIAGEN, Germany 
QIAprep Spin Midiprep Kit Q QIAGEN, Germany 
QIAamp DNA-Blood Mini Kit  QIAGEN, Germany 
QIAquick PCR Purification Kit  QIAGEN, Germany 
QIAquick Gel Extraction Kit  QIAGEN, Germany 
Rapid DNA Dephos & Ligation Kit  Roche, Switzerland 
Rapid DNA Ligation Kit  Roche, Switzerland 
Taq PCR Kit  Thermo Scientific, Germany 
2.1.6 Antibodies and peptides 
IFA antibodies Company 
Anti-mCherry (rat) 1:500  Chromotek, Germany 
Anti-c-Myc (clone 9E10) (mouse) 1:500 Santa Cruz Biotechnology, Germany 
Anti- P. b. HSP70 (mouse) 1:500  Tsuji, M; NYU 
Anti- P. b. UIS4 (1165) (rabbit) 1:500  (Muller et al., 2011) 
Anti-GFP (chicken) 1:1,000  Abcam, Germany 
Anti-MSP1 (mouse) 1:500 Prof. Dr. A. Holder, National Institute  
for Medical Research, London,UK 
Anti- P. b. CSP 1:500  (Yoshida et al., 1981) 
Anti-sporozoite surface antigens (polyclonal) 
1:300 
2x WT immunized mice 
Anti-LC3 1:100  Nanotools 
Anti mouse/rabbit/rat/chicken Alexa 546-, 
Alexa 594-, Alexa 488- or Alexa-633- 
conjugated secondary antibodies 1:1,000 
Invitrogen, Germany 
Hoechst 33342 1:5,000 Invitrogen, Germany 
 
FACS antibodies Company 
CD3 (500A2) – PerCP-Cy7 eBioscience, Germany 
CD8 (53.-6.7) – PerCP-Cy5.5 eBioscience, Germany 
CD8 (53.-6.7) – PO eBioscience, Germany 
CD11a  (M17/4) – e450 eBioscience, Germany 
IFN-γ (XMG1.2) – APC eBioscience, Germany 
IFN-γ (XMG1.2) – PE eBioscience, Germany 
TNF-α (MP6-XT22) – FITC eBioscience, Germany 
FITC-Dextran Invitrogen, Germany 
 
Peptides Sequence Company 
PbTRAP130-138 SALLNVDNL Peptides & Elephants, Germany 
PbS20318-326 VNYSFLYFL Peptides & Elephants, Germany 
OVA257-264 SIINFEKL Peptides & Elephants, Germany 
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2.1.7 Enzymes 
Enzymes Company 
Restriction endonucleases  New England Biolabs, Fermentas 
T4-DNA-Ligase  Fermentas, Germany 
Taq DNA Polymerase  Fermentas, Germany 
Platinum Taq DNA Polymerase (HF)  Invitrogen, Germany 
Dream Taq Thermo Fisher, Germany 
2.1.8 Stocks and working solutions 
Nycodenz stock (autoclaved, protected from light): 
KCl 3 mM (250 mM stock) 
EDTA 0.3 mM (0.5 M stock) 
Tris pH 7.5, 5 μM 
Nycodenz 110.4 g 
ddH2O to 400 ml 
Solution stored at 4°C 
Lysogeny Broth (LB) medium (pH 7.5): 
Bacto-tryptone 10 g 
Bacto-yeast extract 5 g 
NaCl 5 g 
ddH2O to 1,000 ml 
Medium stored at RT 
LB-Agar: 
LB-Medium 1,000 ml 
Bacto-Agar 15 g 
Solution stored at 4°C 
Transfection Medium: 
RPMI1640 160 ml 
FCS (origin USA) 40 ml 
Gentamycin 50-60 μl 
Solution stored at 4°C 
Pyrimethamine H2O (pH 3.5 - 4.5): 
Pyrimethamine 0.35 g 
DMSO 50 ml 
H2O add 5 L 
Solution stored at RT (in the dark) 
Heparin/PBS: 
Heparin 40 μl 
PBS 960 μl 
Solution stored at 4°C 
Ketamine/Xylazine hydrochloride: 
Ketamine (100 mg/ml) 1 ml 
2 % Rompun (Xylazine) 150 μl 
1x PBS 2.85 ml 
Solution stored at 4°C 
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4% Paraformaldehyde (pH 7.2) 
Paraformaldehyde powder 20 g  
NaOH 2M 10 μl (clear solution) 
10x PBS 50 ml pH 7.2  
ddH2O add 100 ml (55-60°C) 
Solution stored at -20°C (long-term)/4°C (short term) 
50x TAE-buffer (pH 7.8) 
Tris 2 M 
Sodium acetate 250 mM 
EDTA 0.5 mM 
Solution stored at RT 
Freezing solution  
Alsever’s Solution 90 ml  
Glycerol 10 ml  
Solution stored at 4°C 
Percoll solution 
RPMI complete (37°C) 27.1 ml  
Percoll (37°C) 14.2 ml 
10x PBS (autoclaved, 37°C) 1.6 ml 
2.1.9 DNA oligonucleotides 
2.1.9.1 Cloning primers 
Number Purpose Restriction 
site 
Sequence 
1 5’ UIS4 fwd BssHII CATGAGCGCGCCTTTATGTTTTTTGAAA
GATTTAAC 
2 5’ UIS4 rev XbaI GCTCATCTAGATTCAGACGTAATAATTA
TGTGCTG 
3 HSP101 ORF 
fwd 
XbaI CATCTAGAATGGTACGGAACATTGCTAA
AAATTATTTATTTG 
4 HSP101 ORF rev AgeI GCCCTTGCTCACACCGGTTGACAATGAA
AGGTTAATAACAATGTTG 
5 5’ EF1a fwd BssHII CATGAGCGCGCGATTTACATGGCGTTTT
ATGTTTATATG 
6 5’ EF1a rev XbaI GCTCATCTAGATTTTATAAAATTTTTAT
TTATTTATAAGCAAATATA 
7 linker fwd  CGAGTGGCCACGTGGCCACCAGAACCA
CCACCGGTTCATG 
8 linker rev  CATGAACCGGTGGTGGTTCTGGTGGCC
ACGTGGCCACTCG 
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2.1.9.2 Genotyping primers 
Number Purpose Locus 
/Plasmid 
Sequence 
9 5’ integration rev HSP101+++ 
(Myc) 
GCTCATCTAGATTCAGACGTAATAAT
TATGTGCTG 
10a WT fwd Silent 6 locus GACAGCGCATATGATGGATG 
11a WT rev Silent 6 locus TTTGAGAAATTGCGTATTCGTA 
12c 3 integration fwd HSP101+/ 
+++ (Myc) 
ATGAAATACCGCTCCATTTTTCC 
13 5’ integration rev HSP101+ 
(Myc) 
CATCTAGATTTTATAAAATTTTTATTT
ATTTATAAGCAAATATA 
14 3’ integration fwd  HSP101++ GACTGAGGTTGTGTGATGGC 
15 3’ integration rev  HSP101++ GAGCCAAATTGTTCAATGTTTAAT 
16 5’ integration fwd  HSP101++ CTATAAATTTAGTAGAAATGGTACGG
AAC 
17 5’ integration rev  HSP101++ GACACTTATATATTTATACTAAGTTCG 
18b 5’ Integration SLARP locus CGCTACATTATACAATGAACTTTTCC  
19c,f 5’ Integration  CAATTTGTTGTACATAAAATAGGCAG  
20c,g 3’ Integration  ATGAAATACCGCTCCATTTTTCC  
21c 3’ Integration  CCAGCTTTTATTTTCCATAATATCC  
22c WT fwd  GAGACATATCAAATAATTACTACATA
CCACC 
23c WT rev  GGGGTTCATAATTATATTTTCATTAGG
GTCC  
24b 5’ Integration P36p/P36 
locus 
AAATGTTTGTATGTTTGGAATATCAG
G  
25c 5’ Integration  TAATAATTGAGTCTTTAGTAACGAATT
GCC  
26c 3’ Integration  GATGGAAGCGTTCAACTAGCAGACC  
27b 3’ Integration  ATTCGCGTTTAATCTTTTAATTATACC  
28c WT fwd  GCCTAATGCAAAATATTATCCCGATTT
AG  
29c WT rev  GCTAGTCCTTTGTTCCCATTATATG  
30d 5’ UTR fwd UIS4 locus CAAATAATTGTGTATGTAATATTTAAG
TGTAGAATGGAAT 
31e ORF rev  UIS4 locus TAAATCATTCGGCCCATACATA 
32d 3’ UTR rev  UIS4 locus CTCTATAACATTATTTTTCCTTTTCTC
TTACTT 
a kindly provided by Prof. Dr. Taco Kooij, Radboud Institute for Molecular Life Sciences, 
Netherlands. 
b  kindly provided by Dr. Sanketha Kentirapalan. 
c  kindly provided by Dr. Katja Müller, Hu Berlin. 
d  kindly provided by Dr. Josephine Grützke. 
e  kindly provided by Dr. Alyssa Ingmundson, Hu Berlin 
f  P2 was also used as fwd primer for validating 5’ Integration in the ∆P36p/P36 parasite line. 
g  P3 was also used as fwd primer for validating 3’ Integration in the ∆P36p/P36 parasite line. 
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2.1.9.3 qRT-PCR primers 
Number Purpose Sequence 
33a HSP70 fwd GCTAACGCAAAAGCAAAGC 
34a HSP70 rev TCGGTAAAAGCTACATAGGATG 
35b UIS4 fwd CCCATTGATGAGACAAACGATTCAAAACC 
36b UIS4 rev TCCATGTTATAAACGTTATTTCCTTCACCC 
37b EF1α fwd GAAATTGAGATGGAAGGATTAACTTG 
38b EF1α rev CAATCCTCATCACTTAATCCCAC 
39c HSP101 fwd TTTGTTATTGTCTGTGCTCAAGG 
40c HSP101 rev GCAAAGGTTTTAATTGGTTATGACC 
41c PTEX150 fwd CCAAAGTTTTAGCTATTACCGC 
42c PTEX150 rev TTATTTGTGTTGCCATTGTTGCC 
43c EXP2 fwd CAACAAATATTGTAAAATGTGACGC 
44c EXP2 rev TGACTAATAATATCCACCACATACG 
45c PTEX88 fwd GAATACTTGATGAACTTCCCGG 
46c PTEX88 rev TAATCCATTATTAGCAGCCATTCC 
47c TRX2 fwd CAAGATTGGAACAAAGCAGC 
48c TRX2 rev TTGTAACAAAATGCTCATTTTTTGC 
49a Pb18 fwd AAGCATTAAATAAAGCGAATACATCCTTAC 
50a Pb18 rev GGAGATTGGTTTTGACGTTTATGTG 
51a mGAPDH fwd CGTCCCGTAGACAAAATGGT 
52a mGAPDH rev TTGATGGCAACAATCTCCAC 
53a GFP fwd GATGGAAGCGTTCAACTAGCAGACC 
54a GFP rev AGCTGTTACAAACTCAAGAAGGACC 
a  kindly provided by Dr. Katja Müller, HU Berlin. 
b  kindly provided by Prof. Dr. Olivier Silvie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, 
France. 
c  kindly provided by Dr. Joachim Matz, HU Berlin. 
2.1.10 Database and software 
2.1.10.1 Online 
PlasmoDB 
NCBI PubMed 
NCBI Blast 
GeneDB 
2.1.10.2 Software 
4Peaks 
Adobe Illustrator CS6  
ImageJ / Fiji 
Image Lab 
FlowJo 8.7.3 
GraphPad Prism 6 
Microsoft Office 2011 
Microsoft EndNote X7 
RStudio  
Serial Cloner 2-6-1 
SnapGene 
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2.2 Methods 
2.2.1 Molecular- and microbiological methods 
2.2.1.1 Plasmid design for P. berghei transfection 
2.2.1.1.1 Generation of P. berghei ∆SLARP, ∆P36p/P36, ∆SLARP/P36p/P36 knockouts  
Parasite lines were generated in P.b. ANKA clone 507 (for ∆P36p/P36) and clone 15cyl (for 
∆SLARP, ∆SLARP/P36p/P36) by double homologous recombination.  
sKO parasites: Marker-free ∆SLARP and ∆P36p/P36 parasites were kindly provided by Olivier 
Silvie (Manzoni et al., 2014, Manzoni et al., 2017). For generation of ∆SLARP, the GOMO 
plasmid comprising of 5’ and 3’ homologous sites flanking the SLARP ORF, hDHFR, as a 
selection marker and mCherry (mCh) as well as GFP as indications for positive integration of the 
plasmid was used as described (Manzoni et al., 2014). Recycled, marker free, P.b. ANKA ∆SLARP 
parasites served as recipient strain for the tKO parasite line. ∆P36p/P36 plasmids were designed 
using the pBART vector (Kooij et al., 2012) including P36p 5’ and 3’ UTR regions, a GFP cassette 
and a Toxoplasma gondii pyrimethamine selection cassette (kindly provided by Sanketha 
Kentirapalan).  
tKO parasites: Plasmids were linearized up- and downstream of 5’ and 3’ UTR homologous 
regions and integrated into ∆SLARP parasites using homologous recombination. Josephine 
Scholz performed transfection and cloning of ∆SLARP/P36p/P36 parasites. 
2.2.1.1.2 Generation of P.berghei HSP101+, HSP101++, HSP101+++ plasmids for HSP101 
 overexpression 
HSP101+/HSP101+++: Plasmids were design using the pBART-SIL6 vector (Kooij et al., 2012) 
harboring drug selectable hDHFR-yFcu cassette for positive/negative clone selection, a GFP 
under the PbHSP70 promoter for parasite life cycle analysis, a mCherry/triple c-Myc (3xMyc) 
Tag sequence for protein tagging, 3’PbPPPK-DHPS as 3’ UTR as well as two sequences for stable 
integration into the silent 6 locus. HSP101 ORF (PbANKA_0931200), generated with primers 3 
und 4, was inserted with XbaI and AgeI in front of the mCherry/3xMyc tag. For HSP101+ a 
constitutively low expression promoter 5’ EF1α (PbANKA_113330), generated with primers 5 
und 6, an for HSP101+++ liver stage specific strong expression UIS4 (PbANKA_0501200), 
generated with primers 1 und 2, were integrated with BssHII and XbaI in front of HSP101 ORF. 
mCherry was excised in HSP101+ Myc and HSP101+++ Myc plasmids and replaced by a 
sequence, generated with primers 7 und 8,  linking HSP101 ORF and 3xMyc.  
HSP101++: endogenous promoter swap plasmids were kindly provided by Joachim Matz. 
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2.2.1.2 Polymerase chain reaction (PCR) 
To amplify P. berghei gene of interest (GOI) or untranslated region of interest (UROI) for 
subsequent molecular cloning, a polymerase chain reaction (PCR) was performed. Specific 
primers (s. ch. 2.1.9.1) were designed for GOIs and UROIs. GOIs were amplified using Platinum® 
Taq Polymerase High Fidelity, which comprises a proof reading enzyme for higher fidelity. 
Reagents Concentration 
10x HiFi PCR Buffer 1x 
50 mM MgSO4 2.0 mM 
2 mM dNTP Mix  0.2 mM 
10 µM fwd primer 0.2 µM 
10 µM rev primer 0.2 µM 
P. berghei ANKA DNA <400 ng 
Platinum® Taq Polymerase High Fidelity (5U/µl) 1U/rxn 
ddH20 final volume to 50 µl 
 
Reagents for each reaction were briefly mixed, spun down and amplified using the following 
conditions:  
Step Temperature (°C) Time 
Initial Denaturation 94 2 min 
 
30 cycles 
Denaturation 94 30 s 
Annealing 55 30 s 
Extension 60 1.2 min/kb 
Final Extension 60 15 min 
Hold 4 ∞ 
   
Amplification of UROIs was performed with Dream Taq DNA Polymerase according to 
manufacturer's protocol.  
Reagents Concentration 
10x Dream Taq Buffer 1x 
2 mM dNTP Mix  0.2 mM 
10 µM fwd primer 0.2 µM 
10 µM rev primer 0.2 µM 
P. berghei ANKA DNA <400 ng 
Dream® Taq Polymerase High Fidelity (5U/µl) 1.25 U 
ddH20 final volume to 50 µl 
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Samples were briefly mixed and amplified under the following conditions: 
Step Temperature (°C) Time 
Initial Denaturation 95 5 min 
 
30 cycles 
Denaturation 95 30 s 
Annealing 55 30 s 
Extension 64 1.2 min/kb 
Final Extension 64 15 min 
Hold 4 ∞ 
   
Samples were subsequently purified with Qiagen PCR Purification kit according to 
manufacturer’s protocol.  
2.2.1.3 Agarose gel electrophoresis 
To determine whether amplification of GOI and UROI was successful, PCR products were 
separated according to bp length with agarose gel electrophoresis. Efficiency of all PCRs was 
examined on 1% agarose TAE gels (agarose, 1x TAE) run at 100 V for 40 minutes with 0.1% 
SYBR Safe, for DNA visualization, and documented with a gel documentation system. 
2.2.1.4 Enzymatic DNA restriction digest 
In order to generate customized plasmids for P. berghei transfection, PCR products and plasmid 
vectors were incubated with specific restriction enzymes to generate compatible 3’ or 5’ 
overhangs for subsequent plasmid ligation and transformation. Purified PCR products (inserts) 
and vectors were digested as follows:  
Reagents Concentration 
10x NEB Buffer 1x 
Insert/vector <800 ng 
NEB restriction enzyme 1.25 U 
ddH20 final volume to 30 µl 
 
Digestion of insert and vector DNA was performed at 37°C/50°C degrees depending on 
respective enzyme digestion conditions for 2-6 hours. Heat inactivation at >60°C for 20 seconds 
was used to terminate the enzymatic reaction. Digested samples were purified with Qiagen PCR 
Purification Kit according to manufacturer’s protocol.  
2.2.1.5 Ligation  
To generate plasmids of interest, the digested, purified vectors and inserts were ligated guided by 
newly formed compatible ends using Rapid DNA Ligation Kit according to manufacturer’s 
protocol. In brief:   
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Steps Reagents Concentration 
1 5x DNA dilution buffer 1x 
 Vector 100 ng 
 Insert 1:3 (Vector/Insert ratio) 
 distilled H20 Final volume 10 µl 
2 2x T4 Ligation buffer 1x 
3 T4 Ligase 0.01 U/µl 
 
Reaction was incubated at room temperature (RT) for 5 minutes.  
2.2.1.6 Transformation of competent E. coli bacteria 
Ligated plasmids were inserted into E. coli bacteria for growth and selection. Chemically 
competent E. coli bacteria were thawed on ice, mixed with 24 mM (final concentration) β-
mercaptoethanol and 5 µl ligation reaction and incubated for 30 minutes on ice. The bacterial 
solution was heat-shocked for 45s at 42°C and subsequently placed on ice for 2 minutes. After 
addition of 200 µl LB-medium, transformed bacteria were plated on an agarose plate (1% 
ampicillin) under sterile conditions and grown over night at 37°C. Positive bacterial clones 
harboring the desired plasmid were selected by colony PCR. 
2.2.1.7 Culturing of E. coli 
To upscale plasmid yield, plasmid harboring bacterial clones were grown over night in liquid 
cultures. Mini (5ml) or Midi (250ml) LB-cultures, were inoculated with a small amount of 
bacteria harboring the desired plasmid and grown over night at 37°C in an incubator and shaker 
for liquid E. coli cultures. Plasmids were extracted with the Qiagen Mini- or Midi Plasmid 
Extraction Kit according to manufacturer’s protocol. Subsequent restriction digest was used to 
confirm plasmid clone and the desired sequence changes were analyzed by Sanger sequencing. 
2.2.1.8 Overnight enzymatic plasmid digest 
For the transfection of P. berghei parasites plasmid DNA was linearized to produce free 5’ and 3’ 
homologous ends. Plasmids were digested over night on a shaker at 37°C.  
Reagents Concentration 
10x NEB Buffer 1x 
Final plasmid 30 µg 
NEB restriction enzyme 
(ApaLI or PvuI) 
9 µl 
ddH20 final volume to 500 µl 
 
1 µl of enzyme was added the next day and the digest was incubated for another hour. 
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2.2.1.9 DNA ethanol precipitation 
In order to obtain clean plasmid DNA for subsequent transfection of P. berghei parasites, 
plasmids underwent an ethanol precipitation step.  The digested plasmid was incubated at -80°C 
for 30 minutes with 2.5x volume of 100% ethanol and 10% (of digested plasmid solution) 3M 
natriumacetate (pH 4.8) (NaOAc). The mixture was centrifuged at 4°C for 30 minutes and the 
pellet washed with 70% ethanol. After another centrifugation the pellet was air dried and 
resolved in 10-30 µl distilled H2O to a concentration of 1 µg/µl. 
2.2.1.10 RNA isolation 
For analyzing P. berghei stage specific gene expression, parasite mRNA was extracted, serving as 
a template for subsequent cDNA amplification and qRT-PCR analysis. Parasite samples from 
different life cycle stages were mixed with 500 µl TRIzol, incubated at RT for 5 minutes, mixed 
with 200 µl Chloroform and incubated for 3 minutes at RT. After centrifugation the upper layer 
was transferred to a new eppendorf tube and mixed with 250 µl isopropanol, 60 µl 5M 
ammonium acetate (pH 7) and 1.5 µl glycogen and incubated at –20°C for 20 minutes to 
precipitate RNA. Pelleted samples were washed with ice-cold 70% ethanol and the air-dried pellet 
resuspended in 30 µl RNase/DNase-free water. RNA samples are subsequently treated with 
DNase to removal traces of DNA. 
2.2.1.11 Complementary DNA (cDNA) synthesis 
mRNA samples were reverse-transcribed into cDNA for quantitative real-time PCR analysis. 
cDNA was synthesized with Ambion RETRO Script kit according to manufacturer’s protocol 
using 5 µl RNA template. Samples were incubated at 42°C for 60 minutes followed by 10 minutes 
at 90°C. 
2.2.1.12 Quantitative real-time PCR (qRT-PCR) 
Rapid real time quantification of parasite specific gene expression was used to determine parasite 
burden in liver and stage specific gene expression in transgenic and WT parasites. qRT-PCRs 
were performed in optical 96-well plates in triplicates. 
Reagents Concentration 
SYBR GREEN I Master Mix 6.25 µl 
cDNA sample (dilution 1:30) 5 µl 
100 µM fwd primer 0.025 µl 
100 µM rev primer 0.025 µl 
distilled H20 0.75 µl 
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Gene specific primer combinations (s. ch. 2.1.9.3) were used to amplify ~100-200 bp fragments 
for target gene ORFs. Simultaneous amplification of a house-keeping gene (e.g. PbHSP70, 
mGAPDH) enabled determination of ∆CT for relative (m)RNA expression. An additional sample 
without cDNA was used as a negative control. Samples were processed as follows: 
Step Temperature (°C) Time 
Initial Denaturation 95 15 min 
 
40 cycles 
Denaturing 95 15 s 
Annealing 55 15 s 
Extending 65 45 s 
Final extension 64 15 
Denaturation  
Melt curve 
 
95 15 s 
Annealing 60 1 min 
Melting 95 15 s 
   
Data was analyzed with Excel 2011. Quantity was calculated by using ∆∆Ct method comparing nr 
of cDNA copies of GOI compared to endogenous cDNA. ∆∆𝐶𝑡 = 2!∆!"  !!"#$%$$&'()  !"#"!  ∆!"  !"#$%!  !"#"    
2.2.1.13 DNA isolation 
Parasite DNA was extracted from blood stage cultures for genotyping transgenic parasite lines 
and for amplification of parasite specific GOIs and UROIs from WT genomic DNA. Infected 
blood was retrieved by tail vein puncture or heart puncture and washed once with 1x PBS. To 
rupture the red blood cells the sample was incubated with 0.2 Saponin and centrifuged at 2800 
rpm for 8 minutes. The pellet was washed until the color of the supernatant was clear and 
resuspended in 200 µl 1x PBS. Parasite DNA was extracted using Qiagen Blood DNA Kit 
according to manufacturer’s protocol. DNA was eluted in 80 µl distilled H2O. 
2.2.2 Plasmodium berghei analysis 
2.2.2.1 Animal statement 
Animal experiments were performed according to rules of the German “Tierschutzgesetz in der 
Fassung vom 18. Mai 2006 (BGB1, IS. 1207)" with implements the directive 2010/6 3/EU from 
the European Union with the experimental number G0249/15.  
Transgenic parasites were generated and the life cycle was maintained in NMRI mice obtained 
from Charles River. Immunization experiments and immunoprofiling were performed with 
C57BL/6 mice purchased from Janvier and Charles River. All mice were bred in house.  
Anopheles stephensi mosquitoes were reared at 80% humidity and 28°C and infected by a blood 
meal on parasitized mice.  
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2.2.2.2 Infection of mice 
In order to culture blood stage P. berghei parasites, mice were infected with 100 µl thawed 
cryopreserved blood stage parasites intravenously or 200 µl peritoneal or by transferring a 
desired amount of fresh parasitized blood. Parasitemia was monitored with Giemsa-stained thin 
blood smears. 
2.2.2.3 Molecular genetics in P. berghei  
To study the function e.g. by C-or N-terminal tagging, knockouts or overexpression of 
Plasmodium genes of interest, parasites can be genetically manipulated by conventional 
homologous crossover. Parasites are haploid during asexual blood stage development, thus hold 
perfect conditions for straightforward genetic manipulation. Recent advances in molecular 
genetics have advanced the filed in particular for P. falciparum (de Koning-Ward et al., 2015). 
Nevertheless, double homologous crossover in P. berghei is relatively efficient and remains the 
major technique for parasite genetic manipulation. P. berghei molecular genetics are performed 
in vivo as parasites are maintained in mice. To yield mature schizonts for transfection, insertion 
of linearized plasmids harboring Plasmodium genes for desired genetic crossover, ring stages and 
trophozoites are cultured over night in vitro. Transfected schizonts are injected into mice where 
double or single homologous crossover can take place (van Dijk et al., 1995, Janse et al., 2006). 
2.2.2.3.1 Overnight P. berghei schizont culture 
For genome editing of P. berghei ANKA, transfections were performed in late blood stage 
parasites (schizonts). Since schizonts sequester on blood vessel walls of infected mice, ring stages 
and trophozoites are grown into schizonts in vitro. P. berghei schizonts do not rupture in vitro. 
NMRI mice were infected with P. berghei ANKA and parasites were grown until a parasitemia of 
~3-5%. One ml of whole blood was collected by heart puncture, carefully mixed with transfection 
medium (sterile filtered: RPMI, 10% FCS USA, 1% Gentamycin) supplemented with 0.0225 U 
Heparin (37°C) and centrifuged at 1500 rpm for 10 minutes without brake. The pellet was 
resuspended in a small amount of transfection medium and underlayered with transfection 
medium in an Erlenmeyer flask (pre-warmed under culture conditions). The Erlenmeyer flask 
was incubated for 18-22 hours at 37°C and 5%CO2, 80% N2 and 60% humidity. Schizont 
development was confirmed by Giemsa-stained blood smears. 
2.2.2.3.2 Purification of P. berghei schizonts 
To obtain purified schizonts, 35 ml of the culture was placed in a 50 ml flacon and underlayered 
with 55% Nycodenz (37°C). Flacon tubes were centrifuged for 20 minutes at 1500 rpm and RT 
without brake and with accurate balance to obtain schizonts between the gradient layers. 
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Schizonts accumulating in a brown ring on top of the Nycodenz were carefully transferred to a 
new 50 ml tube using a pasteur pipette. For washing, the falcon tube was filled up to 30 ml with 
transfection medium to remove any remains of Nycodenz and centrifuged for 10 minutes at 1500 
rpm. The schizont pellet was resuspended in adequate amount (1-10 ml dependent on number of 
desired transfections) of transfection medium and split into eppendorf tubes (ca. 4 transfections 
per infected mouse) and centrifuged at full speed for 15 seconds to pellet schizonts. 
2.2.2.3.3 Transfection of P. berghei schizonts 
5-10 µg linearized DNA was mixed with 100 µl T cell nucleofactor solution. Schizont pellets were 
mixed with DNA solution, transferred to an electroporation cuvette and electroporated using 
AMAXA Nucleofector device (program U33). Electroporated parasites were mixed with 
additional 50 µl transfection medium and intravenously injected into NMRI mice.  
Selection of transgenic parasites: Transgenic parasites harbor an hDHFR cassette enabling 
resistance against pyrimethamine. Parasites grew under pyrimethamine (70 mg/L) selection 
administered to the mice in the drinking water starting day one post transfection, for 
approximately 6-8 days post infection.  
2.2.2.4 Genotyping of parasite lines 
The clonal and isogenic transgenic parasite lines were genotyped using 5’ and 3’ integration and 
WT specific primer combinations (s. ch. 2.9.1.2). Thus, parasite blood was collected and parasite 
gDNA was extracted followed by a PCR using Dream Taq according to 2.2.1.2. 
2.2.2.5 Generation of an isogenic parasite line (by FACS cloning) or a clonal parasite line 
(by limiting dilution) 
Flowcytometric (FACS) clonal selection: Expression of GFP or mCherry in transgenic parasites 
during blood stage development allowed selection of isogenic clonal populations. Once 
transgenic parasites grew to a parasitemia of 0.1-0.8% in NMRI mice one drop of blood was 
mixed with 1 ml Alsever’s solution and filtered into a FACS tube. 100 GFP or mCherry positive 
parasites were sorted into RPMI/20% FCS USA and intravenously injected into one or two mice. 
Isogenic parasite populations were grown under pyrimethamine selection until a parasitemia of 
~1-3%, parasitized blood was isolated by heart puncture was and stored in 100 µl aliquots in 
freezing solution (45% Alsever’s solution, 55% Glycerin) at -80°C or liquid nitrogen. The residual 
blood was used for gDNA isolation and subsequent genotyping. 
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Conventional clonal selection: Once parasitemia reached ~0.1-1% parasites were cloned were 
subjected to of limiting dilution. Giemsa-smears were used to determine parasitemia (counting 3 
independent areas) and used to calculate one parasite/100 µl. 
7  𝑥  10!    𝑁𝑟  𝑜𝑓 𝑅𝐵𝐶1 𝑚𝑙  𝑏𝑙𝑜𝑜𝑑 𝑥  𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑚𝑖𝑎  𝑥  10!!  𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑠=   𝑁𝑟. 𝑜𝑓  𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑖𝑧𝑒𝑑  𝑅𝐵𝐶  𝑝𝑒𝑟  µμ𝑙  𝑏𝑙𝑜𝑜𝑑 
Ten mice were infected with one clone each. Transgenic parasites were selected by providing 
pyrimethamine in the drinking water and growth rate was monitored by Giemsa-stained thin 
blood smears. Parasite populations were grown until a parasitemia of ~1-3% and stored in 100 µl 
aliquots in freezing solution (45% Alsever’s solution, 55% Glycerin) at -80°C or liquid nitrogen. 
The residual blood was used for gDNA isolation and subsequent genotyping. 
2.2.2.6 Crossing of two transgenic P. berghei parasites 
For sexually crossing two parasite lines in the mosquito, female NMRI mice were intravenously 
infected intravenously (i.v.) with 100 µl thawed transgenic parasite stabilates (stabilate/mouse). 
On day 4, parasitemia was determined and five million parasites of each line were intravenously 
injected into one naïve female NMRI mice for subsequent mosquito infection. 
2.2.2.7 Infection of mosquitoes  
In order to analyze parasite development in mosquitoes in vivo with subsequent retrieval of 
sporozoite for mouse infection, mosquitoes were infected with WT and transgenic parasites. 
Three days prior to feeding female NMRI mice were infected with 10 million iRBCs. 
Exflagellation of male gametes was examined by counting exflagellation centers per field. A drop 
of blood from a tail vein puncture of infected mice was placed on a glass slide with a cover slip 
and incubated at 20°C (RT) for 10 minutes before analyzing exflagellation with 400x 
magnification of the light microscope. Mosquitoes were starved three hours prior to infection. 
Infected mice were anaesthetized with 56 µl Ketamine/Xanthoxin/g (mouse weight) and 
mosquitoes were able to take a blood meal for one hour at RT. 
2.2.2.8 Oocyst, midgut and salivary gland sporozoite infectivity 
Oocyst production and midgut sporozoites formation were analyzed on day 10 and day 14 and 
compared to WT parasites. Midguts of infected female mosquitoes were harvested and 
percentage of infected mosquitoes per 10 mosquitoes was determined. Salivary gland invasion by 
sporozoites was analyzed at day 17 post infection by extracting salivary glands of infected female 
mosquitoes. Sporozoite load per infected mosquito were compared to WT parasite infected 
mosquitoes.  
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2.2.2.9 Isolation of salivary gland and haemocoel sporozoites 
In order to obtain salivary gland sporozoites, infected mosquitoes were dissected in RPMI 
complete medium (RPMI, 10% FCS, 1% Penicillin/Streptomycin), for in vivo infection of mice. 
For in vitro infections of cultured hepatoma cells, sporozoites were dissected in DMEM complete 
medium (DMEM, 10% FCS, 1% Penicillin/Streptomycin). Salivary glands were grinded with a 
pestle and centrifuged at 4°C for 3 minutes at 10,000 rpm, resuspended in medium and diluted 
1:10 to be counted in a Neubauer chamber.  
To retrieve haemocoel sporozoites mosquitoes were dissected alive on ice to reduce motility. 
After removal of legs and wings, one third of (V-VII abdominal segment) the abdominal tip was 
cut off and the tip of a 1 ml BD Micro Fine syringe filled with pure RPMI was placed between the 
forelegs and hind legs. Roughly 50-100 µl (one drop) was inserted and collected on parafilm. The 
medium with the haemocoel sporozoites was transferred to an eppendorf tube while measuring 
the volume to calculate the numbers of sporozoites in the total volume. Sporozoites were counted 
in a Neubauer chamber. 𝑇𝑜𝑡𝑎𝑙  𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠𝑁𝑟. 𝑜𝑓  𝑑𝑖𝑠𝑠𝑒𝑐𝑡𝑒𝑑  𝑚𝑜𝑠𝑞𝑢𝑖𝑡𝑜𝑒𝑠 = 𝑁𝑟. 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠/𝑚𝑜𝑠𝑞𝑢𝑖𝑡𝑜 
2.2.2.10 Analysis of live sporozoites and immunofluorescence assay (IFA) 
Live analysis of sporozoites: Sporozoites were incubated for 10 minutes with 1:50 Phalloidin to 
reduce gliding motility during live imaging and 1:5,000 Hoechst 33342 for nuclear staining. 8-
well glass slides were coated with 10 µl sporozoite solution and covered with a cover slip. 
Sporozoite protein (GFP, mCherry) expression was analyzed with an Axio vision fluorescent 
microscope with 400x or 630x magnification. 
Immunofluorescence assays (IFA) of sporozoites: Specific protein expression in sporozoites was 
analyzed via immunofluorescence assays. 8-well glass slides were precoated with 3% BSA (in 
RPMI) for 10 minutes at 37° in a humid chamber. 1x104 isolated salivary gland sporozoites/ well 
were incubated at 37°C in a humid chamber for 15 minutes for sporozoite settling. Slides were 
fixed with 4% paraformaldehyde (PFA) for 15 minutes at RT, permeabilized with 0.2% TritonX-
100 and blocked with 3% BSA for 15 minutes at RT. Primary antibodies were added for one hour 
at 37°C followed by three washing steps and one hour incubation at 37°C in a humid chamber 
with fluorophore-linked secondary antibody and 1:5,000 Hoechst 33342 for nuclear staining. 
Both staining steps were performed in RPMI containing 2% TritonX-100 and 3% BSA. Slides 
were mounted with Fluoromount G and analyzed with Axio vision observer fluorescence 
microscope. Images were obtained at 630x magnification. 
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2.2.2.11 Sporozoite motility assay 
Gliding ability of sporozoites is essential for liver stage infection. To access whether transgenic 
sporozoites are able to glide, sporozoite motility assays were performed. 8-well glass slides were 
precoated with 3% BSA (in RPMI) for 30 minutes at 37° in a humid chamber. 1x104 isolated 
salivary gland sporozoites/ well were incubated at 37°C in a humid chamber for 20 minutes for 
sporozoite settling and gliding. Sporozoites display circular movement on two-dimensional glass 
surface, shedding surface proteins such as TRAP and CSP. Primary α-sporozoite surface 
polyclonal antibody was added for 1 hour at 37°C followed by three 1x PBS washing steps and 
one hour incubation at 37°C in a humid chamber with the secondary antibody goat α-mouse 
Alexa-Fluoro 488 and Hoechst 33342 for nuclear staining. All stainings were performed in RPMI 
containing 3% BSA. Slides were mounted with Fluoromount G and analyzed with Axio vision 
observer fluorescent microscope. Percentages of gliding vs. non-gliding sporozoites were 
determined for each well. 
2.2.2.12 Ratio of intra- vs. extracellular sporozoites 
To determine sporozoites' ability to attach or enter hepatocytes, cultured Huh7 hepatoma cells 
were infected with sporozoites in vitro and analyzed for cell attachment or intracellular 
development. One day prior to the experiment 3x104 Huh7 cells/well were plated in an 8-well 
Labtek glass slide. Next day, sporozoites were isolated from infected mosquitoes’ salivary glands 
and cells were infected with 1x104 sporozoites/well (~100µl DMEM complete) in triplicates, 
centrifuged at 1500 rpm for 5 minutes without brake at RT and incubated for two hours at 37°C 
and 5%CO2. Infected cells were washed three times, fixed with 4% PFA for 10 minutes at RT, 
washed and blocked with 3%BSA (in PBS) for 1 hour at 37°C. After blocking, cells were 
incubated with the primary α-CSP antibody, staining extracellular parasites, in 3%BSA (in PBS) 
for one hour at 37°C. Cells were washed prior to adding the secondary antibody goat α-mouse 
Alexa-Fluoro 546 (1:1,000) for one hour at 37°C. Subsequently, cells were washed intensively to 
remove assess of secondary antibody and permeabilized with 3% BSA, 0.2% Triton-X forone1 
hour at 37°C. Primary α-CSP antibody was applied again to cells for one hour at 37°C, cells were 
washed and incubated with secondary antibody goat α-mouse Alexa-Fluoro 488 (1:1,000) 
staining intra- and extracellular parasites and Hoechst 33342 (1:5,000) staining host cell and 
parasite nucleus for one hour at 37°C. After additional washing steps cells were mounted with 
Fluoromount G and analyzed with the Axio vision fluorescence microscope. Based on stainings, 
ratios of both red and green extracellular parasites / only green intracellular parasites were 
counted per well. 
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2.2.2.13 C57BL/6 P. berghei sporozoite infection 
In order to analyze infectivity and liver stage development in vivo, mice were infected with 
Plasmodium sporozoites. Sporozoites were diluted in 200µl pure RPMI and 1x104 or 1x105 each 
were intravenously injected in C57BL/6 mouse.  
Bite back assays were used to resemble natural mosquito infections. 15 infected mosquitoes were 
kept in a separate container allowing targeted blood meal on one C57BL/6 mouse. Mice were 
anesthetized with 60 µl Ketamine/Xanthoxin intraperitoneal (i.p.) and mosquitoes were allowed 
to feed for 15 minutes. Mosquitoes were analyzed for successful feeding by examining blood 
uptake in the mosquito midgut. 
2.2.2.14 Blood stage parasite detection: Giemsa-stained thin blood smears  
Tail vein punctures for blood smears were performed day 3-14 post sporozoite infection. After 
fixation in methanol, smears were stained with a 10% Giemsa solution and analyzed for presence 
of blood stage parasites. Parasitemia was determined as followed: 𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑚𝑖𝑎   % = 𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑  𝑓𝑖𝑒𝑙𝑑𝑠𝑅𝐵𝐶 𝑓𝑖𝑒𝑙𝑑 𝑥  𝑐𝑜𝑢𝑛𝑡𝑒𝑑  𝑓𝑖𝑒𝑙𝑑𝑠   𝑥100 
2.2.2.15 Pre-patency analysis 
In order to determine whether transgenic as well as WT parasites are able to develop in the liver 
and infect RBCs, mice were infected with sporozoites (s. ch. 2.2.2.2) and blood stage parasite 
development was analyzed as described in 2.2.2.14. Infected mice were monitored from day 3-14 
post infection for parasite development. Results of pre-patency analysis were plotted Kaplan-
Meyer-curves using Graphpad Prism. 
2.2.2.16 Determining experimental cerebral malaria (ECM) 
Cerebral malaria is a complication of severe malaria. C57BL/6 mice infected with WT sporozoites 
develop ECM approximately 7 days post infection. Animals infected with sporozoites were 
monitored for up to 10 days for ECM development. Ruffled fur, hunching, wobbly gait, limb 
paralysis, convulsions and coma are signs of ECM (Riley et al., 2010, Haque et al., 2011). Animals 
that had ≥4 of those symptoms were determine as severe ECM cases and sacrificed with neck 
fracture.  
2.2.2.17 P. berghei blood stage IFA 
Parasite blood stage protein expression was determined in immunofluorescence assays (IFA). 
Infected RBC were retrieved by tail vein punctures of infected mice, mixed with 1x PBS and 
placed on a poly-L-lysine covered 12 mm ø cover slips in a 24-well plate to settle for 60 minutes. 
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Cells were fixed with 4% PFA / 0.0075% fresh glutaraldehyde (GA) at RT. After three washing 
steps cells were permeabilized with 0.2% TritionX-100 (in PBS) for 20 minutes at RT. Cells were 
washed and blocked with 3% BSA, 0.2% TritonX-100 (in PBS) for 30 minutes at RT on a shaker. 
Primary antibody was added in blocking solution for one hour at RT, shaking, followed by three 
washing steps and incubation with fluorophore labeled secondary antibody and Hoechst 33342 in 
blocking solution for one hour at RT, shaking. Additional washing steps removed remaining 
secondary antibody before cells were mounted with Fluoromount G on a glass slide. Cells were 
analyzed with Zeiss Axio Observer immunofluorescence microscope and images were taken at 
640x magnification. 
2.2.2.18 Parasite burden in mouse livers 
Prime/boost immunized animals were challenged with freshly dissected sporozoites five months 
post immunization and the livers were harvested at 42 or 48 hours post challenge infection. (Half 
of the liver was taken for CD8+ T cell analysis the other half for parasite load analysis). Mice 
livers were homogenized in TRIzol and subsequently total RNA was extracted from the cells. 
cDNA was generated by reverse transcription with the RETRO Script Kit. Quantitative real-time 
PCR (qRT-PCR) analysis was performed with primers specific for Pb18s rRNA and mouse GAPH 
for normalization (Table S1). Relative liver parasite levels were determined with the ∆∆Ct 
method.  
2.2.3 Cell biological methods 
2.2.3.1 Maintenance of hepatoma cells 
Cell lines were kept according to standard cell culture conditions for human hepatoma cell lines 
Huh7 and HuhB3H. In brief: Huh7 cells were thawed at 37°C and cultured in DMEM complete 
(DMEM, 10% FCS, 1% Penicillin-Streptomycin) in T25 or T75 flasks at 37°C and 5% CO2. 
HuhB3B cells were cultured in RPMI supplemented with 5% FCS, 10 mM HEPES, 1x MEM non-
essential amino acids and 2 mM L-Glutamine in T25 or T75 flasks at 37°C and 5% CO2. 
Passaging of cells was performed every three days, splitting 1:10 of a confluent culture. Cells were 
incubated with 1 ml (T25) or 3 ml (T75) trypsin for 3 minutes, spun down at 1200 rpm for 2 
minutes and resuspended in an adequate amount of culture medium. Cells remained in culture 
for up to 15 passages. Both cell types were stored in freezing solution (10% DMSO, 20% FCS, 
70% culture medium) in a freezing container at -80°C for 24 hours and then transferred to liquid 
nitrogen (for long term storage) or -80°C (for short time storage). 
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2.2.3.2 Infection of hepatoma cells 
Hepatoma cells were infected as described in 1.2.2.12. Infected cells were incubated at 37°C and 
5% CO2 for 4h, 16h, 24h, 48h and 72h. Cells were washed at two hours post infection to remove 
non-invaded sporozoites and then medium was changed daily. Growth was terminated by 
fixation with 4% PFA for 10 minutes at RT.  
2.2.3.3 Live imaging of infected hepatoma cells 
For protein export analysis of infected Huh7 cells with crossed transgenic parasite lines, live 
imaging of parasites was performed. Infected cells in Ibidi slides were washed once with 1x PBS 
and remained in PBS solution for the time of imaging. Live imaging was performed with a Zeiss 
Axio Observer immunofluorescence microscope with 1,000x lens. Duration of analysis was kept 
at a minimum to ensure cell survival. 
2.2.3.4 Immunofluorescence assays (IFAs) of infected hepatoma cells  
Infected cells were blocked with PBS/10%FCS and permeabilized with 0.2% Triton for 1h at 37°C. 
Primary antibodies (α-GFP, α-USI4, α-MSP1, α-mCherry, α-Myc, α-CSP or α-LC3, for dilutions 
s. ch. 2.1.6) were applied for one hour at 37°C. After washing, cells were incubated with the 
respective fluorescently labeled secondary antibody (α-chicken Alexa Fluor 488, α-mouse Alexa 
Fluor 546, α-mouse Alexa Fluor 488, α-rat Alexa Fluor 546 α-rat Alexa Fluor 488, α-rabbit Alexa 
Fluor 546, α-rabbit Alexa Fluor 488, for dilutions s. ch. 2.1.6) and Hoechst 33342 for one hour at 
37°C. Subsequently, cells were washed and mounted with Fluoromount G. 
2.2.3.5 Microscopical analysis of exo-erythrocytic forms (EEFs) IFAs 
Stained and fixed cells were analyzed with a Zeiss Axio Observer immunofluorescence 
microscope. Pictures of parasites were taken with 630x magnification for immunofluorescence 
pictures and 10-20 pictures of infected cells per well were taken for size analysis of the parasite. 
Pictures were analyzed with Fiji using a previously coded macro. Parasite size was determined for 
all strains at 24h, 48h and 72h post infection.  
Each well of duplicates/ triplicates of all time points (24h, 48h and 72h) was completely screened 
to determine the amount of infected host cells per well.  
2.2.3.6 Transmigration assay 
Upon arrival at the liver, sporozoites transmigrate through several hepatocytes before infecting a 
final cell to undergo maturation into thousands of merozoites. During the process of 
transmigration, sporozoites create holes in hepatoma cell membrane. Transmigration assays take 
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advantage of this process, with help of a normally non cell-permeable dye, in order to analyze 
whether transgenic sporozoites are able to transmigrate through hepatoma cells.  
One day prior to infection 1x106 Huh7 cells per well were seeded in a 24-well plate and kept in 1 
ml DMEM complete at 37°C and 5% CO2. The next day, salivary gland sporozoites were isolated 
from infected mosquitoes and incubated with 0.5 mg/ml FITC-dextran. Huh7 cells were 
subsequently infected in duplicate or triplicates with 75.000 sporozoites/well (~280µl/well). 
Additionally, two wells received parasites(-)/dextran(+) medium to account for natural dextran 
uptake of uninfected cells and a further two wells received parasites(-)/dextran(-) medium as a 
negative control. Infected cells, were centrifuged at 1800 g for 5 minutes without brake and 
incubated for two hours at 37°C and 5% CO2. After washing (three to five x) with PBS, cells were 
trypsinized with 200 µl/well and collected in an eppendorf tube. Additional five to seven washing 
steps with medium removed excess of dextran. For subsequent FACS analysis cells were 
resuspended in 200µl 1% PFA/PBS and stored at 4°C in the dark until analysis. Cells were 
transferred to FACS tubes through a cell strainer and analyzed with MACSquant (Channel 
FSC/FITC) for amount of dextran positive cells/sample. Parasites(-)/dextran(-) cells were used to 
set the 0% threshold and parasite(-)/dextran(+) cells were used to set threshold for natural 
dextran influx. All were analyzed with MACSQuant gating for FFC/FITC. Results were 
subsequently analyzed with FlowJo. 
2.2.3.7 RNA isolation of infected hepatoma cells 
To determine expression of liver stage specific genes, relative mRNA levels were determined in 
WT and transgenic parasites. 3 x105 Huh7 cells/well were plated in a 24-well plate. Next day, 
salivary gland sporozoites were isolated from infected mosquitoes and Huh7 cells were infected 
with 100.000 sporozoites/well (in 200 µl DMEM complete). For parasite sedimentation plates 
were centrifuged for 10 minutes at 3000 rpm, no brake, and incubated at 37°C and 5%CO2. Two 
hours post infection, cells were washed once to remove extracellular sporozoites. After 16h, 24h, 
48h or 72h cells were trypsinized with 200 µl for 3 minutes at 37°C, and carefully resuspended in 
DMEM. Cells were transferred to 50 ml falcon tubes and washed with additional 20 ml DMEM. 
After 5 minutes centrifugation at 1200 rpm with brake, the pellet was resuspended in 500 µl 
TRIzol and RNA was extracted for subsequent cDNA synthesis and qPCR analysis as described in 
chapter 1.2.1.10. 
 
 
 
 
Material and Methods 
  50 
2.2.4 Immunological analysis 
2.2.4.1 Immunization of C75BL/6 mice 
Immunizations of C57BL/6 mice were performed with 1x104 sporozoites intravenously in a 
prime/boost regimen (day 0 and day 7 or day 10). For γ-sporozoites, parasites were irradiated for 
2h at 1.2x104 cGy to induce DNA damage resulting in liver stage attenuation. For attenuation 
with AZ, mice were given 4,8 mg/mouse AZ in 200 µl sodium chloride (NaCl) i.p. Immunized 
animals were challenged with 1x104 WT sporozoites injected intravenously 37, 67, 97 or 120 days 
post immunization. Daily thin blood smears were performed day 3-14 and stained with Giemsa 
to analyze blood stage parasitemia. 
2.2.4.2 Dissection of mouse livers and spleens 
∆SLARP/P36p/P36: For the analysis of IFN-γ producing effector-memory CD8+ T cells after one 
and two months post boost immunization. Animals immunized and challenged for protection 
experiments were, if blood stage positive, treated with pyrimethamine in the drinking water for 
10 consecutive days to clear blood stages from circulation. One month post challenge (one and 
two months challenge) spleens and livers were excised. For the dataset generated five months 
post immunization, animals were immunized in a prime/boost regime, challenged after five 
months and spleens were excised after 42h after the challenge.  
Retrieval of splenic and hepatic lymphocytes: Animals were perfused with PBS and liver and 
spleen harvested. For retrieval of splenic lymphocytes, the spleen of each animal was 
homogenized with the help of a 40 µm cell strainer in complete RPMI (RPMI, 10% FCS, 2% 
Penicillin/Streptomycin). The cell suspension was centrifuged 1800 rpm for 3 minutes and red 
blood cells were lysed with 1 ml 1x BD PharmLyse buffer for 10 minutes at RT. Lysis was stopped 
by adding 4 ml complete RMPI and after centrifugation the pellet was resolved in 1 ml complete 
RPMI for further analysis. For the retrieval of liver cells, the liver of each mouse was 
homogenized by passing the livers through a 70 µm cell strainer in complete RMPI. Cell 
suspension was centrifuged for 10 minutes at 4 °C at 1200 rpm. The pellet was resuspended in a 
40% percoll solution (37°C) and centrifuged for 20 minutes at 2000 rpm at RT without brake. 
Pellet was resuspended and lysed as described for splenic cells.  Pellets were resuspended in a 
final volume of 150 µl RPMI complete for further analysis.  
2.2.4.3 Restimulation of lymphocytes 
In order to activate TNF-α and IFN-γ production, cells (~2 million cells/well or 1-2x105 hepatic 
lymphocytes) were plated in a 96 well flat bottom plate and restimulated with 10µg/ml (1:1,000) 
TRAP-SALLNVDNL, S20-VNYSFLYLE or OVA-SIINFEKL (as a negative control) MHCI-H2 
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Kb/D6 CD8-peptides and Brefeldine A (1:1,000) for inhibition of retrograde ER-transport. Plates 
were incubated for 5-6 hours at 37°C and 5% CO2 and subsequently at 4°C overnight. All 
centrifugation steps were performed in PBS/1% FCS for 3 minutes at 1800 rpm. Next, cells were 
washed and extracellular stained with fluorescently labeled antibodies (CD11a (M17/4), CD8 (53-
6.7), CD3 (500A2)) was performed in PBS/1%FCS for one hour at 4°C in the dark, followed by 
fixation with 4% PFA for 15 minutes at RT (dark). After two subsequent washing steps with 
PERM-wash buffer, the extracellular stain IFN-γ (XMG1.2) and TNF-α (MP6-XT22)) was 
applied for 1h at 4°C (dark) in PERM-wash buffer. Cells were washed and resuspended in 150 µl 
PBS/1% FCS buffer for subsequent FACS analysis with the MACSquant. Cells were gated to 
exclude doubles and lymphocyte population was determined using FSC/SSC. Data was collected 
from the whole restimulated sample or 1 million events for the lymphocyte population. 
Computational analysis was performed with FlowJo. 
2.2.4.4 Antibody titers 
Serum of prime/boost-immunized animals was retrieved one, two or five months post boost 
immunization. Approximately 50 µl blood was taken from the tail vein of animals with a 
heparinized capillary. Blood was centrifuged at 1800 rpm for 10 minutes to separate serum from 
the red blood cells, which was stored at 80°C for further analysis. Air-dried sporozoites were 
prepared with 5-10,000 WT sporozoites in PBS/well of epoxy covered eight well glass-slides for 
antibody staining. After fixation in Aceton (ice-cold), slides were rehydrated with PBS and 
blocked with PBS/3%BSA solution for 30 minutes at 37°C. Serum of each immunized or naïve 
animal was diluted in serial dilutions of 1:10,000, 1:33,000, 1:100,000, 1:33,0000 and sporozoite 
slides were incubated with the serum for 1h at 37°C. After several washing steps, slides were 
incubated with fluorescently labeled secondary antibody (goat α-mouse Alexa-Fluor 488) for one 
hour at 37°C. Nuclei were stained with Hoechst 33342. Slides were mounted with Fluoromount G 
(Southern Biotech) and analyzed for the lowest dilution with detectable sporozoites staining with 
help of a Zeiss Axio vision fluorescence microscope.  
2.2.5 Statistical analysis 
Data was analyzed with Excel, FlowJo V8.7, GraphPad Prism V5.0c. Statistical significance was 
analyzed by non-parametrical Whitney-U test for non-normally distributed data (infected 
hepatoma cells) and one-way ANOVA for normally distributed data (antibody titers). Log rank 
(Mantel-Cox) test was applied for Kaplan-Meyer-curves and slope of parasite growth curves was 
analyzed using R Studio.   
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3 Results 
3.1 Pre-clinical analysis of a triple genetically attenuated parasite (tKO GAP) 
vaccine candidate 
Attacking and eliminating Plasmodium parasites in the liver prior to the symptomatic blood 
infection is one of the most promising malaria vaccine strategies. In the case of malaria, 
experimental immunizations with genetically arrested liver stages (GAPs) have proven safe and 
efficacious against challenge infections in mice, primates, and humans. Thus far, only one GAP-
vaccine candidate, parasite harboring a targeted deletion of the master regulator of liver stage 
development SLARP, provides complete life cycle arrest in vivo and in vitro, but fails to induce 
sterile protection. In contrast, ∆P36p/P36 parasites elicit potent immunity but cause occasional 
breakthrough infections. To decipher whether transgenic parasites harboring a triple gene 
deletion ∆SLARP/P36p/P36 (tKO GAP) perform better in safety and efficacy compared to their 
single knockout counterparts, pre-clinical immunization and challenge studies were conducted. 
Comparative immune profiling of mice immunized with tKO and single GAPs as well as 
irradiated WT (γ-WT) parasites were done prior to and after challenge infections in spleens, 
livers and peripheral blood to capture pathogen-specific host responses. To examine synergistic 
or antagonistic effects of combining gene knockouts with different liver stage developmental 
defects, the following questions were asked i) are vaccine safety requirements fulfilled in this tKO 
GAP, ii) can immunizations with tKO GAPs confer sterile protection against Plasmodium 
challenge infections and iii) can underlying immune mechanisms be deciphered and correlated 
to increased or reduced immunity. Comparing the tKO to the original KO GAPs is critical to 
fully evaluate the advantages of a multiple KO GAP. 
3.1.1 Generation of a ∆SLARP/P36p/P36 parasites 
To investigate the vaccine potential of a triple genetically attenuated parasite, a single and a 
double knockout parasite were combined by sequential deletion of SLARP and P36p/p36 using 
the GOMO- followed by pBART-strategy and subsequent FACS-based isolation of isogenic 
parasites (Fig. 8A) (Manzoni et al., 2014)(kindly provided by Josephine Scholz, Master thesis 
2015). Diagnostic PCR confirmed successful deletions of SLARP and P36p/P36 in the triple 
knockout parasites (Fig. 8B). 
As expected from observations of ∆SLARP and ∆P36p/P36 phenotypes (van Dijk et al., 2005, 
Silvie et al., 2008), blood infection, comprising asexual replication and differentiation into sexual 
stages, was indistinguishable between ∆SLARP/P36p/P36 and WT parasites (data not shown). 
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Similarly, development in the Anopheles vector, including colonization of the mosquito midgut, 
sporogony, and maturation of sporozoites was normal (Table S1). Accordingly, preclinical 
testing of safety and immunogenicity of these triple knockout parasites in a murine malaria 
vaccine model could be performed. 
 
Figure 8 Generation of ∆SLARP/P36p/P36 parasites 
A Schematic representation of the SLARP and P36p/P36 loci of the original ∆SLARP (upper grey box) and 
the generated ∆SLARP/P36p/P36 (lower grey box) parasites. ∆SLARP parasites harbor a modified SLARP 
locus, where SLARP is replaced by GFP (green) and an intact P36p/P36 locus of which P36 3’ UTR and 
P36p 5’ UTR (red) were used for generating ∆SLARP/P36p/P36 by double homologous recombination. 
While eliminating P36p and P36, a GFP reporter sequence (green, for parasite life cycle analysis) and 
TgDHFR/Ts resistant cassette (for positive selection with pyrimethamine) are incorporated. Grey lines 
indicate regions used for genotyping recombined parasites and the numbers refer to integration (INT) and 
WT specific primer combinations. B Genotyping PCR of ∆SLARP/P36p/P36 parasites. 5’ and 3’ integration 
and WT specific primer combinations (A) verified successful recombination events. Absence of WT signal 
for SLARP and P36p/P36 loci from ∆SLARP/P36p/P36 confirmed their isogenic purity. ∆SLARP, 
∆P36p/P36 and P.b. ANKA WT gDNA were used as a control. 
3.1.2 Complete arrest but inferior protection in ∆SLARP/P36p/P36-immunized 
animals 
To analyze the safety profile of ∆SLARP/P36p/P36 in comparison to ∆SLARP and ∆P36p/P36 
sporozoites, the most susceptible mouse strain for P. berghei, C57BL/6 mice (Scheller et al., 
1994), was infected by i.v. injection of 1x104 sporozoites (Table 2). Daily monitoring of blood 
infection revealed complete pre-erythrocytic life cycle arrests in mice infected with 
∆SLARP/P36p/P36 and ∆SLARP sporozoites. As described previously (van Dijk et al., 2005), 
infections with ∆P36p/P36 sporozoites resulted in occasional breakthrough infections, which 
develop into fulminant blood infections. Together, ∆SLARP/P36p/P36 parasites arrest fully in the 
liver and are as safe as ∆SLARP sporozoites for GAP immunization. 
 
. 
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Table 2 Safety of genetically attenuated P. berghei lines. 
Parasite strain Blood stage-positive micea Prepatent periodb 
   ∆SLARP/P36p/P36 0/34 (0%) - 
   ∆SLARP 0/34 (0%) - 
   ∆P36p/P36 4/34 (12%) (>6 days) 
   WT 10/10 (100%) 3 days 
a Mice were inoculated by i.v. injection of 1x104 sporozoites. Shown are numbers and respective 
percentage of infected to total animals. 
b The prepatent period is defined as time to detection of first blood stage parasites.  
Animals were immunized twice in a seven day interval with 1x104 ∆SLARP/P36p/P36, ∆SLARP, 
∆P36p/P36, and γ-WT sporozoites. Challenge of immunized mice and naïve control animals by 
intravenous injection of 1x104 normal sporozoites was performed 37 days after the 
immunization. This prime/boost/challenge protocol typically leads to intermediate protection, 
permitting the identification of superior and inferior vaccine candidate effects (Fig. 9). Pre-
patency analysis after challenge revealed that mice immunized with ∆SLARP/P36p/P36 were least 
protected in comparison to mice immunized with the cognate single knockout sporozoites. 
 
Figure 9 Inferior protection in ∆SLARP/P36p/P36 sporozoite immunizations. 
A Schematic representation of the immunization procedure. C57BL/6 mice were immunized and boosted 
at a 7-day interval with 1x104 sporozoites i.v., challenged with 1x104 WT sporozoites i.v. at 36 days post 1st 
immunization and blood infection was monitored by daily microscopic examination of Giemsa-stained 
blood films. B Kaplan-Meier analysis of time to pre-patency after sporozoite challenge reveals inferior 
protection in ∆SLARP/P36p/P36-immunized animals. Mice were immunized with ∆SLARP/P36p/P36 
(pink), ∆SLARP (yellow), ∆P36p/P36 (turquoise), or γ-WT (dark grey) sporozoites. WT sporozoite 
challenge was performed 36 days post immunization and non-immunized control animals (naïve, light 
grey) confirmed sporozoite infectivity by patent blood stage infection 3 days post inoculation. Infected 
animals were treated orally with pyrimethamine in the drinking water to clear parasitemia. Statistical 
analysis: Log rank (Mantel-Cox) test n.s., non-significant; **, p< 0.01 
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In comparison, γ-WT sporozoites protected best against follow-up infection. As expected, WT 
challenge two months post prime/boost ∆SLARP/P36p/P36 and γ-WT immunizations reduced 
protection against follow-up infections in all cohorts, eliminating all protective effects in 
∆SLARP/P36p/P36 immunized mice (Josephine Scholz, Master thesis 2015). In comparison, three 
immunizations elicited complete protection in all animals immunized with ∆SLARP, ∆P36p/P36 
or γ-WT sporozoites (Josephine Scholz, Master thesis 2015). Together, these challenge data 
suggest an antagonistic effect of the two gene knockouts in GAP-induced protection.  
3.1.3 High liver parasite load in tKO immunized cohorts after WT challenge 
To estimate whether parasite load in the liver after challenge in prime/boost immunized cohorts 
correlates with the protection profile, tKO, single KO and γ-WT-immunized animals (0/7) 
received a high dose of WT sporozoites five months post immunization, followed by liver 
excision after 42 hours and Pb18s mRNA levels assessment relative to the mouse GAPDH levels 
(Fig. 10). As expected, ∆P36p/P36-immunized animals had a ~100-fold reduction in parasite 
load compared to non-immunized animals (naïve). Challenged mice that were immunized with 
∆SLARP parasites revealed slightly higher parasite loads than ∆P36p/P36-immunized animals 
indicating reduced protection. Both original KO immunized cohorts had lower parasite loads in 
the liver compared to tKO immunized animals which is in concordance with reduced protection 
against follow-up infections. However, tKO immunized and challenged animals still had a ~10-
fold reduction in parasite load compared to non-immunized animals. Corroborating this notion, 
γ-WT-immunized animals had the lowest liver parasite burden correlating with good protection. 
Taken together, reduced liver load in tKO immunized animals was observed. However ∆SLARP 
and ∆P36p/P36-immunized cohorts revealed even higher reduction in parasite load confirming 
the results seen in the immunization profile.   
 
Figure 10 Elevated parasite load in livers of ∆SLARP/P36p/P36-immunized and challenged mice 
Quantitative RT-PCR analysis of relative parasite rRNA levels in immunized and challenged cohorts. 
C57BL/6 mice were immunized twice in a 7-day interval with 1x104 ∆SLARP/P36p/P36 (pink), ∆SLARP 
(yellow), ∆P36p/P36 (turquoise), or γ-WT sporozoites (dark grey). 30 days later immunized animals and 
naïve control (light grey) were inoculated with 1x104 WT sporozoites. The livers were excised 42h post 
challenge, RNA was extracted and cDNA amplified. ∆∆CT Pb18s rRNA levels normalized to the murine 
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GAPDH mRNA levels are depicted showing relative parasite load in the liver of individual immunized and 
challenged animals (dots) of two independent experiments, as well as the general mean ±SD. Only 
significant differences are shown. **, p<0.01 
3.1.4 Immunization with tKO induces high antibody titers 
Antibodies against Plasmodium sporozoites hamper attachment to and invasion of hepatocytes. 
As a first measure of protection, antibodies bind to surface proteins of sporozoites, a mechanism 
exploited by subunit vaccine RTS,S (Stoute et al., 1997). GAPs do not only induce production of 
antibodies against one target protein, but rather induce production of an array of antigens 
against all sporozoites surface proteins (Offeddu et al., 2012). Measuring antibody titers of tKO, 
single KO and γ-WT-immunized animals determines antigen exposure and induction of 
antibody production by (t)KOs. Serum of prime/boost immunized animals one, two and five 
months post immunization were taken and measured in a dilution series staining air-dried 
sporozoites. High antibody titers were observed one month post infection for tKO and control 
groups (Fig. 11A). Antibody titers dropped after two-thirds two months post infection in all 
groups. However, overall antibody titers did not decline further after 5 months post infection in 
all groups (Fig. 11B). However, ∆SLARP-immunized animals had significant lower antibody 
titers compared to the other immunized cohorts one and two months post infection. Concluding, 
high antibody titers were observed in all of the immunized animals with a steady decrease after 
the first months post immunization, questioning overall contribution of antibodies to GAP-
induced protection.  
 
Figure 11 High antibody titers after ∆SLARP/P36p/P36 immunization 
Reciprocal antibody titers of ∆SLARP/P36p/P36 (pink), ∆SLARP (yellow), ∆P36p/P36 (turquoise), or γ-
WT (dark grey) immunized animal cohorts. Serum was taken from C57BL/6 immunized/boosted animals 
at 30, 60 or 150 days post immunization. Air dried WT sporozoites were exposed to the serum in a 
dilution series of 1: 10,000, 1: 33,000, 1: 100,00, 1: 330,000 and visualized by α-mouse Alexa-fluor 488 
secondary antibody. Titers were compared to stainings with serum of naïve mice (light grey). Each dot 
presents serum dilution of an individual mouse. Depicted are only significant statistical differences of 
cohorts compared to ∆SLARP/P36p/P36-immunized mice. *, p<0.05,***, p<0.001. A Reciprocal antibody 
titers of immunized animal cohorts one and two months post immunization. B Reciprocal antibody titers 
of immunized animal cohorts five months post immunization.  
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3.1.5 Exo-erythrocytic development is attenuated in tKO in vitro 
Another factor contributing to GAP vaccine-induced immunity is thought to be the 
developmental status and persistence of arrested liver stages inducing protective CD8+ T cells. 
Developmental arrest at late liver stages, as shown for parasites under drug cover, is believed to 
induce superior protective immunity (Borrmann & Matuschewski, 2011). Furthermore, parasites 
that arrest early, but persist longer in the liver, have shown to induce protective CD8+ T cell 
production (Putrianti et al., 2009). To determine whether reduced tKO GAP vaccine efficacy can 
be explained by limited or impaired parasite liver stage development, hepatoma cells were 
infected in vitro with tKO, single KO GAPs and WT parasites and growth and infectivity of these 
sporozoites were analyzed (Fig. 12). The approximate time point of tKO liver stage arrest was 
determined by comparing the size of tKO, single KO and WT parasites at 24, 48 and 72 hours 
post infection, as P. berghei liver stage development is completed after 72 hours (Fig. 12A). tKO 
size of ~8µm was similar to single GAPs at 24 hours p.i. whereas WT parasites were significantly 
larger in size (~32µm). Size difference at 48 hours post infection between GAPs and WT 
increased significantly by ~10-fold, due to WT parasite growth and GAPs developmental arrest.  
 
Figure 12 Reduced size and number of ∆SLARP/P36p/P36 exo-erythrocitic stages in vitro 
3x104 hepatoma (Huh7) cells were infected with 1x104 ∆SLARP/P36p/P36 (pink), ∆SLARP (yellow), 
∆P36p/P36 (turquoise), and WT (light grey) sporozoites per well in two independent experiments with 
three technical replicates each. A EEF sizes of ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 or WT P.b. 
parasites. 20 parasites per technical replicate per time point were measured by immunofluorescence 
microscopy and analyzed with Fiji for determining the size (µm) of the parasite. Depicted are individual 
parasites per time point (dots) and the mean ±SD. Statistical analysis was performed on the means of the 
replicates: Mann-Whitney-U test, only significant differences to tKO parasites at each time point are 
shown. ***, p<0.001. B EEF numbers in ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 or WT P.b. infected 
Huh7 cells measured by immunofluorescence microscopy. Numbers of EEF per well were counted in all 
replicates per time point. Depicted are the numbers of each replicate and the combined mean ±SD. 
Statistical analysis: Mann-Whitney-U-test. Only significant differences to tKO parasites at each time point 
are shown. *, p<0.05,**, p<0.01 
 
Results 
  58 
Liver stage arrest around 12-18 hours post infection in KO GAPs has been reported previously 
and, as expected, tKO parasites arrest at a similar time point. The arrest in ∆SLARP is most likely 
due to the downregulation of PVM resident proteins, UIS and other important liver stage genes, 
whereas ∆P36p/P36 parasites seem to lose their ability to build and maintain the PVM by absence 
of the 6-cysteine domain protein (van Dijk et al., 2005, Aly et al., 2008, Silvie et al., 2008). 
Sporadic larger parasites in the ∆P36p/P36 line indicate a potential reason for the occasional 
breakthrough infections observed in this GAP parasite line. Determining parasite infection rates 
in vitro can give insight into sporozoite infectivity and parasite persistence in the liver. To 
estimate whether reduced infectivity and persistence of tKO parasites could be an explanation for 
lower vaccine efficacy, 30,000 Huh7 cells were infected with 1x104 tKO sporozoites and 
compared to original KOs and WT infections (Fig. 12B). Numbers of ∆SLARP/P36p/P36 
parasites were similar to ∆SLARP parasites revealing a significant 50% reduced infection rate 
compared to ∆P36p/P36 and WT. Induction of long-lasting protective CD8+ T cells is important 
for an effective vaccine candidate. Small-scale studies reported high induction of CD8+ T cells by 
persistent liver stage parasites under drug cover (Scheller & Azad, 1995, Mueller et al., 2007, 
Putrianti et al., 2009). Rapidly decreasing parasite numbers between 24 and 48 hours post 
infection indicate lack of persistence and death of parasites. Persistence of parasites was similar 
in all transgenic parasites, however larger numbers of persisting parasites in ∆P36p/P36 and WT 
are likely contributing to the superior protection in immunized animals. 
Immunofluorescence images of tKO and original KOs display absence of UIS4, a PVM resident 
protein (Fig. 13). ∆P36p/P36 parasites showed no sign of UIS4 expression, an indicator for 
(post)-transcriptional downregulation of gene expression, as shown for SLARP (Silvie et al., 
2008) or absence of a PVM. In contrast, WT parasites expressed UIS4 at 24h and 48h post 
infection as well as lower presence of UIS4 at 72h post infection (Fig. 13C). Since UIS4 is not an 
indicator for PVM presence, as it could be absent from an otherwise excitant PVM, staining for 
recruitment of host cell LC3, an autophagy marker, to the parasitophorous vacuole of early liver 
stage parasites was performed (Prado et al., 2015, Thieleke-Matos et al., 2016) (Fig. 13A). As 
expected, ∆P36p/P36 parasites were not labeled with LC3, since LC3 recruitment requires an 
intact PVM, which is absent in ∆P36p/P36 parasites (Labaied et al., 2007, Wacker et al., 2017). 
Similar results were observed for ∆SLARP/P36p/P36 suggesting inability to establish a PVM. 
Surprisingly, LC3 recruitment was not present in ∆SLARP parasites, likely due to insufficient 
PVM remodeling after invasion, as an intact PVM is required for proper LC3 recruitment (Prado 
et al., 2015). In contrast, WT parasites were labeled with LC3 at 24h post infection. To examine 
parasite development into mature liver stage schizonts, transgenic parasites were stained with the 
merozoite surface antigen MSP1 (Fig. 13B). As expected, all transgenic parasite lines were 
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lacking MSP1 staining as developmental arrest occurred before maturing into late liver stages. In 
contrast, WT parasites showed MSP1 presence in mature liver stages and schizonts (Fig. 13C). 
 
Figure 13 ∆SLARP/P36p/P36 exo-erythrocytic stages do not harbor a parasitophorous vacuole 
A Immunofluorescence microscopy analysis (IFA) of α-UIS4 (red) or α-LC3 (red) and α-GFP (green) 
∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 and WT P.b. parasites at 24 hours post hepatoma cell (Huh7) 
infection shows absence of UIS4 in and recruitment of host LC3 to GAP parasites. Nuclear staining was 
performed with Hoechst 33342 (blue). Upper panel is showing α-UIS4 (red) or α-LC3 (red) staining only, 
lower panel is displaying the merged image. (Scale bar 10 µm) B Representative immunofluorescence 
images of α-UIS4 (red) or α-MSP1 (red) localization in ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 and WT 
P.b. parasites in infected Huh7 cells at 48 hours p.i.. Upper panel is showing α-UIS4 (red) or α-MSP1 (red) 
staining only, lower panel is displaying the merged image with α-GFP (green) and nuclear staining with 
Hoechst 33342 (blue). (Scale bar 10 µm) C IFA of α-UIS4 (red) or α-MSP1 (red) and α-GFP (green) 
stained ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 and WT P.b. parasites at 72 hours post Huh7 infection 
reveals  absence of UIS4 and MSP1 in GAP parasites. Nuclear staining is displayed with Hoechst 33342 
(blue). Upper panel is showing α-UIS4 (red) or α-MSP1 (red) staining only, lower panel is displaying the 
merged image. (Scale bar 10 µm) 
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In vitro studies indicated an early arrest of tKO parasites, absence or insufficient remodeling of a 
PVM, decreased hepatocyte infection rate and reduced persistence of arrested parasites in the 
liver, a prerequisite for sufficient CD8+ T cell priming, providing an explanation for lower 
protection in tKO immunized animals. 
3.1.6 CD8+ T cells in tKO animals decline after two months post infection 
CD8+ T cells have been shown to play a major role in protection against malaria infections. As 
seen for immunizations with parasites under drug cover, eliciting high CD8+ T cell titers 
contributes to a significant increase in protection (Borrmann & Matuschewski, 2011). In 
contrast, immunization with heat killed sporozoites, which fail to attach, transmigrate and invade 
hepatocytes, establish only low CD8+ T cell titers along with protection of these whole parasite 
vaccines (Hafalla et al., 2006). To investigate whether CD8+ T cells are induced by tKO, single 
KO and γ-WT-immunized animals and if this in turn can explain the difference in protection, 
amounts of IFN-γ producing effector memory CD8+ T cell titers were determined in the spleen 
and liver of prime/boost immunized animals one month post WT challenge (Fig. 14). Animals 
were immunized with tKO, single/double KO or γ-WT (d0/7) and challenged one, two or five 
months post immunization. Spleens and livers of challenged animals were excised one month 
post challenge (one and two months challenges) or 42h post challenge (five months challenge). 
Animals that developed a blood stage infection were cured with pyrimethamine in the drinking 
water for two weeks. Spleens and livers of immunized animals were processed and restimulated 
with brefeldin A and sporozoite specific CD8+ T cell peptide epitopes TRAP130-138 and S20318-326, 
and OVA257-264 as a negative control not recognized in H2-Kb restricted C57BL/6 mice. 
Furthermore, control naïve animals were included that have not been in contact with any 
parasites. Restimulated spleen and liver cells were stained with α-CD3 and α-CD8 antibodies to 
determine CD3+CD8+ positive lymphocytes and α-CD11a antibody for activated T cells as well as 
intracellular α-IFN-γ and α-TNF-α antibodies for detection of parasite specific cytokine 
production of activated CD8+ T cells and measured with FACS (Fig. 14A).  
Despite decreased EEF numbers for tKO and ∆SLARP, immunized and challenge animals 
displayed similar robust numbers (~0.2%) of IFN-γ producing CD8+ T cells amongst all GAP and 
control groups for lymphocytes stimulated with TRAP after one month post challenge (Fig. 
14B+C). Cells from naïve animals as well as cells stimulated with the control peptide OVA 
showed no induction of IFN-γ producing CD8+ T cells. Surprisingly, CD8+ T cell numbers 
dropped significantly to 0.08% two months post immunization in ∆SLARP/P36p/P36-vaccinated 
animals, whereas in single/double KO and γ-WT vaccinated mice CD8+ T cell numbers were 
similar to or even higher than one month post infection.  
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Figure 14 Reduced longevity of CD8+ T cells in ∆SLARP/P36p/P36-immunized mice 
Analysis of CD8+ T cells elicited in immunized cohorts. C57BL/6 mice were immunized in a prime/boost 
regimen (7 days apart), challenged one or two months post immunization and treated with pyrimethamine 
water before excision of spleen one month post challenge. Splenic cells were restimulated with CD8+ 
TRAP peptide epitopes and stained with fluorescently labeled antibodies for analysis with MACSQuant. A 
Depicted is the gating strategy used for FACS analysis one and two months p.i.. Doublets were excluded, 
before gating for lymphocytes. CD8+/CD3+ positive cells were analyzed for activation with CD11a+ for 
IFN-γ secretion. B Examples of mean IFN-γ secretion by CD8+ T cells in immunized cohorts one and two 
months post immunization compared to naïve controls. C Percentage of IFN-γ secreting CD8+ T cell in 
immunized cohorts. Depicted are IFN-γ producing CD8+ T cells of individual mice (dots), as well as the 
mean of each group ± SD. Only significant statistical differences of each group compared to 
∆SLARP/P36p/P36 immunized mice are shown. *, p<0.05,***, p<0.001. The baseline represents mean naive 
+2xSD. 
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As expected, numbers of IFN-γ secreting CD8+ T cell decreased further in all cohorts five months 
post immunization with ∆SLARP/P36p/P36 still harboring the lowest numbers of IFN-γ 
producing CD8+ T cells (Fig. S1A). Similar trends could be seen for spleens stimulated with S20 
(Fig. S1B) and TNF-α producing CD8+ T cells stimulated with TRAP (Fig. S2A) and S20 (Fig. 
S2B). Splenic cells restimulated with OVA did not show elevated CD8+ T cell presence (Fig. 
S1EC and Fig. S2C). 
3.2 Inducing PTEX-dependent export in liver stages for an improved malaria 
vaccine candidate 
Host cell remodeling is critical for successful Plasmodium replication inside erythrocytes and 
achieved by targeted export of parasite-encoded proteins into the host cell cytoplasm. In 
contrast, during liver infection, the malarial parasite appears to avoid protein export, perhaps to 
limit exposure of parasite antigens by infected liver cells via MHCI. Matz et al. have previously 
shown that the ATPase of the protein translocon of exported proteins (PTEX), termed HSP101, is 
not expressed during early to mid liver infection (Matz et al., 2015). Thus, hypothesizing that this 
protein might be a limiting factor explaining the absence of liver stage PTEX-dependent export.  
To clarify PTEX component expression during the Plasmodium life cycle and in particular in 
liver stages, relative mRNA levels (to PbHSP70) of all PTEX components were determined in 
mixed blood stages, oocysts, sporozoites and liver stages (at 24, 48 and 72 hours post infection). 
Expectedly, core components (PTEX150, EXP2 and HSP101) were highly expressed in mixed 
blood stages as well as the auxiliary component PTEX88. Surprisingly, expression of the potential 
cargo unfolding helper protein TRX2 was low in blood stages. Similarly, expression of all 
components was decreased in sporozoites indicating that PTEX is dispensable for the motile 
transmission stage. Interestingly, mid liver stages revealed expression of all core components 
with very low expression for HSP101. In contrast to previous findings from Matz et al., HSP101 
mRNA levels decreased up to 48 hours post infection before meeting EXP2 like levels at 7 hours 
post infection (Fig. 15). 
Thus, HSP101 mRNA is highly expressed in all life cycle stages except for liver stages, 
demonstrating that HSP101 might be the limiting factor for successful early liver stage export. I 
therefore asked the questions 1) whether HSP101 can be overexpressed in liver stages, 2) how 
transgenic HSP101 expression influences the parasite’s life cycle, 3) if HSP101 is the limiting 
factor for liver stage export and 4) whether PTEX reconstitution in early liver stages leads to 
increased protection in immunized cohorts. 
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Figure 15 Relative mRNA levels of PTEX components during P. berghei life cycle 
Quantitative RT-PCR analysis of parasite gene expression in infected Huh7 cells. A ∆∆CT mRNA levels of 
HSP101, EXP2, PTEX150, PTEX88 and TRX2 in blood stages, sporozoites and 48h p.i. in liver stages 
normalized to PbHSP70. Data is displayed as mean of two to five independent experiments with three 
replicates each for HSP101 and PTEX150 and as mean of three technical replicates of one independent 
experiment for EXP2, TRX2 and PTEX150 ±SD. B ∆∆CT mRNA levels of HSP101 normalized to PbHSP70 
in blood stages (BS), oocysts (O), sporozoites (S) and 16h, 24h, 48h and 72h p.i. in liver stages (LS). Data is 
displayed as mean of two to four independent experiments with three replicates each for BS, S, LS 48h and 
72h p.i. and mean of three technical replicates of one independent experiments for O, LS 16h and 24h p.i. 
±SD.  
3.2.1 Normal life cycle development of parasites with constitutively weak to 
moderate HSP101 overexpression  
3.2.1.1 Generation of HSP101 overexpression parasites 
To characterize induced PEXEL-dependent protein export in early P. berghei liver stages, 
transgenic parasite lines overexpressing HSP101 were generated. This strategy would allow PTEX 
reconstitution, since other major PTEX components (PTEX150, EXP2, TRX2 and PTEX88) are 
expressed during liver development. Reconstitution of the PTEX export machinery can facilitate 
protein export in early liver stages, thus may promote presentation to and recognition of 
parasites by the host immune system. 
First, transgenic parasites were generated using two different overexpression strategies: 1) by 
endogenous promoter swap, 2) by insertion of a HSP101 copy under the control of a 
constitutively active promoter into the silent 6 locus. Plasmids for P. berghei transfection were 
assembled using the pBART-SIl6 vector (Kooij et al., 2012) harboring drug selectable hDHFR-
yFcu cassette for positive/negative clone selection, a GFP under the control of the PbHSP70 
promoter for facilitating parasite life cycle analysis or for acquiring isogenic lines by FACS 
cloning. In addition, a mCherry/triple c-Myc (3xMyc) tag sequence for protein tagging, 
3’PbPPPK-DHPS as 3’ UTR as well as two sequences for stable integration into the silent 6 locus. 
For the HSP101 extra copy overexpression plasmid pHSP101+ or pHSP101+Myc, HSP101 ORF  
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Figure 16  Stable integration of pHSP101+/Myc and pHSP101++ 
A Schematic representation of integration of linearized pHSP101+/Myc into the silent locus on 
chromosome 6 of P.b. ANKA parasites. The pHSP101+/Myc illustrates the plasmids used to generate 
HSP101+/HSP101+Myc parasites. Two sequences (yellow) homologous to the silent 6 locus were used for 
recombination. By double homologous recombination, an additional copy of HSP101 under the control of 
EF1α promoter (light green), a GFP reporter sequence (green, for parasite life cycle analysis) and 
TgDHFR/Ts resistant cassette (for positive selection with pyrimethamine) were incorporated. Shown is 
the double homologous crossover of plasmid and silent 6 locus and the final recombined silent 6 locus in 
HSP101+/HSP101+Myc parasites. Grey lines indicate regions used for genotyping recombinant parasites 
and the numbers refer to integration and WT specific primer combinations. B Schematic representation of 
integration of linearized pHSP101++ into the HSP101 locus on chromosome 9 of P.b. ANKA parasites. 
The pHSP101++ illustrates the plasmid used to generate HSP101++ parasites. Two sequences of HSP101 5’ 
UTR and N-terminal ORF (light blue) homologous to the sequence in the HSP101 locus allow double 
homologous recombination, thereby inserting a new promoter PTEX150 (blue) for HSP101 expression, a 
GFP reporter sequence (green, for parasite life cycle analysis) and TgDHFR/Ts resistance cassette (for 
positive selection with pyrimethamine) and an mCherry/3xMyc sequence, which is not expressed due to a 
missing start codon. Depicted is the double homologues crossover of plasmid and HSP101 locus leading to 
the final recombined HSP101 locus in HSP101++ parasites. Grey lines indicate regions used for 
genotyping recombined parasites and the numbers refer to integration (INT) and WT specific primer 
combinations.  C+D Genotyping PCR of HSP101+ and HSP101++ parasites. 5’ and 3’ integration and WT 
specific primer combinations (A+B) verified successful recombination events. Absence of WT signal from 
HSP101+/Myc and HSP101++ confirmed their isogenic purity. P.b. ANKA WT gDNA was used as a 
control.  
(PbANKA_0931200) was inserted into the XbaI-AgeI restriction site in frame with the 
mCherry/3xMyc tag. Upstream of HSP101 a constitutively low expressing promoter EF1α 
(PbANKA_113330) was inserted into the BssHII-XbaI restriction site (Fig. S3A). mCherry was 
excised in pHSP101+Myc plasmids and replaced by a small sequence (TGGTGGTTCTGGTG-
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GCC) linking HSP101 ORF and 3xMyc (Fig. S3B). pHSP101++ endogenous promoter swap 
plasmids were kindly provided by Joachim Matz (Fig. S3C). In brief, 5’ UTR of HSP101 was 
inserted into the NaeI-AgeI restriction site in the pBART vector (Kooij et al., 2012). Additionally, 
N-terminal HSP101 ORF was integrated under the control of PTEX150 promoter. 5’UTR and N-
terminal HSP101 served as homologous recombination sites.  
In order to generate stable transgenic parasite lines, P.b. ANKA parasites were transfected with 
ApaLI linearized plasmids creating free homologous ends using Amaxa electroporation enabling 
double homologous recombination (Fig. 16). For HSP101+/Myc, pHSP101+ or pHSP101+Myc 
linearized plasmids integrated in the silent locus in chromosome 6 and positive recombination 
events were selected with pyrimethamine in the mice drinking water followed by FACS cloning 
of GFP-positive iRBCs to generate isogenic transgenic parasite lines (Fig. 16A). For HSP101++ 
transgenic parasites, pHSP101++ integrated between the endogenous HSP101 5’UTR and ORF 
inducing a new constitutively active promoter for HSP101 expression (Fig. 16B). Similarly, 
HSP101++ positive clones were selected by pyrimethamine and a stable isogenic line was 
established by FACS cloning. To verify successful integration, transgenic parasites were 
genotyped using oligonucleotides specific for 5’ and 3’ integration as well as for the WT locus (s. 
ch. 2.1.9.2). As expected, pHSP101+ or pHSP101+Myc as well as pHSP101++ integrated at the 
desired sites as shown by 5’ and 3’ integration specific amplification and isogenic lines could be 
confirmed by absence of WT specific amplifications (Fig. 16C+D). 
Taken together, stable isogenic HSP101 overexpressing P.b. ANKA parasite lines were generated, 
showing that constitutive low overexpression of HSP101 does not interfere with parasite blood 
stage development. These parasite lines enable further characterization of the life cycle 
progression with constant HSP101 overexpression and eventually liver stage export analysis. 
3.2.1.2 Normal life cycle progression of HSP101+ and HSP101++ parasites 
To examine the phenotype of HSP101+/Myc and HSP101++, parasite development was analyzed 
throughout the parasite life cycle. Phenotypic analysis can provide answers to whether low to 
moderate overexpression of HSP101 leads to developmental delay and/or arrest. Normal life 
cycle progression of HSP101+ and HSP101++ line is key to successful liver stage export 
evaluation. 
Successful generation of stable isogenic lines confirmed that low to moderate overexpression of 
HSP101 does not interfere with blood stage development. To demonstrate that HSP101 is 
expressed in blood stages, a blood stage immunofluorescence assay was performed with 
HSP101+/Myc parasites. Weak expression of HSP101, depicted in red for mCherry tag, was 
observed in HSP101+ blood stages (Fig. 17B). Notably, in gametocytes HSP101-mCherry 
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localized to the PVM, where PTEX complex assembles. Similarly, normal blood stage 
development was observed for HSP101+Myc parasites (Fig. S4B).  
To further investigate transgenic parasite development during sexual reproduction in the 
mosquito vector, female Anopheles stephensi mosquitoes were allowed to feed on mice infected 
with HSP101+ or HSP101++ parasites. Successful development in the mosquito was determined 
at day 10 for oocyst, day 14 for midgut sporozoites and day 17 for salivary gland sporozoite 
formation and results were compared to P. berghei WT parasites (P. bergreen) (Matz et al., 2013), 
also expressing GFP under the control of HSP70 promoter to account for any potential 
developmental delays due to GFP expression. Similar to WT, HSP101+ showed oocysts 
development on the outside of mosquito midguts and WT-like numbers of midgut sporozoites 
on day 14 post infection (Fig. 17A). Midgut infectivity and numbers of salivary gland sporozoite 
in HSP101+ and HSP101++ revealed no differences to WT (Table S2). HSP101 was moderately 
expressed in HSP101+ oocysts and sporozoites (Fig. 17A).  
Thus, development of transgenic parasite lines HSP101+/Myc and HSP101++ in the mosquito 
vector showed no significant difference to WT parasite and can be further analyzed for exo-
erythrocytic growth and liver stage export. 
 
Figure 17 Normal HSP101+ oocyst and sporozoite development 
A+B Live imaging of sporozoites (nuclear staining with Hoechst 33342 1:5,000 and motility inhibition 
with 1:50 Phalloidin, scale bar: 5 µm), oocyst at day 14 post mosquito infection harboring midgut 
sporozoites (scale bar: 10 µm) and infected mosquito midguts at day 10 p.i. harboring Plasmodium oocysts 
(scale bar: 100 µm). Expression of HSP101-mCh is displayed in red and transgenic parasite marker GFP 
staining the parasite’s cytoplasm in green. B Live imaging of asexual blood stages throughout the 
replication cycle: ring stages, trophozoites and gametocytes. Cells were stained with Hoechst 33342 1:5,000 
for nuclear staining. Expression of HSP101-mCh is displayed in red was observed in the PVM. Transgenic 
parasite marker GFP staining the parasite’s cytoplasm is shown in green. Scale bar: 5 µm. 
Parasite liver stage development is key to establish a symptomatic blood stage infection. Upon a 
bite of an infected mosquito, sporozoites travel to the liver where they grow from one sporozoite 
into thousands of liver-merozoites, which subsequently infect red blood cells (RBC). To examine 
whether HSP101+ and HSP101++ parasites are able to complete exo-erythrocytic development 
and establish a patent blood stage infection, cohorts of C57BL/6 mice were intravenously infected 
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with a high dose of HSP101+ and HSP101++ sporozoites and monitored for blood stage pre-
patency, parasite growth and experimental cerebral malaria (ECM) development (Fig. 18).  
To evaluate whether parasites are able to undergo normal liver stage development and initiation 
of blood stage infection, parasite blood stage development was monitored with the help of 
Giemsa-stained thin blood smears starting 3 days post infection. Intra-hepatic development in 
C57BL/6 mice takes up to 50-60 hours post infection enabling asexual blood stage parasite 
detection 3 days post infection (Khan & Vanderberg, 1991). Interestingly, a one day delay in pre-
patency was observed in mice infected with HSP101+ parasites as compared to WT, which 
developed a patent blood stage infection 3 days post infection (Fig. 18A). Similar results were 
observed for HSP101+Myc sporozoite i.v. injection whereas bites of 15 infected mosquitoes 
reversed the delays seen in pre-patency (Fig. S4A). Furthermore, these findings were confirmed 
by quantifying relative parasite RNA levels in mice livers 48 hours post infection. To determine 
parasite load in the liver of infected animals, livers were excised, parasite and host RNA extracted 
and a qRT-PCR conducted on RNA derived cDNA measuring ∆∆CT levels of parasite Pb18s to 
mouse GAPDH. As expected, no significant difference was observed in HSP101+ parasite burden 
in the liver compared to parasite burden in WT infected mice (Fig. 18G). Notably, HSP101+ 
RNA levels showed a trend of increased parasite load in the liver. In in vivo infection a 
proportion of exo-erythrocytic stages has fully matured at 44 hours post infection and starts to 
rupture to release merosomes to induce blood stage infections (Khan & Vanderberg, 1991). Since 
a delay in pre-patency was observed for HSP101+ parasites, the majority of parasites might still 
be present in the infected liver. Similar to HSP101+, pre-patency was determined for mice 
infected with HSP101++ parasites. Pre-patency analysis showed no significant difference to WT 
parasites, but a trend towards 0.5 days delay in blood stage development was observed (Fig. 18B). 
Thus, the results clearly demonstrate that transgenic parasites complete liver stage development 
but are found to have a delay in pre-patency by 0.5-1 day.  
Based on observing a patent blood stage infection in HSP101+ and HSP101++ infected mice, it 
was investigated how and if HSP101 overexpression influences parasite growth and whether it 
determines disease outcome. To answer the first question, blood stage parasitemia of HSP101+ 
and HSP101++ infected mice was measured from day 3 to 7 using Giemsa-stained thin blood 
smears of individual mice. Parasite growth of HSP101+ was similar to WT except the one-day 
delay in patency (Fig. 18C). Similarly, there was no significant difference detected in HSP101++ 
parasite growth compared to WT (Fig. 18D).  
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Figure 18 HSP101+ and HSP101++ liver stage development is slightly affected while remaining normal 
blood stage maturation 
A+B Kaplan-Meier curve of blood infection over time after sporozoite infection. C57BL/6 mice were 
infected with 1x104 HSP101+ (green), HSP101++ (blue) or WT (dark grey) sporozoites or by bites of 15 
HSP101++ infected mosquitoes and blood infection was monitored by daily microscopic examination of 
Giemsa-stained blood smears of three (for HSP101+) and two (for HSP101++) independent biological 
experiments. Statistical analysis: Log rank (Mantel-Cox) test, n.s., non-significant; *, p<0.05. C+D Blood 
stage growth (parasitemia %) 3-8 days post sporozoite infection is unaffected in comparison to WT 
infections. Giemsa-stained thin blood smears from pre-patency analysis were additionally used for 
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quantifying parasitemia of three (for HSP101+) and two (for HSP101++) independent biological 
experiments. Shown is the mean of all experiments ±SD. Statistical analysis: growth slope difference n.s., 
non-significant. E+F Kaplan-Meier curve depicts survival of mice over time after sporozoite infection. 
Experimental cerebral malaria (ECM) in HSP101+ (green), HSP101++ (blue) and WT (dark grey) infected 
C57BL/6 mice was monitored 6-12 days post sporozoite infection of three (for HSP101+) and two (for 
HSP101++) independent biological experiments. Statistical analysis: Log rank (Mantel-Cox) test n.s., non-
significant; *, p<0.05. G Relative parasite rRNA levels 48 hours post sporozoite infection are unaffected in 
HSP101+ infected mice. C57BL/6 mice were infected with 1x104 HSP101+ (green) or WT (dark grey) 
sporozoites. The livers were excised 48h post challenge, RNA extracted and cDNA amplified. Quantitative 
real-time PCR on Pb18s rRNA against the murine GAPDH mRNA is depicted showing relative parasite 
load in the liver of individual infected animals (dots), as well as the general mean ±SD. Only significant 
differences are shown. Statistical analysis: Mann-Whitney-U-test n.s., non-significant; 
In order to analyze pathology of blood stage infections, mice were monitored for ECM 
development within 6-8 days post sporozoite inoculation. ECM is a severe form of malaria, where 
parasites are able to cross the blood-brain barrier. C57BL/6 mice frequently develop ECM under 
laboratory conditions and it is used as a marker for disease progression and severity. 
Interestingly, HSP101+ and HSP101++ mice developed ECM despite the 0.5-1 day delay in pre-
patency. However, only 20% of animals developed ECM if infected with HSP101+ compared to 
70% of WT infected mice (Fig. 18E). In contrast, only 50% of HSP101++ infected animals 
developed ECM (Fig. 18F), however this was consistent with ECM development in WT infected 
mice in this experiment.  
Taken together, the results show that pre-patency is minimally affected in HSP101+ and 
HSP101++ infected mice, but does not interfere with subsequent parasite growth. However, delay 
in pre-patency in HSP101+ infected mice heavily influences disease outcome as compared to WT 
and HSP101++ infections. These results demonstrate that neither pre-patency nor parasite 
growth but disease progression is severely affected by low to moderate overexpression of HSP101. 
3.2.1.3 HSP101 overexpression does not interfere with exo-erythrocytic development of 
HSP101+ and HSP101++ parasites in vitro 
Having found the before mentioned 0.5-1 day delay in pre-patency, reasoned in depth studies of 
HSP101+ and HSP101++ liver development, asking whether HSP101 is expressed in HSP101+ 
and HSP101++ liver stages, how it influences sporozoite infectivity and exo-erythrocytic 
development and if other liver stage signature proteins are affected by HSP101 overexpression. 
In order to answer these questions, hepatoma cells were infected in vitro with a constant number 
of infective transgenic and WT control sporozoites and EEF growth and HSP101 expression were 
monitored and sizes as well as numbers of infected cells were quantified. Figure 20 presents 
transgenic parasite growth in vitro. In HSP101+, parasites overexpression of HSP101 and 
localization to the PV could be detected at 24, 48 and 72 hours post infection by staining the red 
mCherry tag as well as the HSP70 as parasite cytoplasm marker and Hoechst for nuclear staining 
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(Fig. 20A). To verify PVM presence and maintenance, HSP101+ parasites were stained with 
antibodies against the PVM resident protein UIS4 (red). USI4 staining was detected in the PV 
and TVN at 24, 48 and 72 hours post infection. For HSP101++ parasite growth was monitored 
with the help of antibody staining against HSP70 (green) or GFP (green) and UIS4 (red) or LC3 
(red), an early host cell autophagy marker labeling the PVM from the host cell side, to indicate 
parasite growth and PVM presence and maintenance, respectively. HSP101++ EEF growth rates 
were similar to WT and UIS4 expression was detected in the PV and TVN at 24, 48 and 72h post 
infection (Fig. 20B). Similarly, LC3 was observed at 16 hours post infection (Fig. 20C). In 
contrast to HSP101+, HSP101 expression in HSP101++ could not be verified with 
immunofluorescence assay (IFA), as a tag to visualize HSP101 was not included in these 
transgenic parasites. Therefore, liver stage mRNA levels of HSP101 at 16, 24, 48 and 72 hours 
post infection were quantified to estimate protein overexpression (Fig. 19). As expected, HSP101 
mRNA levels were markedly elevated at 24 and 48 hours in HSP101++ compared to weak 
expression in WT (Fig. 19). Thus, it was shown for both HSP101+ and HSP101++ that HSP101 
could be overexpressed in low levels without interfering with the parasite’s liver development or 
expression of PVM proteins indicating full maintenance of PVM throughout the liver stage. 
 
Figure 19 Elevated liver stage HSP101 mRNA levels in HSP101++ parasites 
Relative liver stage HSP101 mRNA levels in HSP101++ parasites. Total RNA was extracted from 
HSP101++ or WT P.b. infected Huh7 cells at 16, 24, 48 and 72 hours p.i., followed by a qRT-PCR on RNA 
derived cDNA. ∆∆CT of HSP101 mRNA levels were normalized to HSP70 mRNA levels. Depicted is the 
mean of two (one for 24 hours) independent experiments ±SD. 
Taken together, HSP101+ and HSP101++ parasites revealed WT-like infection, development and 
persistence of parasites in infected cells with consistent HSP101 and signature PVM protein 
expression, demonstrating that HSP101 overexpression is possible without interfering with 
parasite infectivity and growth.  
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Figure 20 HSP101 is overexpressed in exo-erythrocytic stages of HSP101+ and HSP101++ and localizes to the 
parasite’s PV 
A Immunofluorescence microscopy analysis (IFA) of α-mCherry (HSP101, red) and α-HSP70 (green) 
stained HSP101+ and WT P.b. parasites at 24, 48 and 72 hours post hepatoma cell (Huh7) infection shows 
localization of HSP101 to the parasite’s PV. Nuclear staining was performed with Hoechst 33342 (blue). 
Upper panel is showing mCherry (HSP101) staining only and lower panel is displaying the merged image. 
(Scale bar 10 µm) B Localization of UIS4 by IFA in HSP101+, HSP101++ and WT P.b. parasite infected 
Huh7 cells at 24, 48 and 72 hours p.i.. Upper panel is showing α-UIS4 (red) staining only, lower panel is 
depicting the merged image with α-HSP70 (green) and nuclear staining with Hoechst 33342 (blue). (Scale 
bar 10 µm) C IFA of α-LC3 (red) and α-GFP (green) stained HSP101++ and WT P.b. parasites at 24 hours 
post Huh7 infection reveals LC3, a host autophagy marker, localization to the parasite’s PVM. Nuclear 
staining is displayed with Hoechst 33342 (blue). Upper panel is showing α-LC3 (red) staining only, lower 
panel is displaying the merged image. (Scale bar 10 µm) 
3.2.1.4 Reduced protection in HSP101+ and HSP101++-immunized cohorts 
Immunization with late liver stage arresting parasites e.g. ∆PALM and ∆MFS6 have shown to 
induce superior protection compared to immunization with early arresting irradiated sporozoites 
(Haussig et al., 2011, Kenthirapalan et al., 2016). One reason apart from increased persistence 
and parasite biomass is the expansion of parasite antigens possibly increasing parasite 
recognition by the host’s immune system by late liver stage protein export. To define the role of 
protein export in protection efficacy in HSP101+ and HSP101++ potentially PTEX reconstituted 
parasites, immunization experiments were carried out in C57BL/6 mice. Cohorts of C57BL/6 
received a prime/boost vaccination within 10 days, with either a 1x104 of HSP101+, HSP101++ or 
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WT sporozoites that were chemically attenuated with azithromycin (AZ) and were challenged 
with 1x104 of WT sporozoites 3 months later (Fig. 21A). AZ treatment leads to a delayed death 
phenotype, resulting in merozoite release and first round of blood stage replication before death. 
This model was chosen to enable comparison of the influence of protein export in transgenic 
parasites and natural late liver stages. Additionally, mice only received two immunizations as 
three immunizations have shown to fully protect from subsequent infection.  
 
Figure 21 Inferior protection in HSP101+ and HSP101++-immunized animals 
Kaplan-Meier analysis of blood infection over time after sporozoite challenge reveals inferior protection in 
HSP101+ and HSP101++-immunized animals. A Schematic representation of immunization procedure. 
C57BL/6 mice were immunized and boosted at a 10-day interval with 1x104 sporozoites i.v., challenged 
with 1x104 WT P.b. sporozoites i.v. 87 or 260 days post 1st immunization and blood infection was 
monitored by daily microscopic examination of Giemsa-stained blood films. (modified pictures from 
Smart, servier medical art) B Protection of mice immunized with irradiated HSP101++ (γ-HSP101++, 
blue) and γ-WT (dark grey) sporozoites. WT P.b. sporozoite challenge was performed 87 days post 
immunization and non-immunized control animals (naïve, light grey) confirmed sporozoite infectivity by 
patent blood stage infection 3 days post inoculation. Statistical analysis: Log rank (Mantel-Cox) test  **, p< 
0.01, ***, p< 0.001 C Protection of mice immunized with HSP101+ (green) and WT (dark grey) 
sporozoites under AZ drug cover. Challenge with WT P.b. sporozoites was performed 87 days post 
immunization and non-immunized control animals (naïve, light grey) confirmed sporozoite infectivity by 
patent blood stage infection 3 days post inoculation. Statistical analysis: Log rank (Mantel-Cox) test n.s., 
non-significant. D Protection of mice immunized with irradiated HSP101++ and γ-WT sporozoites under 
AZ drug cover against WT P.b. sporozoite challenge 260 days p.i.. Blood stage development was 
monitored and WT P.b. sporozoites infectivity was confirmed in non-immunized animals (naïve, light 
grey) by patent blood stage infection 3 days post inoculation using Giemsa-stained thin blood smears. 
Statistical analysis: Log rank (Mantel-Cox) test n.s., non-significant. 
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To decipher differences in potent protection of the transgenic vaccine, a semi-protective two 
immunizations scheme was chosen. Only 60% of HSP101+ immunized animals were protected 
against WT infection after 3 months, however, protection in cohorts immunized with WT were 
not significantly higher (80% protection). Naive mice that received a challenge infection of 1x104 
WT sporozoites to determine WT sporozoite infectivity developed a patent blood stage infection 
3-4 days post infection (Fig. 21C). Unexpectedly, only 20% of irradiated HSP101++ immunized 
mice were protected compared to 70% of γ-WT sporozoite immunized mice against challenge 
infections. Control mice were again blood stage positive three days post infection confirming 
normal WT sporozoite infectivity (Fig. 21B). Protection in HSP101++ under AZ drug cover 
immunized animals vanished completely when challenged at 260 days post immunization (Fig. 
21D). 
Collectively, slightly lower protection was observed in HSP101+ and HSP101++-immunized mice 
as compared to mice immunized with WT sporozoites, both under AZ drug cover or after 
irradiation of sporozoites. This indicates that HSP101 overexpression leading to potential early 
liver stage export does not lead to superior protection in immunized cohorts but tends to lower 
efficacy. 
3.2.2 Absence of PEXEL-dependent export in HSP101+ and HSP101++ liver stages 
Reduced protection levels in mice immunized with HSP101 overexpressing parasites hints 
towards the absence of early liver stage export in these parasites. Based on observing reduced 
protection in HSP101+ and HSP101++ immunized mice, I asked whether HSP101+ and 
HSP101++ parasites actually export proteins during early liver development, whether different 
PEXEL sequences influence export efficiency and when export commences in early liver stages.  
To answer these questions, crossing of transgenic parasites with different reporter lines were 
performed to analyze PEXEL-dependent export in liver stages (Table 3). In order to confirm 
export in HSP101+Myc and HSP101++, transgenic parasites were crossed by co-infection of 
mosquitoes with export reporter lines. These reporter lines contain CS-PEXEL or IBIS-PEXEL 
fused in frame to mCherry for subsequent export analysis using IFA. The PEXEL constructs are 
under the control of IBIS promoter, which is active in several life cycle stages, or UIS4 promoter, 
that is liver stage specific. Transgenic and reporter lines were sexually crossed in mosquitoes 
feeding on a double infected mouse and subsequently mixed cultures of sporozoites were isolated 
to infect Huh7 cells in vitro (Fig. 22A). 25% of the mixed sporozoite cultures carry one 
chromosome each with the desired genetic modification as visualized by fluorescent tags (GFP in 
HSP101 overexpression parasites and mCherry in reporter constructs). The other 75% are a 
mixture of WT, HSP101 overexpression parasites (only green) or reporter parasites (only red) 
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sporozoites. To evaluate export in exo-erythrocytic stages, infected Huh7 were imaged live as 
well as after antibody staining. Strikingly, the reporter construct UIS4::CS-PEXEL-mCh stayed 
confined to the PV of HSP101+Myc as seen for reporter constructs in WT parasites. UIS4::CS-
PEXEL-mCh remained in the parasite PV 16, 40 and 48 hours post infections (Fig. 22B). Similar 
observations were made for further transgenic crossings with a list of different other reporter 
constructs (Table 3). CSP is among the only two proteins reported to translocate during early 
liver stage development, whether this is the case remains controversial (Singh et al., 2007, 
Cockburn et al., 2011). This notion was not confirmed in HSP101+Myc parasites as staining of 
endogenous CSP at 4 hours post infection revealed confinement of CSP to the PV (Fig. 22C). 
 
Table 3 Export ability of reporter lines in HSP101+Myc or HSP101++ parasites 
Transgenic parasites Reporter line Export (Yes/No) 
HSP101+Myc UIS4::CS-PEXEL-mCh N 
 UIS4::IBIS-PEXEL-mCh N 
 IBIS::IBIS-PEXEL-mCh N 
 UIS4::CS-PEXEL-OVA N 
HSP101++ UIS4::CS-PEXEL-mCh N 
 UIS4::IBIS-PEXEL-mCh N 
 IBIS::IBIS-PEXEL-mCh N 
 UIS4::CS-PEXEL-OVA N 
 
Thus, protein export could not be confirmed in HSP101+Myc and HSP101++ parasites neither by 
using a range of PEXEL sequences nor at different time points during liver stage maturation, 
demonstrating that low overexpression of HSP101 does not lead to PEXEL-dependent protein 
export. 
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Figure 22 Export is blocked in HSP101+ parasites 
A Schematic representation of sexually crossing two P.berghei lines in the mosquito vector. Transgenic 
parasite HSP101+Myc (green) were co-infected with UIS4::CS-PEXEL-mCh (red) expressing parasites in 
NMRI mice and sexually crossed in mosquitoes. 25% of the mixed sporozoites carry one chromosome each 
with the desired genetic modification as visualized by fluorescent tags (GFP in HSP101 overexpression 
parasites and mCherry in reporter constructs, red and green). The other 75% are a mixture of 25% WT 
(grey), 25% HSP101 overexpression parasites (only green) or  25% reporter parasites (only red) 
sporozoites. Hepatoma cells were infected with genetically mixed sporozoites and export of reporter 
constructs was monitored. B Live imaging of of hepatoma cell infection at 16, 40 and 48 hours with mixed 
sporozoite, HSP101+Myc/UIS4::CS-PEXEL-mCh (termed crossed, red and green), HSP101+Myc (green), 
UIS4::CS-PEXEL-mCh (red). The mCherry (red) of the reporter construct remains confined to the PV in 
transgenic lines expressing GFP (green) at all time points p.i.. 1st panel is showing mCherry (UIS4::CS-
PEXEL-mCh) only, 2nd panel is displaying GFP (HSP101+Myc) only, 3rd panel is showing the merged 
image and the last panel merge and DIC. (Scale bar: 10µm) C Immunofluorescence microscopy analysis 
(IFA) of α-CSP (red) and α-GFP (green) stained HSP101+Myc and WT P.b. parasites at 4 hours post 
hepatoma cell (Huh7) infection shows localization of CSP to the parasite’s PV. Nuclear staining was 
performed with Hoechst 33342 (blue). (Scale bar 10 µm) 
Results 
  76 
3.2.3 Abort of pre-erythrocytic development in strong HSP101 overexpressing 
parasites 
3.2.3.1 Generation and in vivo life cycle analysis of HSP101+++ parasites reveals impaired 
pre-erythrocytic development 
Protein export machineries are complex systems relying on constant adequate amounts of 
component expression, correct protein folding and complex assembly. The stoichiometric ratio 
of complex proteins can be an important factor for correct protein complex assembly. Having 
observed that HSP101 can be weakly overexpressed without interfering with the life cycle, but 
thereby failing to enable protein export, I asked whether high liver stage specific overexpression 
of HSP101 interferes with pre-erythrocytic development. Moreover, I raised the questions 
whether strong overexpression enables PTEX assembly, thereby commencing liver stage export 
and how this could have an effect on protection efficacy of the transgenic vaccine candidate. 
 
Figure 23 Stable integration of pHSP101+++/Myc 
A Schematic representation of integration of linearized pHSP101+++/Myc into the silent locus on 
chromosome 6 of P.b. ANKA parasites. The pHSP101+++/Myc illustrates the plasmids used to generate 
HSP101+++/Myc parasites. By double homologous recombination an additional copy of HSP101 under 
the control of UIS4 promoter (dark red), a GFP reporter sequence (green, for parasite life cycle analysis) 
and TgDHFR/Ts resistance cassette (for positive selection with pyrimethamine) are incorporated. Shown 
is the double homologous crossover of the plasmid’s two sequences (yellow) homologous to the silent 6 
locus into the locus and the final recombined silent 6 locus in HSP101+++/Myc parasites. Grey lines 
indicate regions used for genotyping recombined parasites and the numbers refer to integration and WT 
specific primer combinations. B Genotyping PCR of HSP101+++ and HSP101+++Myc parasites. 5’ and 3’ 
integration and WT specific primer combinations (A) verified successful recombination events. Absence 
of WT signal from HSP101+++/Myc confirmed their isogenic purity. WT gDNA was used as a control.  
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In order to study the influence of strong HSP101 overexpression on liver stage development and 
export, parasites overexpressing HSP101 under the liver stage specific UIS4 promoter were 
generated similarly as described in 3.2.1 for HSP101+ parasites. For HSP101+++ parasites UIS4 
5’ UTR was integrated in the BssHII-AgeI restriction site instead of the EF1α 5’ UTR, upstream of 
HSP101 ORF for acquiring pHSP101+++/3xMyc (Fig. S5A). mCherry was excised and replaced 
by a linker, to ensure correct Myc expression, in pHSP101+++Myc (Fig. S5B). Successful 
pHSP101+++ and pHSP101+++Myc integration into the silent 6 locus on chromosome 6 of P.b. 
ANKA with subsequent FACS cloning to receive isogenic lines was confirmed by genotyping 
PCR with specific primer pairs (s. ch. 2.1.9.2) for 5’ and 3’ integration and absence of WT locus 
amplification (Fig. 23).  
 
Figure 24 Complete arrest of pre-erythrocytic stages of HSP101+++ parasites in vivo 
A Kaplan-Meier curve showing percentage of blood stage positive mice over time after infection with 
sporozoites. C57BL/6 mice were infected i.v. with 1x104 or 1x105 HSP101+++ (dark red) or WT (dark 
grey) sporozoites or natural transmission by exposure to 15 HSP101+++ (dark red) infected mosquitoes. 
Blood infection was monitored by daily microscopic examination of Giemsa-stained thin blood smears 
starting 3 days p.i.. Data is representative of eight independent experiments with five mice each for 
infections with 1x104 HSP101+++ of which two were performed with a different isogenic parasite line. 
Experiments of infections with 1x105 and natural infections were performed in two independent 
experiments. Statistical analysis: Log rank (Mantel-Cox) test, ***, p<0.001. B Relative parasite rRNA levels 
48 hours post sporozoite infections are significantly reduced in HSP101+++ infected mice. C57BL/6 mice 
were infected with 1x104 HSP101+++ (dark red) or WT (dark grey) sporozoites. The livers were excised 
48h post challenge, RNA extracted and cDNA amplified. Quantitative real-time PCR on Pb18s rRNA 
against the murine GAPDH mRNA is depicted showing relative parasite load in the liver of individual 
infected animals (dots), as well as the general mean ±SD. Only significant differences are shown. Statistical 
analysis: Mann-Whitney-U-test , **p<0.01. 
HSP101+++ and HSP101+++Myc developed normally in blood and mosquito stages (Table S3). 
To estimate whether strong overexpression interferes with parasite liver stage development, 
C57BL/6 mice were infected intravenously with a high dose of infective sporozoites and pre-
patency was analyzed 3 to 10 days post infection. Surprisingly, mice remained blood stage 
negative compared to mice infected with WT sporozoites, which developed a patent blood stage 
infection 3 days post infection (Fig. 24A and Table 4). To rule out that sporozoites numbers 
influence disease outcome, mice were infected with a ten times higher dose of sporozoites, 
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however, strikingly infected mice remained blood stage negative. In addition, cohorts were 
exposed to bites of infectious mosquitoes to demonstrate the natural infection routes. Similarly 
to the previous infections no blood stage parasites were observed. Notably, HSP101+++Myc 
infected animals developed blood stages on day 5 post infection whereas in two experiments 
remained blood stage negative (Fig. S6A). To exclude that mCherry overexpression is the reason 
for the parasite’s developmental arrest, mice were infected with UIS4::mCh (Silvie et al., 2014) or 
:::HSP101-mCh (Matz et al., 2015) sporozoites and parasite development was monitored 3 to 10 
days post infection. In contrast to HSP101+++, mice developed a patent blood stage infection 
after 3 days similar to WT parasites (Fig. S8A and Table 4). To confirm the pre-patency 
observations, parasite load in the hosts’ livers was determined. C57BL/6 mice were infected with 
a 1x104 of sporozoites, liver excised 48h post infection and parasite and host RNA extracted. 
Relative parasite load was determined by comparing levels of parasite Pb18s RNA to host 
GAPDH RNA. Parasite liver load was over 1,000-fold reduced in HSP101+++ infected animals 
compared to WT infected mice, indicating either a low infection rate or an early liver stage arrest 
(Fig. 24B). 
Table 4 Pre-patency of HSP101 overexpressing P. berghei parasites 
 
a Shown are numbers and respective percentage (in brackets) of infected to total animals.  
b The prepatent period is defined as time to detection of first blood stage parasites after sporozoite 
infection. Shown are the day of commencing blood stage infection and in brackets the average start of the 
prepatent period. 
 
Parasite strain Route of infection Blood stage-
positive micea 
Prepatent periodb 
HSP101+ i.v. 1x104 spz    13/14 (92%) >3 days (4) 
HSP101+Myc i.v. 1x104 spz 1/1 (100%)   4 days 
 infectious mosquito bite 2/2 (100%)   3 days 
HSP101++ i.v. 1x104 spz 7/7 (100%) >3 days (3.5) 
 infectious mosquito bite           1/1 (100%)   3 days 
HSP101+++ i.v. 1x104 spz     0/39 (0%) - 
 i.v. 1x105 spz      0/10 (0%) - 
 infectious mosquito bite         0/7 (0%) - 
 i.v. 1x104 haemocoel spz        0/5 (0%) - 
HSP101+++Myc i.v. 1x104 spz         8/20 (40%) >5 days (5.5) 
 infectious mosquito bite 7/7 (100%) >4 days (6) 
::HSP101-mCh infectious mosquito bite 6/6 (100%) >3 days (3) 
UIS4::mCh i.v. 1x104 spz 5/5 (100%) >3 days (3) 
WT i.v. 1x104 spz 40/40 (100%) >3 days (3) 
 i.v. 1x105 spz 1/1 (100%)   3 days 
 infectious mosquito bite 4/4 (100%)   3 days 
 i.v. 1x104 haemocoel spz 1/1 (100%)   3 days 
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Taken together, parasites strongly overexpressing HSP101 can be generated but high HSP101 
expression leads to full abortion of liver stage development and a low relative parasite load in the 
liver, demonstrating that HSP101 expression and potentially PTEX assembly is tightly regulated 
in Plasmodium parasites. 
3.2.3.2 Gliding is impaired in HSP101+++ sporozoites 
Based on the before mentioned reduced parasite load in the liver, I speculated that sporozoite 
motility and in consequence sporozoite infectivity is impaired in HSP101+++ parasites. This 
raises the questions whether HSP101 is overexpressed in sporozoites and if overexpression 
interferes with sporozoite motility and infectivity. 
To answer the first question, live imaging of salivary gland sporozoites was conducted. Strong 
expression of mCherry was observed in HSP101+++ sporozoites in sharp contrast to HSP101+ 
overexpression (Fig. 25A). The difference in overexpression between the two parasite lines can 
clearly be explained by the difference in promoter activity, which was measured by qRT-PCR by 
comparing relative mRNA levels of WT P.b. PTEX150, endogenous HSP101, UIS4 and GFP, 
under the control of EF1a promoter, expression relative to PbHSP70 (Fig. 24B). This notion was 
confirmed by qRT-PCR analysis of HSP101+++ compared to WT P.b. HSP101 transcript levels 
normalized to PbHSP70 (Fig. 24C). Moreover, overexpressed HSP101 localized in vesicle-like 
compartments throughout the whole sporozoite in contrast to endogenously tagged HSP101, 
which was reported to localize to the apical end of the sporozoite (Fig. 24A, Matz et al., 2015).  
 
Figure 25 Strong vesicular overexpression of HSP101 in HSP101+++ sporozoites 
A Live imaging of HSP101+++ and WT P.b. salivary gland sporozoites at day 17 post mosquito infection. 
Expression of HSP101-mCh is displayed in red and transgenic parasite marker GFP, staining the parasite’s 
cytoplasm, in green. Nuclear staining was performed with Hoechst 33342 1:5,000 and motility inhibition 
with 1:50 Phalloidin (Scale bar: 5 µm). B Quantitative RT-PCR analysis of sporozoite gene expression. 
∆∆CT mRNA levels of PTEX150, UIS4, HSP101 and GFP, under the control of EF1α promoter, in 
sporozoites normalized to PbHSP70. Data is displayed as mean of two to four independent experiments 
with three replicates each ±SD. C Quantitative RT-PCR analysis of sporozoite gene expression reveals 
increased HSP101 levels in HSP101+++ sporozoites. ∆∆CT HSP101 mRNA levels of HSP101+++ 
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compared to WT P.b. sporozoites were normalized to PbHSP70. Data is displayed as mean of two 
independent experiments with three replicates each ±SD.  
Having found divergent HSP101 expression levels and localization in HSP101+++ compared to 
WT sporozoites, I asked whether this influences sporozoite motility and infectivity. To examine 
sporozoite motility, gliding assays were performed. Once sporozoites are injected during an 
infectious mosquito bite, they travel through the dermis to reach the next blood vessel in which 
they travel to the liver where they infect hepatocytes and undergo liver stage development. 
Sporozoite gliding ability was analyzed in vitro by staining and counting gliding trails (CSP 
protein trails which are deposited by sporozoites). Strikingly, the gliding ability of HSP101+++ 
was significantly reduced by 40% as compared to WT (Fig. 26A). To rule out overuse of ATP by 
increased HSP101 levels, a triple ATPase, sporozoite gliding was also examined with sporozoites 
incubated with ATP and glucose. HSP101+++ sporozoites were able to restore motility, however, 
subsequent in vitro sporozoite infection of hepatoma cells resulted in liver stage developmental 
arrest (Fig. S9C). Similarly, to exclude that mCherry expression in sporozoites accounts for the 
defect in gliding and exo-erythrocytic growth, haemocoel sporozoites, where UIS4 promoter is 
not active, were used for subsequent in vitro and in vivo infections. Despite the enhanced 
sporozoite motility, in vitro hepatoma cell infections led to a complete developmental arrest and 
in vivo infections of C57BL/6 mice did not result in patent blood stage infections (Fig. S9). Once 
sporozoites reach the liver they transmigrate through several hepatocytes before infecting a final 
one where they mature into merozoites. The observed gliding defect let to the question whether 
the 20% of sporozoites that were able to glide were also able to transmigrate through hepatoma 
cells before infecting a final hepatoma cell for initiating liver stage growth. During 
transmigration sporozoites create holes in the hepatocyte membranes (Mota et al., 2001). To 
determine transmigration ability, Huh7 cells were infected with sporozoites in dextran 
containing medium. Dextran is a membrane non-permeable dye. Sporozoites created holes 
during migration where dextran could enter the cells and percentage of dextran influx was 
measured with FACS. Transmigration was significantly reduced by 30% in HSP101+++ parasites 
(Fig. 26B). Natural non–sporozoite induced dextran influx was accounted for by a negative 
control of dextran and cells only.  
Taken together, strong overexpression was detected in HSP101+++ sporozoites and gliding and 
transmigration ability were strongly inhibited, demonstrating that strong HSP101 overexpression 
has influence on sporozoite motility. 
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Figure 26 Gliding and transmigration are impaired in HSP101+++ sporozoites 
A Impaired sporozoite gliding motility of HSP101+++. Salivary gland HSP101+++ sporozoites were 
excised at day 17 and left to settle and subsequently glide on a BSA-covered 2-dimensional glass slide. 
Sporozoite surface protein trails shed by gliding sporozoites were stained with α-sporozoite surface 
antibody and Hoechst 33342 for nuclear staining. Shown is a representative immunofluorescence image of 
HSP101+++ and WT P.b. salivary gland sporozoites (Scale bar: 5 µm). Three independent experiments 
(dots) were used to determine the percentage of gliding sporozoites. Depicted are the mean ±SD. 
Statistical analysis: Mann-Whitney-U-test **, p<0.01 B Impaired transmigration of HSP101+++ 
sporozoites. Shown is the FACS quantification of dextran-positive hepatoma cells after two hours post 
sporozoite infection. 1x106 Huh7 cells were infected with 7.5x104 HSP101+++ or WT P.b. sporozoites or 
dextran+/sporozoites- (as a control for dextran influx without sporozoite infection) and analyzed with 
FACS for dextran influx using MACSquant. Upper panel: Examples of gating strategy: FITC (dextran) is 
blotted against FFC for dextran-/sporozoite-, dextran+/sporozoite- and dextran+/sporozoite+ (WT) cells. 
Lower panel: Depicted are individual percentages of dextran positive cells of each replicate of three 
independent experiments (with three replicates each) ±SD. Statistical analysis: Mann-Whitney-U-test *, 
p<0.05, 
3.2.3.3 Liver stage development is arrested in HSP101+++ parasites in vitro 
HSP101+++ sporozoites are strongly impaired in their gliding ability, however, the 20% that are 
able to glide are also able to transmigrate through hepatoma cells, demonstrating that a second 
defect during hepatocyte entry or development prevents patent blood stage infections. Therefore, 
I was prompted to analyze HSP101+++ infectivity and liver stage development in vitro. To define 
the role of strong HSP101 overexpression for sporozoite infectivity, hepatoma cells were infected 
with HSP101+++ sporozoites and percentage of intra- and extracellular sporozoite were 
quantified two hours post infections. Unexpectedly, similar numbers of intracellular parasites 
were detected after hepatoma cell infection with HSP101+++ and WT parasites. Notably, a trend 
towards lower infection rate was observed in HSP101+++ infected cells (Fig. 27A). HSP101+++ 
sporozoites showed no sign of decreased in vitro infectivity, hence, suggesting that a second 
defect in liver stage development might account for the lack of patent blood stage infection. 
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Figure 27 HSP101+++ arrests during liver stage development 
3x104 hepatoma (Huh7) cells were infected with 1x104 HSP101+(dark red) and WT (dark grey) sporozoites 
per well. A Normal invasion of HSP101+++ sporozoites. Hepatoma cells were infected with HSP101+++ 
or WT P.b. sporozoites. After fixation, extracellular sporozoites were stained with α-CSP antibody and α-
mouse Alexa546 (red) and after a permeabilization step stained again with α-CSP antibody and α-mouse 
Alexa488 (green) for intra- and extracellular parasites. This allows differentiation of attached (red and 
green) and invaded (green) sporozoites. Representative immunofluorescence image shows one attached 
(red, green) and one invaded (green) sporozoite. Nuclear staining was performed with Hoechst 33342. 
Intracellular sporozoites were quantified by determining attachment versus invasion per 100 parasites per 
replicate. Results represent the mean of replicates of three independent experiments and the overall mean 
±SD. Statistical analysis: Mann-Whitney-U-test, ns, not significant. B Representative immunofluorescence 
microscopy images of α-mCherry (HSP101, red) and α-HSP70 (staining the parasite’s cytoplasm in green) 
stained HSP101+++ and WT P.b. parasites at 24, 48 and 72 hours post hepatoma cell (Huh7). Nuclear 
staining was performed with Hoechst 33342 (blue) (Scale bar: 10 µm). C EEF sizes of HSP101+++ and WT 
P.b. parasites at 24 hours. 20 parasites per technical replicate of two independent experiments were 
measured by immunofluorescence microscopy and analyzed with Fiji for determining the size (µm) of the 
parasite. Depicted are individual parasites per time point (dots) and the mean ±SD. Statistical analysis was 
performed on the means of three replicates: Mann-Whitney-U test, ***, p<0.001. 
Liver stage development goes hand in hand with parasite expansion from ~5 µm2 to 800 µm2  and 
can be used as an estimate for parasite maturation in the liver. In order to confirm liver stage 
arrest, EEF size at 24 hours post infection was measured. EEF sizes were significantly reduced in 
HSP101+++ parasites with only ~ 25 µm2 in size compared to ~35 µm2 in WT parasites at 24 
hours post infection (Fig. 27C). Moreover, developmental arrest is clearly visualized in images of 
antibody stained EEFs, where HSP101+++ EEFs remain smaller in size at 24 hours post infection 
(Fig. 27B). Notably, HSP101-mCh signal localized to the whole parasite and was not confined to 
the PV of the parasite (Fig. 28). As HSP101+++ parasites revealed a similar phenotype as 
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described for ∆UIS4 (Mueller et al., 2005), experiments confirming presence of UIS4 and other 
PVM residual proteins were conducted to rule out false integration into and destruction of UIS4 
locus. To exclude the possibility of accidental ∆UIS4 parasite generation, the UIS4 locus of 
HSP101+++ was characterized by genotyping using WT UIS4 locus specific primer pairs and 
relative mRNA levels of UIS4 were determined in HSP101+++ sporozoites. Genotyping revealed 
the presence of an intact UIS4 locus and relative UIS4 mRNA levels in HSP101+++ were similar 
to mRNA levels of WT parasites (Fig. S10).  
 
Figure 28 HSP101+++ exo-erythrocytic stages establish and maintain a PVM 
A Immunofluorescence microscopy analysis (IFA) of α-mCherry (HSP101, red) and α-HSP70 (staining the 
parasite’s cytoplasm in green) stained HSP101+++ and WT P.b. parasites at 24, 48 and 72 hours post 
hepatoma cell (Huh7) infection shows distorted localization of HSP101. Nuclear staining was performed 
with Hoechst 33342 (blue). Upper panel is showing mCherry (HSP101) staining only, lower panel is 
displaying the merged image. (Scale bar 10 µm) B Localization of UIS4 by IFA in HSP101+++ and WT P.b. 
parasites infected Huh7 cells at 24, 48 and 72 hours p.i.. Upper panel is showing α-UIS4 (red) staining 
only, lower panel is depicting the merged image with α-HSP70 (green) and nuclear staining with Hoechst 
33342 (blue). (Scale bar 10 µm) C IFA of α-LC3 (red) and α-GFP (green) stained HSP101+++ and WT P.b. 
parasites at 16 and 24 hours post Huh7 infection reveals LC3, a host autophagy marker, localization to the 
parasite’s PVM. Nuclear staining is displayed with Hoechst 33342 (blue). Upper panel is showing α-LC3 
(red) staining only, lower panel is displaying the merged image (Scale bar 10 µm).  
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Furthermore, EEF were stained for presence of UIS4, a PVM resident protein, and LC3, a host 
cell autophagy marker. The presence of UIS4 could be confirmed in HSP101+++ parasites at 24, 
48 and 72 hours post infection, regardless of the developmental arrest before 24 hours post 
infection. Presence of LC3 at 16 and 24 hours post infection confirmed an intact PVM of 
HSP101+++ parasites (Fig. 28B). Notably, the minority of HSP101+++Myc parasites that develop 
beyond 24 hours post infection revealed HSP101 and UIS4 expression in the parasite’s PV and 
recruitment of LC3 16 and 24 hours post in vitro hepatoma cell infection (Fig. S7) 
Taken together, successful invasion of hepatoma cells was not impaired in HSP101+++ 
sporozoites, however liver stage arrest was observed at 24 hours post infection even though 
parasites were able to build and maintain an intact PVM, demonstrating that strong 
overexpression of HSP101 leads to pleiotropic defects: an impaired sporozoite motility and a 
liver stage developmental arrest. 
3.2.3.4 HSP101+++ parasites elicit weak protection against follow-up infection 
Complete liver stage arrest is a prerequisite for a safe GAP-based vaccine candidate. ∆SLARP 
parasites are so far the only known GAP-based vaccine candidate to fully arrest during liver stage 
development. However, efficacy of ∆SLARP parasites has shown to be low compared to other 
GAP-based vaccines (Kreutzfeld et al., 2017). Here, we generated a new fully arresting GAP 
vaccine candidate with the potential to induce better protection by increased visibility of the 
parasite to the immune system due to regulated protein export into the hepatocyte cytoplasm. 
Table 5 Protection after immunization with HSP101 overexpressing P. berghei sporozoite  
Parasite strain Immunization/ 
Challenge shedulea 
Blood stage-
positive miceb 
Prepatent Periodc 
HSP101+ (+AZ) 0/10 (87) 3/5 (60%) (>5 days) 
γ-HSP101++  0/10 (87) 8/10 (80%) (>5 days) 
HSP101++ (+AZ) 0/10 (260) 4/6 (70%) (>4 days) 
HSP101+++ 0/10 (87) 15/17 (88%) (>3 days) 
 0/10 (260) 4/4 (100%) >3 days 
HSP101+++Myc 0/10 (87) 10/10 (100%) >4 days 
WT +AZ 0/10 (87) 13/30 (40%) >5 days 
 0/10 (260) 8/8 (100%) >4 days 
γ-WT  0/10 (87) 3/10 (30%)  
naive - 22/22 (100%) >3 days 
a Mice were inoculated by i.v. injection of 1x104 sporozoites. Shown are immunization days and 
challenge post immunization in brackets. 
bShown are numbers and respective percentage of infected to total animals. 
c The prepatent period is defined as time to detection of first blood stage parasites after sporozoite 
infection. 
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To define the impact of strong HSP101 overexpression on vaccine efficacy, C57BL/6 mice were 
immunized in a prime/boost regime with a 10 days interval, challenged three months later with 
WT sporozoites and monitored for blood stage infection 3-10 days post challenge (Fig. 29A). 
Interestingly, the majority of HSP101+++-immunized animals became blood stage positive 4-6 
days post infection in contrast to immunizations with AZ attenuated WT sporozoites, which lead 
to 55% of animals being protected against subsequent sporozoite challenge. Sporozoite infectivity 
was confirmed by challenging naïve mice, which developed a patent blood stage infection 3-4 
days later (Fig. 29B and Table 5). A challenge of immunized cohorts 260 days post immunization 
completely eliminated all protective effects (Fig. 29C). 
Conclusively, HSP101+++ fulfills whole sporozoite vaccine safety requirements, but fails to 
protected against challenge infections, demonstrating that early liver stage arrest and reduced 
liver load of HSP101+++ does not lead to superior immunity in immunized cohorts. 
 
Figure 29 Inferior protection in HSP101+++-immunized mice 
Kaplan-Meier analysis of percentage of blood stage infected mice over time after sporozoite challenge 
reveals inferior protection in HSP101+++-immunized animals. A Schematic representation of 
immunization procedure. C57BL/6 mice were immunized and boosted at a 10-day interval with 1x104 
sporozoites i.v., challenged with 1x104 WT P.b. sporozoites i.v. 87 or 260 days post 1st immunization and 
blood infection was monitored by daily microscopic examination of Giemsa-stained blood films. B 
Protection of mice immunized with HSP101+++ sporozoites (dark red) and WT sporozoites attenuated by 
co-administration of AZ (dark grey). WT P.b. sporozoite challenge was performed 87 days post 
immunization and non-immunized control animals (naïve, light grey) confirmed sporozoite infectivity by 
patent blood stage infection 3 days post inoculation. Statistical analysis: Log rank (Mantel-Cox) test n.s., 
non-significant,  **, p< 0.01 C Protection of mice immunized with HSP101+++ sporozoites (dark red) and 
WT sporozoites under AZ drug (dark grey). Challenge with WT P.b. sporozoites was performed 260 days 
post immunization and non-immunized control animals (naïve, light grey) confirmed sporozoite 
infectivity by patent blood stage infection 3 days post inoculation. Statistical analysis: Log rank (Mantel-
Cox) test n.s., non-significant  
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4 Discussion 
4.1 Pre-clinical analysis of a triple genetically attenuated parasite (tKO GAP) 
vaccine candidate 
Many GAP-based vaccines for immunization against Plasmodium have been explored in the last 
decade, promoting the idea of whole sporozoites vaccines. However, drawbacks for all candidates 
in safety or protection limit their vaccine potential. This study describes for the first time a side-
by-side preclinical study of a triple KO (∆SLARP/P36p/P36) malaria vaccine candidate compared 
to its single and double KO counterparts (∆SLARP, ∆P36p/P36). Surprisingly, even though 
similar infection and exo-erythrocytic growth rates were observed in vitro for the tKO parasites 
and for the original KO parasites, inferior vaccine efficacy was observed already one month after 
immunization with tKO parasites. Thus, it can be hypothesized that the combination of two 
knockout lines has an antagonistic effect on the protective capacity, potentially caused by 
deficient antigen presentation and failure to induce long-lasting CD8+ T cell responses in the 
spleen, leading to a decreased vaccine efficacy of ∆SLARP/P36p/P36. 
4.1.1 Complete arrest but inferior protection in ∆SLARP/P36p/P36-immunized 
animals 
Full arrest of GAP-based vaccine candidates in the liver before onset of the symptomatic blood 
stage infection is a prerequisite for a safe vaccine candidate. My results demonstrate that the tKO 
parasites undergo normal blood and mosquito stage development, as described for ∆P36p and 
∆SLARP (van Dijk et al., 2005, Silvie et al., 2008), a necessary prerequisite for sporozoite based 
vaccine candidates. Parasite lines lacking SLARP have been shown to fully arrest in the liver (van 
Dijk et al., 2005, Aly et al., 2008, Silvie et al., 2008, van Schaijk et al., 2014, Kublin et al., 2017), 
whereas parasites lacking either P36p or both P36p/P36 reveal occasional breakthrough 
infections (van Dijk et al., 2005, Labaied et al., 2007). To ensure complete arrest of tKO parasites, 
C57BL/6 mice were infected with a high dose (1x104) of sporozoites and monitored for blood 
stage infection for at least 14 days. The results demonstrate, as described previously by Silvie et 
al., that parasites lacking SLARP fully arrest in the liver without any breakthrough infections 
(Table 2). Corroborating, blood stage infection with ∆SLARP parasites is very unlikely as 
previous studies showed no sign of blood stage pre-patency if mice were infected with 10-fold 
higher dose of sporozoites (Silvie et al., 2008). This side-by-side study revealed for the first time 
breakthrough infections of P. berghei ∆P36p/P36 parasites, as described for P. yoelii (Labaied et 
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al., 2007). Similar breakthrough levels were observed in infections with the P. berghei ∆P36p 
single knockout (van Dijk et al., 2005) 
Results of the current study revealed that ∆SLARP/P36p/P36-immunized animals were less 
protected compared to single KO and γ-WT-immunized animals (Fig. 9). Only ~20% of the mice 
were protected from infectious WT sporozoites when challenged one month after the last 
immunization. 
This is surprising as original KOs performed better compared to the tKO in prime/boost vaccine 
trials. To my knowledge previous studies only looked at prime and two booster immunizations. 
In a comparative study, three immunizations with either ∆P36p/P36, ∆SLARP or γ-WT 
sporozoites led to full protection against a patent blood stage infection (Josephine Scholz, MPIIB, 
Master thesis 2015). This finding confirms the complete protection observed with ∆P36p/P36 
parasites (Labaied et al., 2007). In contrast, ∆SLARP parasites were reported not to be fully 
protective with 75% of the immunized mice developing delayed pre-patency (Silvie et al., 2008). 
In this work-declined protection levels were observed in all immunized cohorts, likely being a 
result of only two immunizations (Fig. 9). Thus, protection seems to decline quickly, as tKO 
immunized mice were not protected against sporozoite challenge two months after the last 
immunization (Josephine Scholz, MPIIB, Master thesis 2015), indicating that long-term 
protection can be hardly achieved by immunizations with ∆SLARP/P36p/P36 sporozoites.  
Quantification of relative liver parasite loads by quantitative qRT-PCR can be used as an 
alternative to determine the protective efficacy of immunizations. In good agreement with the 
findings from the pre-patency study after sporozoite challenge, ~100-fold to 1,000-fold reduction 
of liver parasites in ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 and γ-WT-immunized animals was 
detected (Fig. 10). Similar reductions were observed for ∆P36p (Friesen & Matuschewski, 2011). 
To my knowledge this is the first time a study reports liver load levels after immunization for 
∆SLARP. Of note, individual values of immunized animals varied strongly, ranging over several 
orders of magnitude, indicative of a high degree of individual variation. To explain the 
differences in protection observed in ∆SLARP/P36p/P36 parasites to its original counterparts, 
further phenotypical and immunological characterization of the tKO parasites is required to 
identify the reason for the antagonistic effects. 
4.1.2 Exo-erythrocytic development is attenuated in tKO in vitro 
A hallmark of GAPs is the life cycle arrest during liver stage development. The absence of in vitro 
growth in ∆SLARP/P36p/P36 indicates early liver stage arrest. In concordance with the 
phenotypes observed for ∆SLARP and ∆P36p parasites (van Dijk et al., 2005, Aly et al., 2008, 
Silvie et al., 2008).  Developmentally more advanced liver stage parasites, as reported for ∆P36p 
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(van Dijk et al., 2005), were not observed for ∆SLARP/P36p/P36 (Fig. 12) Thus, ∆SLAP/P36p/P36 
parasites closely resemble ∆SLARP parasites in liver stage growth and arrest in vitro and pose a 
first indication for the absence of breakthrough infections. However, arrest at a very early stage 
in liver development might represent a considerable disadvantage in terms of protection. Silvie et 
al. already noticed a limited capacity to induce sterilizing immune responses in immunizations 
with ∆SLARP parasites most likely due to the early arrest, which substantially limits the antigenic 
repertoire (Silvie et al., 2008). A short development phase significantly reduces the amount of 
antigens, which can be presented on the surface of infected hepatocytes (Kreutzfeld et al., 2017). 
In support of this hypothesis, immunizations with late-arresting GAP, like ∆FabB/F and ∆PALM 
parasites, mount superior immunity and enhance protection against reinfections (Butler et al., 
2011, Haussig et al., 2011, Butler et al., 2012). ∆FabB/F GAP immunizations induce larger 
populations of antigen specific CD8+ T cells, perhaps due to the presence of additional and 
multistage-expressed antigens (Butler et al., 2011). Whether the limited potential of early 
arresting GAPs to amplify biomass or to differentiate plays a role in decreased protection 
remains unclear (Butler et al., 2012). Similarly, tKO sporozoites infectivity and liver stage 
expansion resemble ∆SLARP parasites. As infectivity plays a major role in vaccine efficacy, the 
significant decrease observed in in vitro hepatoma cell infections might explain the observed 
lowered protection in ∆SLARP/P36p/P36 and ∆SLARP-immunized mice (Fig. 12). In contrast, 
∆P36p/P36 revealed hepatoma cell infection rates similar to WT strengthening the hypothesis 
that good protection might be achieved by adequate hepatocyte infections. In order to maintain 
long-term protection, parasite persistence as metabolically active intra-hepatic stages is required 
(Scheller & Azad, 1995). ∆SLARRP/P36p/P36 and ∆SLARP persistence rates, determined by 
steady numbers of liver stage parasites over time, are similar to those of ∆P36p/P36, however the 
overall reduced infection rate of hepatoma cells might be too low to induce elevated immune 
responses. Possible solutions to low infection rates in vaccine candidates could imply upscaling 
of immunization doses to achieve similar parasite loads as observed for γ-WT infections in the 
liver and thus, overall protection. 
Protection from host defense and autophagy mechanisms is achieved by an intact and remodeled 
PVM (Prado et al., 2015, Wacker et al., 2017). ∆P36p and ∆SLARP have been reported to either 
be deficient of PVM establishment and maintenance or PVM remodeling after initial PVM 
acquisition, respectively (van Dijk et al., 2005, Silvie et al., 2008). In vitro studies of tKO infected 
hepatoma cells suggest that ∆SLARP/P36p/P36 parasites are deficient of a PVM, as staining of a 
PVM resident protein USI4 and the host’s autophagy protein LC3, which is recruited to a 
functional parasite PVM, was absent in and around ∆SLARP/P36p/P36 parasites (Fig. 13A). UIS4 
is incorporated into the PVM during remodeling of the initial vesicular membrane, which is 
established upon hepatocyte invasion (Mueller et al., 2005). Labaied et al. reported non-typical 
Discussion 
  89 
UIS4 staining for several early arresting ∆P36p/P36 parasites (Labaied et al., 2007). This 
phenotype was even more pronounced in my study, where UIS4 staining was absent in 
∆P36p/P36 parasites. In contrast, ∆SLARP parasites down regulate important liver stage proteins 
including UIS4 (Silvie et al., 2008). However, integration of PVM proteins is required for 
remodeling of the early liver stage PVM to be intact and functional. Thus, ∆SLARP parasites 
initiate but fail to remodel the PVM and incorporate UIS4, resulting in absent UIS4 staining in 
∆SLARP parasites. To ensure absence of the PVM in ∆SLARP/P36p/P36 parasites, additional 
staining for a host cell autophagy marker termed LC3 was performed. LC3 is recruited and 
incorporated into early fully functional PVMs (Kabeya et al., 2000, Prado et al., 2015, Thieleke-
Matos et al., 2016).  To my knowledge this is the first time the original KOs were stained for LC3 
recruitment in early liver stages. As expected, ∆SLARP/P36p/P36 and ∆P36p/P36 lacked LC3 
staining, however, LC3 recruitment was also absent in ∆SLARP parasites. It is postulated that 
LC3 is only incorporated in mature existing PVMs and not in newly formed double membranes, 
hence, ∆SLARP likely fails to recruit LC3 due to the absence of PVM remodeling (Kabeya et al., 
2000). Concluding, ∆SLARP/P36p/P36 parasites closely resemble ∆SLARP and ∆P36p/P36 during 
in vitro liver stage development, thereby aborting liver stage maturation and failing to establish 
and maintain a functional PVM during intra-hepatic infection. 
4.1.3 High antibody titers but reduced longevity CD8+ T cells in tKO immunization 
mice 
Immunizations with all parasite strains induce profound IgG-antibody titers. In 
∆SLARP/P36p/P36, ∆P36p and γ-WT-immunized mice the antibody titers were significantly 
higher than in ∆SLARP-immunized animals (Fig. 11). It has been argued that IgG-antibody 
responses to sporozoite proteins reflect former exposure (Offeddu et al., 2012). Specific antibody 
titers can be used to predict vaccine intake and can serve as a biomarker. Hence, my results prove 
that IgG-antibodies only partially contribute to the overall protection in GAP-based vaccines. 
Corroborating this notion, CD8+ T cell depleted but not CD4+ or IgG1 antibodies depleted 
BALB/c mice abolished P. yoelii GAP-based vaccine induced protection (Tarun et al., 2007). 
Although CD4+ T cells and antibodies partially contribute to sterile protection, vaccine-induced 
and liver-stage directed CD8+ T cells are the major effector cell populations to elicit sterilizing 
immunity in different rodent models (Schmidt et al. 2010, Nganou-Makamdop et al., 2012). 
Cytolytic CD8+ T cells secreting interferon gamma (IFN-γ) were identified as the mediators of 
protection in a RAS-based immunization study (Schofield et al., 1987, Weiss et al., 1988, Romero 
et al., 1989). Accordingly, my study focused on the analysis of CD8+ T cell responses after 
immunization with ∆SLARP/P36p/P36, ∆SLARP, ∆P36p/P36 and irradiated sporozoites.  High 
parasite-specific IFN-γ ex vivo responses were detected, when stimulated with two different CD8+ 
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T cell epitopes (S20/TRAP). The level of IFN-γ secretion was slightly higher in 
∆SLARP/P36p/P36 and γ-WT-immunized mice compared to ∆SLARP and ∆P36p/P36. However, 
∆SLARP/P36p/P36 failed to induce long-lasting CD8+ T cell responses as numbers dropped 
sharply two months post infection, postulating that reduction in CD8+ T cells contributes to 
reduced efficacy of the ∆SLARP/P36p/P36 vaccine (Fig. 14). Elevated levels of IFN-γ-secreting 
lymphocytes can be found in livers compared to spleens, indicating that cellular immune 
responses occur to a higher extent in the sporozoite target organ (Nganou-Makamdop et al., 
2012, Haussig et al., 2014). It should be noted that vaccine-induced memory CD8+ T cells are 
required but not sufficient to induce sterile protection (Schmidt et al., 2010). Several studies 
observed that efficient priming is a complex interplay between immune cells and different 
immune dominant organs. It is likely that cross-presentation by dendritic cells (DCs) in spleen 
and liver plays a major role in sufficient priming against hepatic infections. However, details of 
underlying immune processes to eliminate infective parasites remain elusive. Further studies 
need to clarify which immune processes contribute to reduced efficacy of this triple KO GAP-
based vaccine. 
Concluding, ∆SLARP/P36p/P36 is a safe vaccine candidate but fails to induce sterile protection 
likely due to decreased hepatocyte infections, failure in growth, maintenance of intra-hepatic 
stages and insufficient maintenance of long-term IFN-γ producing CD8+ T cells. Based on 
inferior protection in ∆SLARP/P36p/P36-immunized cohorts, I conclude that an immunization 
with ∆SLARP parasites only provides similar results as immunization with ∆SLARP/P36p/P36, 
hence, knocking out P36p/P36 does not contribute to vaccine efficacy. My results underscore the 
importance of pre-clinical studies in the robust P. berghei/C75BL/6 vaccine model before 
translation to human clinical trials.  
4.1.4 Conclusion and Outlook 
GAP-based vaccines offer a tremendous potential for exploration of controlled stage arrest and 
immune responses. Whole sporozoite approaches enable antibody and T cell responses to a wide 
range of antigens compared to subunit vaccines, a prerequisite for potent immunity. Cellular 
responses are crucial for pathogen recognition, however, early arresting parasites do not trigger 
substantial immune responses. Establishing a robust cellular immune response might be the first 
step to develop an efficacious vaccine. Investigating tKO sporozoite infectivity and liver stage 
persistence in vivo by quantifying parasite burden in the liver of infected mice by qRT-PCR can 
provide an explanation for the paucity of protection in the tKO GAP vaccine. Further immune 
profiling of the tKO GAP in comparison to a late arresting GAP by examining liver stage specific 
peptide epitopes e.g. KB17, thereby exploring liver stage specific immune responses, might give 
insights into failure of this tKO GAP.  
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Parasites maturing into late liver stages are likely to induce greater quantity and breadth of 
antigen exposure and protect against sporozoite challenge. Generating further double or triple 
GAPs with a robust late stage arrest might increase sterile immunity in immunization/challenge 
studies. Potential candidates have been investigated, however it remains to be determined 
whether combination of two late arresting KO parasites would lead to complete liver stage arrest. 
A recent study tested a double KO of two late liver stage arresting parasite corroborating the 
notion that complete arrest can be achieved in the P. yoelii/BALB/c model, a parasite host 
combination where a complete arrest is easily achieved (Vaughan et al., 2018). Further studies in 
the P. berghei/C57BL/6 model need to confirm this finding. Additionally, genetically engineering 
the parasite to enhanced parasite recognition by the host’s immune system and in turn increase 
CD8+ T cell priming in early liver stages is another promising strategy. 
In conclusion, transition of suitable vaccine candidates from the established mouse models P. 
berghei and P. yoelii to the human strain P. falciparum remains challenging. My work 
demonstrates that small scale pre-clinical studies can evaluate vaccine safety and efficacy, thereby 
deciphering underlying immune mechanisms for inducing sterile long-term protection. 
Ultimately, pre-clinical evaluations can warrant evidence-based design of a P. falciparum GAP 
vaccine before translation to extensive and expensive human clinical trials. 
4.2 Inducing PTEX-dependent export in liver stages for an improved malaria 
vaccine candidate 
Plasmodium switches between intra- and extracellular developmental stages thereby avoiding 
host immune recognition. To impede pathogen recognition, parasites replicate inside a PV for 
intracellular maturation. However, shielding themselves from their host cell leads to nutrient 
depletion, waste acquisition and splenic iRBC killing, thus parasites remodel their host cells to 
ensure efficient replication. As larger parasitic proteins are unable to cross nutrient channels in 
the PVM, a protein translocon (PTEX) is enabling protein export. Export is especially important 
and well understood during intra-erythrocytic maturation, enabling the parasite to avoid splenic 
killing by vascular sequestration of mature blood stage parasites. Surprisingly, during early intra-
hepatic development one of the PTEX core components, the AAA+ ATPase HSP101, is not 
expressed, raising the question whether protein export is feasible in early liver stages (Matz et al., 
2015). To determine whether HSP101 is the limiting factor for liver stage protein export, 
transgenic parasites constitutively or pre-erythrocytically overexpressing HSP101 were 
generated. Subsequent analysis of transgenic parasite life cycle progression and co-expression 
with PEXEL-reporter constructs gave insights into whether HSP101 overexpression interferes 
with parasites’ life cycle, how HSP101 contributes to liver stage export and if immunizations with 
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parasites potentially harboring a functional liver stage PTEX-dependent export machinery leads 
to protective immune responses due to increased parasite recognition. 
4.2.1 Normal life cycle development of parasites with constitutively weak to 
moderate HSP101 overexpression  
This study provides compelling evidence that constitutive low overexpression of HSP101 does 
not interfere with P. berghei life cycle progression. Analysis of HSP101+, a transgenic line 
constitutively overexpressing HSP101 under the control of EF1α promoter, revealed HSP101 
expression in oocysts, sporozoites and asexual blood stages. Endogenous HSP101 localizes to the 
PVM during blood stage development to form a protein translocon (PTEX). Live imaging of 
immunofluorescencely tagged transgenic HSP101 in gametocytes confirmed localization to the 
parasite’s PV, whereas localization in rings and trophozoites were observed throughout the whole 
parasites. One plausible explanation is that EF1α promoter activity peaks in trophozoites (Otto et 
al., 2014), enabling translation of HSP101 for later stages. Thus, these findings suggest no 
interference of transgenic HSP101 in pre-hepatic stages, hence, enabling WT-like life cycle 
progression. 
To characterize intra-hepatic development, mice were infected with transgenic sporozoites. In 
vivo infections demonstrated one day delay in pre-patency for HSP101+ and half a day delay for 
HSP101++, parasites expressing HSP101 under the regulation of PTEX150 promoter. Similarly, 
subsequent blood stage growth started delayed and therefore parasitemia remained lower, 
however slope analysis demonstrated no significant differences in growth rate. Thus, it can be 
postulated that intra-hepatic growth is minorly affected whereas blood stage development 
remains unaffected by HSP101 overexpression (Fig. 18). This notion was strengthened by 
parasite loads of infected mouse livers, which were slightly higher at 48 hours post infection in 
HSP101+ than WT infected cohorts. As budding of merozoite-filled merosomes initiates as early 
as 48 hours post infection in WT parasites (Khan & Vanderberg, 1991), slightly higher parasite 
load in HSP101+ infected mice could indicate a delay in maturation and budding of merosomes 
leading to the observed delay in pre-patency. Notably, the delay in pre-patency influences disease 
outcome as HSP101+ animals had a reduced risk of ECM development. In contrast, HSP101++ 
infected animals harbored the same risk of acquiring ECM as WT infected mice. Pinpointing the 
cause of severe and cerebral malaria has been challenging (Cunnington et al., 2013) and animal 
models fail to mimic human severe malaria cases (Craig et al., 2012). However, high parasite 
biomass is predicted to be the dominant cause of severe malaria. High biomass is caused by 
parasite replication and sequestration, a vicious cycle increasing parasite vascular adherence. In 
the brain this can lead to microvascular obstruction and endothelial dysfunction, which in turn 
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increases the risk of CM development (Cunnington et al., 2013). Taken together, these findings 
suggest an effect of HSP101 overexpression on efficient intra-hepatic development, thereby 
influencing severity of disease outcome. Whether this is actually caused by HSP101 
overexpression itself or subsequent up- or downregulation or obstruction of other liver stage 
proteins remains to be determined. 
In vivo data of HSP101+ and HSP101++ demonstrated that HSP101 overexpression plays a 
critical role during intra-hepatic development. To examine liver stage maturation and exo-
erythrocytic HSP101 overexpression, in vitro HSP101+ and HSP101++ hepatoma cell infections 
were analyzed. WT-like liver stage development was observed for HSP101+ and HSP101++ (Fig. 
20), postulating that liver stage maturation is not affected in vitro. HSP101+ parasites revealed 
HSP101 expression, however, the mCherry tag signal in the PV was weak (Fig. 20A), questioning 
if reconstruction of the machinery is feasible. As HSP101++ parasites lack a tagged version of 
HSP101, mRNA levels confirmed increased liver HSP101 transcription (Fig. 19), however, 
whether HSP101 localizes to the PV remains to be determined. Liver stage maturation is tightly 
linked to PVM establishment, remodeling and maintenance. Parasites lacking P36p/P36, proteins 
important for PVM formation, or UIS4, protein important for PVM remodeling, arrest early 
during liver stage development (Mueller et al., 2005, van Dijk et al., 2005). To exclude 
obstruction of PVM establishment, immunofluorescence assays were used to determine UIS4 
expression in HSP101+ and HSP101++ parasites. UIS4 was observed in the PV of HSP101+ and 
HSP101++ parasites throughout liver maturation, thereby suggesting presence of a remodeled 
PVM. Collectively, transgenic parasites display UIS4 and HSP101 expression in liver stages with 
localization to the PV, thereby ruling out developmental delays due to lack of PV formation and 
promising PTEX reconstruction feasibility, respectively.  
Taking advantage of pathogen stage conversion for immunization strategies is one way to attack 
the parasite at its developmental bottleneck. Studies have shown that superior immunity can be 
achieved by a developmental arrest shortly before liver-to-blood stage conversion, as a bigger and 
broader array of antigens is presented compared to early arresting GAPs. Induction of memory 
CD8+ T cells is increased by antigen presentation via the hepatocyte MHCI pathway and parasite 
antigen release is increased in later liver stages (Butler et al., 2011). Therefore, pre-clinical 
immunization and challenge studies were performed to answer the question whether transgenic 
parasites overexpressing HSP101 can elicit stronger host immune responses due to increased 
parasite recognition. Prime/boost immunizations with HSP101+ and HSP101++ parasites 
attenuated with AZ elicited decreased protection to WT sporozoite challenges 87 and 260 days 
post immunization compared to standard γ-WT or WT under AZ cover immunized control mice 
(Fig. 21 and Fig. 30). In contrast, prime and two booster immunizations with a late arresting 
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overexpression GAP pdh_E1_PFOLS, deficient of pyruvate dehydrogenase E1 alpha subunit, thus 
arresting late, while simultaneously expressing the pore forming bacterial toxin cholesterol-
dependent cytolysin perfringolysin O, elicited complete long term protection in C57BL/6 mice 
(Nagel et al., 2013). Perfringolysin O expression induced premature PVM rupture roughly 30 
hours post infection (Nagel et al., 2013) allowing parasite antigen exposure to the host cell 
cytoplasm, arguing for an increased CD8+ T cell response. While it cannot be excluded that three 
immunization doses lead to better protection, it remains elusive why HSP101+ and HSP101++ 
fail to induce potent protection. An intriguing possibility could be the failure to reconstruct a 
functional protein translocon.  
4.2.2 Absence of PEXEL-dependent export in HSP101+ and HSP101++ liver stages 
To investigate the export potential of these transgenic parasite lines, the expression of a PEXEL-
mCherry reporter protein under the control of liver (UIS4) and liver/blood (IBIS) stage 
promoters (Josephine Grützke. MPIIB, PhD Thesis 2015) in HSP101+ and HSP101++ was 
analyzed. Live imaging of liver stage maturation in parasites overexpressing both, HSP101 and 
mCherry-PEXEL, in vitro revealed confined mCherry signal in the parasite PV and absence of 
mCherry in the host cell cytoplasm, concluding that transgenic parasites were not able to restore 
the PEXEL-dependent export machinery in liver stages (Fig. 30). Four possible reasons could 
contribute to absence of efficient export upon HSP101 expression.  
First, signatures of export-determined proteins, except of the apparent PEXEL, remain poorly 
understood (Spielmann & Gilberger, 2015). Indeed, it is not clear whether blood stage PEXEL 
sequences efficiently label proteins for liver stage export. Grützke et al. showed blood stage 
export of reporter constructs used in this study, but failed to demonstrate mCherry export in WT 
liver stage parasites (Josephine Grützke, MPIIB, PhD Thesis 2015). This raises the question 
whether PEXEL sequences of blood stage proteins, as seen in IBIS-PEXEL, are efficient in liver 
stage export. To clarify this notion, an unconventional PEXEL sequence of CSP, a sporozoite 
surface antigen, linked to mCherry was analyzed for its liver stage export potential, however CS-
PEXEL-mCh remained confined to the PV of the parasite (Fig. 22B). Similarly, endogenous CSP 
was not detected in the host cell cytoplasm at 4 hours post HSP101+ infection (Fig. 22C). These 
findings vary from results observed by Singh et al. where CSP was exported to the host’s 
cytoplasm and nucleus 2-6 hours post infection (Singh et al., 2007). However, these findings 
remain controversial, as CSP might be already released during sporozoite entry and not through 
protein export, which is corroborated by the notion that CSP is constantly shed during 
sporozoite transmigration (Singh et al., 2007, Cockburn et al., 2011). It remains to be determined 
whether CSP PEXEL induces export in a PEXEL-dependent manner. As of now, LISP2 remains 
the only liver stage protein reported to translocate during early (~36 hours p.i.) liver stage 
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development. In contrast to other PEXEL-proteins, C-terminal mCherry tagging of LISP2 lead to 
accumulation of mCherry in the PV, suggesting C-terminal processing of LISP2 (Orito et al., 
2013). Recent sequence analysis revealed two PEXEL motives one at the N-terminal and another 
at the C-terminal end confirming earlier findings of dual processing of LISP2 by Orito et al. 
(personal communication Melanie Shears, John Hopkins School of Medicine, Baltimore). In 
perspective, discovery of liver stage export signals might help to define the liver stage exportome.  
Second, in other infectious organisms, protein translocons fail to export larger stably folded 
proteins, therefore limiting translocation. Bacterial type III secretion system fail to translocate 
stably folded fluorescent proteins (Akeda & Galan, 2005). In this study reporter constructs 
harbored a PEXEL linked to mCherry (Table 3), which is a stably folded and large tag, potentially 
limiting export of the reporter constructs. Arguing against this hypothesis is an observation 
made by Grützke et al. where reporter constructs were translocated during blood stage 
development (Josephine Grützke, MPIIB, PhD Thesis 2015). Moreover, accumulation of CS-
PEXEL-OVA, a smaller protein, in liver stage PVs was observed in HSP101+ and WT parasites 
(Table 3) (Montagna et al., 2014), Collectively, these findings could indicate absence of a 
functional PTEX translocon in general and enough quantity of PV resident transgenic HSP101 in 
particular, as decreased HSP101 levels blocked export and led to vascular accumulation of 
proteins in blood stages (Beck et al., 2014, Elsworth et al., 2014).  
Third, PV and PVM make-up could play an essential role in protein export. Previous studies 
have established a model of regional PV export protein storage (Bullen et al., 2012). These export 
areas localise to bulgy PV regions, which are defined by PTEX assembly which in turn might be 
initiated by host cell determined EXP2 localization (Meibalan et al., 2015, de Koning-Ward et al., 
2016). Results of the current study demonstrate accumulation of mCherry signal in bulgy liver 
PV compartments (Fig. 22B), whether these are defined export areas remains to be determined. 
Corroborating this notion, proteins resistant to unfolding get trapped in loop-like PVM 
extensions in blood stages and unblocking the unfolding capacity only partially recovers protein 
export, as cargo remains spatially segregated from the export machinery (Charnaud et al., 2018). 
Although PV localization of cargo proteins was observed in the current study, previously 
mentioned studies propose that proteins need to remain in defined export zones for efficient 
translocation, which might be determined by yet unknown proteins. Whether this complex 
system relies on further helper proteins, thereby raising the question whether these proteins are 
present in liver stages, remains to be determined. 
Finally, PTEX assembly itself plays a major role in effective protein export. For example, C-
terminal truncation of PTEX150, the linker between the pore spanning EXP2 and the AAA+ 
ATPase HSP101, led to decrease in quantity of other PTEX components (Elsworth et al., 2016), 
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suggesting complex destabilization. In comparison, in this study HSP101 was either C-terminally 
tagged by mCherry together with 3xMyc or 3xMyc alone (Fig. 16A), possibly interfering with 
correct protein folding. Indeed, recent structural analysis of PTEX complex assembly revealed 
stable binding of EXP2 protomer to the C-terminal ends of the HSP101 protomer, thereby 
placing the HSP101 cargo tunnel directly on top of the EXP2-PTEX150 pore (Ho et al., 2018). 
This suggests that interfering with the HSP101 C-terminus and in consequence with correct 
protein folding may prevent PTEX assembly, as incomplete or unstable complex assembly has 
been proposed to inhibit protein translocon activity (de Koning-Ward et al., 2016, Gilson et al., 
2017). Combined with the proposed paucity of a functional PTEX assembly, it remains unclear if 
further proteins are essential in export and whether these proteins are present in liver stages. 
Parasites lacking TRX2 or PTEX88 were able to undergo cell cycle progression, suggesting only a 
minor role in protein export (Matz et al., 2013). Similarly, host cell chaperons are postulated to 
play a role in active protein translocation (Gilson et al., 2017). Further studies will need to 
confirm the role of host cell proteins in export and whether they are present in liver stages. 
Although HSP101 expression was achieved in HSP101+ and HSP101++ parasites (Fig. 20), EF1α 
and PTEX150 are only weak promoters during liver stage development, hence, limiting HSP101 
availability for PTEX formation. Ho et al. indicate that six HSP101 protomers are required for 
each complex and that a stoichiometry of 6:7:7 (HSP101-PTEX150-EXP2) is a prerequisite for 
functional PTEX assembly (Ho et al., 2018). This suggests that HSP101 might not be expressed in 
the right stoichiometric ratios in HSP101+ and HSP101++ parasites to form the complex at the 
liver stage PVM. 
Concluding, HSP101+ and HSP101++ fail to translocate proteins in liver stages either due to 
deficiencies in reporter constructs or correct complex assembly in defined export areas. Learning 
from other infectious agents is difficult, but orthologues of EXP2 can be found in other 
Apicomplexa and HSP101 belongs to the well-studied 1 Clp/AAA+ ATPases, with a conserved 
role in unfolding proteins (Ho et al., 2018). However, as PTEX150 is unique to Plasmodium the 
PTEX export machinery remains unique to Plasmodium species as well. These results warrant 
further work to identify potential liver stage export signals, define involvement of PTEX in liver 
stage export and characterize the liver stage exportome by proteomic approaches. 
4.2.3 Abort of pre-erythrocytic development in strong HSP101 overexpressing 
parasites 
So far, it cannot be ascertained whether HSP101 is the limiting factor in liver stage export. Based 
on the poor export potential of low HSP101 overexpression lines, another HSP101 high 
overexpression parasite, HSP101+++, was generated, which expresses HSP101 under the control 
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of the pre-erythrocytic specific UIS4 promoter. In contrast to HSP101+ and HSP101++, 
HSP101+++ fully arrests during liver stage development in vivo and in vitro (Fig. 24A and Fig. 
27A). This notion was confirmed in dramatically reduced parasite loads in mouse livers 48 hours 
post infection, which in turn indicates poor sporozoite infectivity or early arrest of parasite liver 
development. However, pre-patency of HSP101+++Myc was not in line with the mCherry tagged 
HSP101+++ as blood stage infections were observed in 40% of the infected animals. It should be 
considered that larger and smaller protein tags might influence HSP101 folding and in turn can 
influence PTEX assembly. As mentioned earlier, folded cargo blocks export and nutrient 
channels if not deposited into tubular extensions of the PV (Charnaud et al., 2018). This argues 
against mCherry as a functional tag for HSP101. However, endogenously mCherry tagged 
HSP101 maintained protein translocon activity in blood stages. As HSP101 is essential in blood 
stages and refractory to deletion (Matz et al., 2015), an endogenously mCherry tagged HSP101 
would not have been doable if mCherry influences HSP101 folding. This discrepancy in 
successful exo-eryhtrocytic development between low and high overexpression indicates that 
HSP101 expression is tightly controlled in pre-erythrocytic stages to ensure parasite 
development. 
Reduced parasite burden in mouse livers is associated with reduced liver infection, suggesting 
reduced biomass per parasite, an indicator of early liver stage arrest, or poor sporozoite 
infectivity. Quantitative analysis of P. yoelii versus P. berghei infectivity confirmed superior 
infectivity of P. yoelii sporozoites in C57BL/6, leading to increased intra-hepatic development 
and a higher detected parasite biomass (Briones et al., 1996). The reduced parasite burden in the 
HSP101+++ infected liver points towards decreased sporozoite infectivity. Upon sporozoite 
injection during an infectious mosquito bite, sporozoites glide through the dermis to reach the 
closest blood vessel. Efficient gliding is essential for reaching the liver and crossing the sinusoidal 
barrier (Frevert et al., 2006). HSP101+++ and HSP101+++ Myc sporozoite gliding was drastically 
impaired (Fig. 26 and Fig. 30). UIS4 expression is tightly controlled by cis-regulatory elements 
in its ORF, repressing protein synthesis until hepatocyte invasion. However, promoter activity 
peaks in salivary gland sporozoites enabling transcription and translation of target protein if not 
under the control of UIS4 ORF elements (Silvie et al., 2014). Thus, HSP101+++ parasites 
expressed high amounts of HSP101-mCh, which have a granular staining, suggesting localization 
to dense granules and organelles of the secretory pathway in sporozoites. This finding was 
corroborated by high endogenous UIS4 mRNA levels in WT sporozoites and increased HSP101 
mRNA levels in HSP101+++ sporozoites (Fig. 25B+C.). On the one hand, large amounts of bulky 
proteins in dense granules could block the micronemal pathway. Indeed, obstruction of 
microneme secretion by cysteine protease inhibitors in Toxoplasma gondii impaired invasion and 
gliding motility of the parasite (Teo et al., 2007). Conversely, localization of mCherry in 
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UIS4::mCh, parasites expressing similar amounts of mCherry compared to HSP101+++, was 
observed throughout the whole sporozoite without any granular pattern (Fig. S8B). In addition, 
haemocoel sporozoites, not expressing HSP101 as UIS4 promoter only starts in salivary gland 
sporozoites, were motile, but in vivo infections with HSP101+++ haemocoel sporozoites failed to 
induce patent blood stage infections whereas infections with USI4::mCh lead to WT-like blood 
stage pre-patency (Fig. S8 and Fig. S9). These results demonstrate that overexpression of 
mCherry is not the cause for impaired motility. Gliding experiments of HSP101+++ with 
addition of ATP and glutamine, to compensate potential overuse of ATP by the triple ATP 
HSP101, reversed gliding ability of HSP101+++ sporozoites, but still arrested during liver stage 
development in vitro (Fig. S9). Based on these observations HSP101 overexpression must 
account for the gliding defect. On the other hand, mislocalization of HSP101 might be the key 
mediator of gliding disability. Tagging of endogenous HSP101 revealed localization to the 
sporozoite’s apical end (Matz et al., 2015). One characteristic of gliding motility is the discharge 
of micronemes from the apical end of the parasite. Micronemal proteins can in turn be driven 
towards the parasite’s exterior end where these proteins act on the actomyosin system (Stewart & 
Vanderberg, 1991, Gantt et al., 2000, Ono et al., 2008, Tardieux & Baum, 2016). Indeed, parasites 
deficient of adenylyl cyclase, an enzyme driving cAMP synthesis which in turn mediates 
microneme discharge, showed an bisected infectivity (Ono et al., 2008). In particular, the well-
described sporozoite surface proteins CSP and TRAP play a major role in hepatocyte adhesion 
and invasion (Mota & Rodriguez, 2002). These findings indicate the importance for controlled 
microneme discharge during sporozoite gliding. Whether HSP101 localization to the apical end 
of the sporozoite is essential for gliding, thereby pinpointing the defect seen in HSP101+++ 
parasites, remains elusive.   
To test whether the defect in motility correlates with reduced transmigration and infectivity of 
hepatoma cells, in vitro transmigration, cell invasion and liver growth was analyzed. 
Transmigration efficiency was reduced in HSP101+++ parasites, but in contrast to gliding only a 
quarter of sporozoites were affected. Similarly, sporozoite infectivity, measured by percentage of 
extra- and intracellular parasites two hours post infections, revealed only a trend towards fewer 
numbers of intracellular parasites (Fig. 30). One plausible explanation is that in vitro 
observations of transmigration and sporozoite infection can differ from results obtained from in 
vivo experiments. In vivo to in vitro comparison of parasites deficient of HSP20, a small heat 
shock protein that plays a role in Plasmodium motility, supports this idea as only 50% of mice 
infected with ∆HSP20 developed a blood stage infection, but in vitro EEF numbers remained 
similar to WT (Montagna et al., 2012). Infected hepatoma cells are centrifuged to ensure 
sufficient sporozoite entry, as infection rate of hepatoma cells in vitro is generally below 10%. 
This could limit the observed motility defect in HSP101+++ to cell adhesion and entry in in vitro 
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hepatoma cell infection (Fig. 26). Nevertheless, failure to induce a potent blood stage infection in 
vivo raises the possibility of a second defect of HSP101+++ in liver development.  
Parasite replication in hepatocytes is a prerequisite for onset of blood stage infection. In line with 
the in vivo results of an absent blood stage infection after HSP101+++ sporozoite infection, in 
vitro exo-erythrocytic growth beyond 24 hours post infection was not observed in HSP101+++ 
infected hepatoma cells (Fig. 27 and Fig. 30). In line with the observed in vivo pre-patency of 
HSP101+++Myc, in vitro infections had a number of parasites that grew beyond 24 hours of 
infection. Whether these results correlate with in vivo data or confirm previous assumptions that 
in vitro out-scale in vivo infections needs to be determined. As rhoptry and micronemal release, a 
prerequisite for proper PVM formation (Counihan et al., 2013), might be obstructed in 
HSP101+++, immunofluorescence assays were used to ensure presence of UIS4, a PVM residual 
protein, and LC3, a host autophagy marker labelling the PVM (Mueller et al., 2005, Wacker et al., 
2017). UIS4 was observed in all stages during liver maturation and LC3 up to 24h post infection, 
thereby confirming presence of a remodeled PVM in HSP101+++ parasites. Additional analysis 
of an intact UIS4 locus and WT-like mRNA levels ruled out accidental ∆UIS4 parasite 
generation, as HSP101+++ parasites displayed a similar phenotype to ∆UIS4 parasites (Mueller et 
al., 2005). Transgenic HSP101 expression was confirmed by mCherry detection in IFAs of liver 
stage parasites, but localization to the PVM was only partially observed (Fig. 28). In particular, 
later stages displayed a “blown up” vacuole whith HSP101 localization to distinct areas. One 
possible reason for parasite arrest could be the excessive use of ATP due to overexpression of the 
ATPase HSP101. Assays with supplemented ATP and glutamine could not reverse the observed 
phenotype, ruling out overuse of ATP from the AAA+ ATPase HSP101. Recent studies reported 
that proper assembly of PTEX is important for its functionality (Ho et al., 2018). Corroborating 
this notion, absence of HSP101 in blood stages leads to cargo accumulation in the PV (Beck et 
al., 2014), which in turn can impede parasites to pass cell cycle check points and lead to parasite 
growth arrest (de Koning-Ward et al., 2016). Although not yet supported by data, it is tempting 
to speculate that misfolded mCherry-tagged HSP101 might bind incorrectly to EXP2 nutrient 
channels, thereby blocking nutrient uptake and waste disposal and in turn leading to toxification 
of the parasite. 
The complete liver stage arrest of HSP101+++ warrants further studies on its potential as a GAP-
based vaccine. Prime/boost immunizations with a high dose of HSP101+++ elicited weak 
protection against WT follow-up infections 87 or 260 days post immunizations (Fig. 29 and 
Table 5). Several lines of evidence strongly support that sporozoite infectivity and liver stage 
growth and persistence are prerequisite for potent immunity (Scheller & Azad, 1995, Mueller et 
al., 2007, Putrianti et al., 2009). Consistent with these studies, HSP101+++ parasite burden in the 
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liver was extremely reduced and parasites arrested early during liver development, thereby 
limiting the priming phase of CD8+ T cells and therefore, HSP101+++ does not meet the 
prerequisites of a successful GAP vaccine candidate. Notably, HSP101+++ Myc immunizations 
elicited better protection in agreement with increased liver stage development. Thus, HSP101+++ 
immunizations stretch one more time the importance of sporozoite infectivity and liver 
persistence for efficient immunity against P. berghei infections. 
 
Figure 30 HSP101 overexpressing parasites abort pre-erythrocytic development and lack PTEX-dependent 
export in liver stages 
Conclusion of the results observed in this study. Parasites (red) glide through the dermis to reach the next 
blood vessel (1). Parasites strongly overexpressing HSP101 (HSP101+++, green) are impaired in their 
gliding ability. Motile sporozoites (red) attach and transmigrate through liver cells (2) until they reach a 
final target cell to invade and mature (3) and mature into merosomes harboring thousands of merozoites 
(4). HSP101+++ parasites (green) are affected in their attachment and gliding  (2) ability and completely 
abort liver stage development right after hepatocyte infection (3). Depicted is an early hepatocyte infection 
with a HSP101 overexpressing parasite. HSP101 is expressed and localizes to the PV but the export of 
proteins is absent, probably due to HSP101 misfolding, thereby obstructing proper PTEX assembly. 
Accumulation of export destined proteins in defined export areas and miss assembly of EXP2 and HSP101 
might account for failure of PTEX-dependent export. Obstruction of parasite nutrient channels by cargo 
proteins and misfolded HSP101 blocking EXP2 might lead to the liver stage abort of HSP101+++. 
Therefore, parasite recognition is not increased in HSP101 overexpressing parasites and immunizations 
with these parasites lead to inferior protection (for HSP101+ and HSP101++) and absence of protection 
(for HSP101+++). (several modified pictures from Smart, servier medical art) 
In conclusion, my results demonstrate that strong overexpression interferes with the parasite life 
cycle at its pre-erythrocytic stage, thereby preventing patent blood stage infections. This study on 
efficient HSP101 overexpression in liver stages does not reveal reconstruction of PTEX and 
PEXEL-dependent export, suggesting that HSP101 is not the limiting factor for liver stage export. 
In line with these findings, immunizations with transgenic strong HSP101 overexpressing 
parasites fail to elicit potent immunity against Plasmodium infections, in contrast to late stage 
arresting GAPs that manage to induce potent protection due to increased antigen presentation. 
This suggests that parasites tightly control HSP101 expression in pre-erythrocytic stages to 
maintain life cycle progression and avoid parasite recognition by the host. 
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4.2.4 Conclusion and Outlook 
 HSP101+ and HSP101++ parasites are able to complete the Plasmodium life cycle with only 
minor delays in pre-patency. However, subsequent exploration of export potential led to reporter 
construct confinement in the parasites’ PV. Of outmost importance is to confirm PTEX 
reconstruction. Co-localization experiments with EXP2 and PTEX150 antibodies would confirm 
presence of core components in distinct PV export areas. In particular, Immunoprecipitation 
(IP) assays with HSP101-mCh can identify liver protein complexes formed with HSP101. 
However, EEF material is scarce and would not be sufficient for IP analysis. Parasites lacking 
HSP101 are not viable in blood stages (Matz et al., 2015). Excising endogenous HSP101 in 
recycled HSP101+ (HSP101+ rec) while simultaneously inserting IBIS::PEXEL-GFP/Myc or 
IBIS::GFP/Myc (Table S4), can give insights into functionality of transgenic HSP101. Survival of 
the ∆HSP101/HSP101+/IBIS::(PEXEL)-GFP/Myc parasites will indicate efficient rescue by 
assembly of the complex. Export of PEXEL-GFP/Myc compared to the controls (GFP or Myc 
only) will serve as an indicator for a functional PTEX complex as well as the necessity of the 
PEXEL motive to target proteins for export.  
Additionally, intermediate liver HSP101 overexpression, higher than HSP101++ and lower than 
HSP101+++, might circumvent stoichiometric complications of low levels or toxic effects of high 
levels of HSP101. Parasites with moderate HSP101 levels (EXP2::HSP101) were generated in a 
follow up study on this thesis and preliminary data suggest no phenotypic differences in life cycle 
progression (Table S4). Exploration of different promoters e.g. HSP70 or LISP2 or tags e.g. HA 
or FLAG for liver HSP101 expression (Table S4), might contribute to define mechanisms of 
tightly controlled HSP101 expression in liver stages. 
The core components EXP2, PTEX150 and HSP101 are essential for PTEX assembly and parasite 
survival (de Koning-Ward et al., 2009, Matz et al., 2015). qRT-PCR revealed elevated mRNA 
levels of EXP2, but only intermediate levels for PTEX150 during liver maturation. Attempts to C-
terminally tag PTEX150 in P. berghei and confirm protein presence remained unsuccessful. 
Despite successful C-terminal tagging of PTEX150 in P. falciparum, recent studies demonstrated 
that the C-terminus of PTEX150 extends in a claw-like structure to the ATPase and unfolding 
domain of HSP101 (Ho et al., 2018), explaining loss of stable PTEX assembly upon PTEX150 C-
terminal tagging. To confirm expression of PTEX150 in liver stages, N-terminal tagging with 
mCherry or HA can be applied to assure PV localization (Table S4). PTEX150 mRNA levels are 
reduced in intra-hepatic development compared to EXP2, whether this could have influence on 
stoichiometric 6:7:7 PTEX assembly needs to be determined. In case of translational repression of 
PTEX150, complex assembly would not be feasible by merely overexpressing HSP101. Following 
these assumptions, HSP101 overexpression parasites can be modified to additionally overexpress 
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PTEX150 in liver stages (Table S4). Such parasites can provide a better understanding of liver 
stage protein export and identification of prerequisites for PTEX assembly. 
mCherry accumulation, as seen in bacteria for type III secretion systems (Akeda & Galan, 2005), 
could obstruct additional liver stage protein export. Using smaller tags as FLAG or HA can 
circumvent protein accumulation in the PV. Potentially, this concept of reporter constructs does 
not allow protein detection in the cytoplasm as only limited amount of protein can be exported 
and might be degraded upon host cell arrival. Applying a GFP split in two spatially separated 
compartments and signal detection only upon concurrence, could enable detection of protein 
translocation (Cabantous et al., 2005, Paulmurugan & Gambhir, 2005). Integration of one GFP 
half in hepatoma cells and the other half fused to PEXEL in parasites for targeted liver stage 
export, could enable detection of GFP signal only upon translocation of parasitic GFP half. LISP2 
is the only reported liver protein to be exported around 36 hours post infection. In contrast to 
blood stage PEXEL proteins, it is additionally processed at the C-terminal end (Orito et al., 
2013). Designing a reporter construct with a tagged LISP2 could reveal whether HSP101+ and 
HSP101++ parasites export LISP2 at earlier time points during liver stage maturation. Additional 
antibodies against LISP2 would simplify this approach. 
HSP101+++ parasites have an astonishing phenotype as HSP101 overexpression leads to a 
sporozoite gliding defect and liver stage developmental arrest. It can be hypothesized that 
localization to secretory organelles interferes with gliding motility. Co-localization with 
micronemal, rhoptry or dense granule proteins would confirm this notion. IPs with HSP101 
could reveal protein-protein interactions and potentially answer whether obstruction of 
microneme release is induced by overexpression.  
In order to gain a better immunological understanding of protective immune responses as 
opposed to parasite recognition, pre-clinical analysis and comparative immune profiling of 
HSP101+++ are currently performed as follow up work of this thesis. Sterile protection seems to 
be correlated to parasite development in the liver. HSP101+++, however, arrest early in liver 
stage development leading to the expected weaker protection. Markers of protection were 
identified, but are primarily sporozoite antigens (Hafalla et al., 2011).  
To investigate whether HSP101+ exports antigens into the hepatocyte cytoplasm in vivo and just 
simply lacks detection in vitro, thereby inducing an even stronger immune response, HSP101+ 
parasites can be crossed with parasites expressing OVA or TRAP linked to PEXEL in liver stages 
(Table S4). The CD8 epitopes of these two proteins are known to elicit strong immune responses 
in the host.  Similarly, immunization studies can be performed with these parasite lines and liver 
load and T cell priming of infected animals can be analyzed. The OVA epitope will allow the use 
and analysis of OVASIINFEKL recognising OT-1 transgenic CD8+ T cells. 
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Concluding, PTEX cannot be reconstructed solely by overexpressing HSP101, but rather leads to 
obstruction of parasite life cycle progression and reduced parasite recognition. My work 
demonstrates that liver stage pathogen-host interaction remains relatively poorly understood and 
that parasites tightly control protein export, potentially to remain undetected during liver 
development. Ultimately, deciphering important factors for parasite replication and host-parasite 
interaction during liver maturation can give novel ideas for preventive vaccine candidates.  
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Supplementary Figure 1 IFN-γ secreting CD8+ T cells in spleen are reduced in ∆SLARP/P36p/P36-
immunized animals 
Analysis of CD8+ T cells elicited in immunized cohorts. C57BL/6 mice were immunized in a prime/boost 
regimen (7 days apart), challenged one or two months p.i. and treated with pyrimethamine in the drinking 
water before excision of spleens one month post challenge. For the excision of spleens from immunized 
mice 5 months p.i., animals were immunized in a prime/boost regimen (7 days apart) and challenged 5 
months p.i.. Spleens were excised 42h post challenge. Splenic cells were restimulated with H2-Kb specific 
peptide epitopes (TRAP/S20) and a control OVA/H2-Db and stained with fluorescently labeled antibodies 
for analysis with MACSQuant. FACS files were processed with FlowJo 8.7.3. A Examples of mean IFN-γ 
secreting CD8+ T cells after restimulation with TRAP peptide of immunized cohorts five months post 
immunization compared to naïve controls. Statistical analysis: Mann-Whitney-U test, *, p<0.05 B 
Examples of mean IFN-γ secreting CD8+ T cell restimulation with S20 peptide of immunized cohorts one, 
two and five months post immunization compared to naïve controls. Statistical analysis: Mann-Whitney-
U test, *, p<0.05, ***, p<0.001C Examples of mean IFN-γ secreting CD8+ T cells restimulation with OVA 
peptide, as negative control, of immunized cohorts one, two and five months post immunization 
compared to naïve controls. Dot blot shows comparison of percentage of CD8+ T cell IFN-γ secretion in 
immunized cohorts. Depicted are IFN-γ producing CD8+ T cells of individual mice (dots), as well as the 
mean of the cohort ± SD. Only significant statistical differences of cohorts compared to ∆SLARP/P36p/P36 
immunized mice are shown. Statistical analysis: Mann-Whitney-U test. 
   
 
Supplementary Figure 2 TNF-α secreting CD8+ T cells in spleen are reduced in ∆SLARP/P36p/P36 
immunized animals 
Analysis of CD8+ T cells elicited in immunized cohorts. C57BL/6 mice were immunized in a prime/boost 
regimen (7 days apart), challenged one or two months p.i. and treated with pyrimethamine in the drinking 
water before excision of spleens one month post challenge. For the excision of spleens from immunized 
mice 5 months p.i., animals were immunized in a prime/boost regimen (7 days apart) and challenged 5 
months p.i.. Spleens were excised 42h post challenge. Splenic cells were restimulated with H2-Kb specific 
peptide epitopes (TRAP/S20) and a control OVA/H2-Db and stained with fluorescently labeled antibodies 
for analysis with MACSQuant. FACS files were processed with FlowJo 8.7.3. A Examples of mean CD8+ T 
TNF-α secretion restimulation with TRAP peptide in spleens of immunized cohorts one, two or five 
months post immunization compared to naïve controls. Statistical analysis: Mann-Whitney-U test, *, 
p<0.05, B Examples of mean TNF-α secreting CD8+ T cell restimulation with S20 peptide of immunized 
cohorts one, two and five months post immunization compared to naïve controls. Statistical analysis: 
Mann-Whitney-U test, *, p<0.05, **, p<0.01C Examples of mean TNF-α secreting CD8+ T cell 
restimulation with OVA peptide, as negative control, of immunized cohorts one, two and five months post 
immunization compared to naïve controls. Dot blot shows comparison of percentage of CD8+ T cell TNF-
α secretion in immunized cohorts. Depicted are TNF-α producing CD8+ T cells of individual mice (dots), 
as well as the mean of the cohort ± SD. Only significant statistical differences of cohorts compared to 
∆SLARP/P36p/P36 immunized mice are shown. Statistical analysis: Mann-Whitney-U test. 
   
Supplementary Table 1 Normal development of ∆SLARP/P36p/P36 mosquito stages 
Parasite strain Midgut infectivity (%) 
 
d10-14 
Number of salivary gland 
sporozoites/mosquito 
d17-25 
   ∆SLARP/P36p/P36 83   8680± 6.800 
   ∆SLARP 62 10500± 3.880 
   ∆P36p/P36 57 13100± 7.360 
   WT 57 22900± 2.760 
  a Average numbers of three independent biological experiments 
  b Average numbers of six independent biological experiments 
 
 
Supplementary Figure 3 Plasmid maps of pHSP101+/Myc and pHSP101++ 
A+B Schematic plasmid maps of pHSP101+/Myc. Depicted in light yellow are the silent 6 homologous 
regions for homologous recombination. The EF1a promoter (dark green) was inserted in the BssHII-XbaI 
restriction site upstream of the HSP101 ORF (light pink), which was inserted in the XbaI-AgeI restriction 
site in frame with mCherry (red) and triple Myc taq (pink) or triple Myc only for pHSP101+Myc. GFP 
(bright green) under the control of HSP70 promoter (light green) was included for parasite detection 
throughout the life cycle and positive selection by FACS sorting. The plasmid additionally harbors an 
hDHFR-yFcu (dark blue) under the control of PbDHFR promoter (light blue) for positive/ negative 
selection of transgenic or recycled parasites. C Schematic plasmid map of pHSP101++. Depicted in light 
   
pink are the HSP101 5’ UTR and N-terminus for homologous recombination. A mCherry (red) and a 
triple Myc tag (dark pink) are downstream of the HSP101 5’ UTR, however, mCherry and Myc are not 
expressed due to a lack of a start codon. Additionally, a new promoter PTEX150 (dark blue) was inserted 
upstream of the HSP101 N-terminus. The plasmid contains a GFP (bright green) under the HSP70 
promoter (light green) for parasite detection throughout the life cycle and positive selection by FACS 
sorting. Additionally, an hDHFR-yFcu (dark blue) under the control of PbDHFR promoter (light blue) is 
present in the plasmid for positive/ negative selection of transgenic or recycled parasites.  
Supplementary Table 2 Normal development of HSP101+/Myc and HSP101++ mosquito stages 
 
 
 
 
 
 
  a Average numbers of three independent biological experiments 
  b Average numbers of six independent biological experiments 
c Average number of one experiment only 
 
 
Supplementary Figure 4 Normal life cycle progression of HSP101+Myc 
A Kaplan-Meier curve analysis of time to patency after sporozoite infection. C57BL/6 mice were infected 
with 1x104 HSP101+Myc (green), or WT (dark grey) sporozoites i.v. or by natural transmission by 
exposure to 15 HSP101++ infected mosquitoes and blood infection was monitored by daily microscopic 
examination of Giemsa-stained blood smears. B Live imaging blood stages: ring stage and gametocyte. 
Cells were stained with Hoechst 33342 1:5,000 (blue) for nuclear staining. Expression of transgenic 
parasite marker GFP staining the parasite’s cytoplasm is displayed in green (Scale bar: 5 µm). C 
Immunofluorescence microscopy analysis (IFA) of α-Myc (HSP101, red) and α-GFP (green) stained 
HSP101+ and WT P.b. parasites at 24 and 48 hours post hepatoma cell (Huh7) infection shows 
localization of HSP101 to the parasite’s PV. Nuclear staining was performed with Hoechst 33342 (blue). 
Left panel is showing α-Myc (HSP101) staining only (Scale bar 10 µm). 
Parasites Midgut infectivity 
(%)a 
Numbers of salivary gland 
Sporozoites/Mosquitob 
HSP101+ 50 14250 ±9889 
HSP101++ 70 18440 ±4555 
HSP101+Myc 73 11750c 
WT 47 17458 ±15624 
   
 
Supplementary Figure 5 Plasmid map of HSP101+++ and HSP101+++Myc 
A+B Schematic plasmid maps of pHSP101+++/Myc. Depicted in light yellow are the silent 6 homologous 
regions for homologous recombination. The UIS4 promoter (dark red) was inserted in the BssHII-XbaI 
restriction site upstream of the HSP101 ORF (light pink), which was inserted in the XbaI-AgeI restriction 
site in frame with mCherry (red) and triple Myc tag (pink) or triple Myc only for pHSP101+++Myc. GFP 
(bright green) under the control of HSP70 promoter (light green) was included for parasite detection 
throughout the life cycle and positive selection by FACS sorting. The plasmid additionally harbors an 
hDHFR-yFcu (dark blue) under the control of PbDHFR promoter (light blue) for positive/ negative 
selection of transgenic or recycled parasites.  
Supplementary Table 3 Normal development of HSP101+++/Myc mosquito stages 
 
 
 
 
 
 
 
 
  a Average numbers of three independent biological experiments 
  b Average numbers of six independent biological experiments 
 
 
 
 
Parasites Midgut infectivity (%)a Numbers of salivary gland 
Sporozoites/Mosquitob 
HSP101+++ 90 9214 ±4856 
HSP101+++Myc 90 5160 ±919 
WT 60 8710 ±2307 
   
 
Supplementary Figure 6 Pre-erythrocytic development is severely impaired in HSP101+++Myc parasites 
A Kaplan-Meier curve of blood infection over time after sporozoites infection. C57BL/6 mice were 
infected with 1x104 HSP101+++Myc (dark red) or WT (dark grey) sporozoites or by natural transmission 
by exposure to 15 HSP101+++Myc infected mosquitoes and blood infection was monitored by daily 
microscopic examination of Giemsa-stained blood smears of four (for 1x104 sporozoite infection) and two 
(for natural transmission) independent biological experiments. Statistical analysis: Log rank (Mantel-Cox) 
test, n.s., non-significant, ***p<0.001. B Blood stage growth (parasitemia %) 3-8 days post sporozoite 
infection is unaffected in comparison to WT infections. Giemsa-stained thin blood smears from pre-
patency analysis were additionally used for quantifying parasitemia of one biological experiment. Shown is 
the mean of five mice ±SD. Statistical analysis: growth slope difference n.s., non-significant C Impaired 
sporozoite gliding motility of HSP101+++Myc. Salivary gland HSP101+++Myc and WT P.b. sporozoites 
were excised at day 17 and left to settle and subsequently glide on a BSA-covered 2-dimensional glass 
slide. Sporozoite surface protein trails shed by gliding sporozoites were stained with α-sporozoite surface 
antigen and Hoechst 33342 for nuclear staining. Three independent experiments (dots) were used to 
determine the percentage of gliding sporozoites. Depicted are the mean ±SD. Statistical analysis: Mann-
Whitney-U-test *, p<0.05 D Normal transmigration of HSP101+++Myc sporozoites. Shown is the FACS 
quantification of dextran-positive hepatoma cells after two hours post sporozoite infection. 1x106 Huh7 
cells were infected with 7.5x104 HSP101+++Myc or WT P.b. sporozoites or dextran+/sporozoites- (as a 
control for dextran influx without sporozoite infection) and analyzed with FACS for dextran influx using 
MACSquant. Examples of gating strategy: FITC (dextran) is blotted against FFC for dextran-/sporozoite-, 
   
dextran+/sporozoite- and dextran+/sporozoite+ (WT) cells. Depicted are individual percentages of 
dextran positive cells of each replicate of three independent experiments (with three replicates each) ±SD. 
Statistical analysis: Mann-Whitney-U-test ns: non significant E Impaired sporozoite gliding motility of 
HSP101+++Myc. Shown is a representative immunofluorescence image of HSP101+++Myc salivary gland 
sporozoite. The transgenic parasite and the gliding trail were stained with α-sporozoite surface antibody 
and with Hoechst 33342 for nuclear staining (Scale bar: 5 µm) F Kaplan-Meier analysis of blood infection 
over time after sporozoite challenge reveals no protection in HSP101+++Myc-immunized animals. Mice 
were immunized and boosted after 10 days with HSP101+++Myc or WT sporozoites under AZ drug cover. 
WT P.b. sporozoite challenge was performed 87 days post immunization and non-immunized control 
animals (naïve, light grey) confirmed sporozoite infectivity by patent blood stage infection 3 days post 
inoculation. Pre-patency was monitored 3-14 days p.i. using Giemsa-stained thin blood smears. Statistical 
analysis: Log rank (Mantel-Cox) test, n.s., non-significant, ***, p< 0.001 
 
 
Supplementary Figure 7 HSP101+++Myc  parasites establish a PVM during liver stage development 
A Immunofluorescence microscopy analysis (IFA) of α-Myc (HSP101, red) and α-GFP (staining the 
parasite’s cytoplasm in green) stained HSP101+++Myc and WT P.b. parasites at 24, 48 and 72 hours post 
hepatoma cell (Huh7) infection shows localization of HSP101 to the PV. Nuclear staining was performed 
with Hoechst 33342 (blue). Upper panel is showing Myc (HSP101) staining only, lower panel is displaying 
the merged image. (Scale bar 10 µm) B Localization of UIS4 by IFA in HSP101+++Myc and WT P.b. 
parasites infected Huh7 cells at 24, 48 and 72 hours p.i.. Upper panel is showing α-UIS4 (red) staining 
only, lower panel is depicting the merged image with α-GFP (green) and nuclear staining with Hoechst 
33342 (blue). (Scale bar 10 µm) C IFA of α-LC3 (red) and α-GFP (green) stained HSP101+++Myc and WT 
P.b. parasites at 16 and 24 hours post Huh7 infection reveals LC3, a host autophagy marker, localization to 
the parasite’s PVM. Nuclear staining is displayed with Hoechst 33342 (blue). Upper panel is showing α-
LC3 (red) staining only, lower panel is displaying the merged image (Scale bar 10 µm). 
 
 
   
 
Supplementary Figure 8 Exo-erythrocytic development is still impaired in HSP101+++ haemocoel 
sporozoites or under the addition of ATP 
A Kaplan-Meier curve of time to blood stage pre-patency after sporozoites infection reveals pre-
erythrocytic developmental arrest of HSP101+++ haemocoel sporozoites. C57BL/6 mice were infected 
with 1x104 HSP101+++ (dark red) or WT (dark grey) sporozoites and blood infection was monitored by 
daily microscopic examination of Giemsa-stained blood smears. Statistical analysis: Log rank (Mantel-
Cox) test, n.s., non-significant; *, p<0.05,**, p< 0.01, ***p<0.001. B Live imaging of HSP101+++ 
haemocoel sporozoites. Expression of HSP101-mCh is not present in haemocoel sporozoites as the UIS4 
promoter is not active (upper panel). The transgenic parasite marker GFP, staining the parasite’s 
cytoplasm, is displayed in green. Nuclear staining was performed with Hoechst 33342 1:5,000 and motility 
inhibition with 1:50 Phalloidin (Scale bar: 5 µm). C Immunofluorescence microscopy analysis of α-
mCherry (HSP101, red) and α-HSP70 (green) stained HSP101+++ haemocoel or HSP101+++ salivary 
gland sporozoites incubated with 0.01 mM ATP and glucose at 24, 48 and 72 hours post hepatoma cell 
(Huh7) infection shows liver stage developmental abort. Nuclear staining was performed with Hoechst 
33342 (blue). Upper panel is showing α-mCherry (HSP101) staining only (Scale bar 10 µm). 
 
   
 
Supplementary Figure 9 Normal pre-erythrocytic development of UIS4::mCh and ::HSP101-mCh parasites 
A Kaplan-Meier curve of time to blood stage patency after sporozoite infection reveals normal infection 
with UIS4::mCh and ::HSP101-mCh parasites in vivo. C57BL/6 mice were infected with 1x104 UIS4::mCh 
(dark red) or WT (dark grey) sporozoites or by natural transmission by exposure to 15 ::HSP101-mCh 
infected mosquitoes and blood infection was monitored by daily microscopic examination of Giemsa-
stained thin blood smears. Statistical analysis: Log rank (Mantel-Cox) test, n.s., non-significant. B Live 
imaging of UIS4::mCh sporozoites. Expression of mCherry in sporozoites is displayed in upper panel. The 
transgenic parasite marker GFP, staining the parasite’s cytoplasm, is displayed in green. Nuclear staining 
was performed with Hoechst 33342 1:5,000 and motility inhibition with 1:50 Phalloidin (Scale bar: 5 µm). 
C Immunofluorescence microscopy analysis (IFA) of α-mCherry (red) and α-HSP70 (green) stained 
UIS4::mCh and ::HSP101-mCh parasites at 24, 48 and 72 hours post hepatoma cell (Huh7) infection shows 
normal liver stage development. Nuclear staining was performed with Hoechst 33342 (blue). Upper panel 
is showing α-mCh (or HSP101-mCh) staining only (Scale bar 10 µm). 
 
   
 
Supplementary Figure 10 UIS4 is expressed in HSP101+++ parasites 
A Genotyping of HSP101+++ and HSP101+++Myc parasites by PCR. Presence of an intact UIS4 locus 
(orange) in HSP101+++ was confirmed with UIS4 5’, 3’ UTR and ORF specific primer combinations (in 
grey). P.b. ANKA WT gDNA was used as control. B Quantitative RT-PCR analysis of UIS4 mRNA levels 
in HSP101+++ and WT sporozoites. HSP101+++ and WT sporozoites were excised from salivary gland of 
infected mosquitoes at day 17, RNA was extracted from sporozoites relative mRNA levels normalized to 
PbHSP70 levels. Data is displayed as mean of two technical replicates. 
Supplementary Table 4 Additional transgenic parasite lines and plasmid constructs for liver stage PTEX 
complex  and export analysis 
	  
Name Parasite line/ Plasmid Purpose 
EXP2::HSP101 Parasite line (clonal) HSP101 overexpression 
HSP70::HSP101-Myc Parasite line (mixed) HSP101 overexpression 
HSP101+ rec Parasite line (clonal) recycled parasites for integration of 
other constructs 
HSP101+/ UIS4::CS-PEXEL-OVA Parasite line (clonal) export analysis 
HSP101++/ UIS4::CS-PEXEL-mCh Parasite line (clonal) export analysis 
pEXP2::PTEX150  PTEX150 overexpression 
pEF1α::PTEX150 Plasmid PTEX150 overexpression 
pEF1α::HA-PTEX150 Plasmid PTEX150 overexpression and tagging 
p::HA-PTEX150 Plasmid PTEX150 N-terminal tagging 
p::mCh-PTEX150 Plasmid PTEX150 N-terminal tagging 
pPTEX150::mCh-PTEX150 Plasmid double crossover PTEX150 N-
terminal tagging 
p∆HSP101/IBIS::IBIS-PEXEL-GFP Plasmid knockout of endogenous HSP101 
while inserting a reporter construct 
p∆HSP101/IBIS::IBIS- PEXEL-Myc Plasmid see above 
p∆HSP101/IBIS::IBIS-GFP Plasmid knockout of endogenous HSP101 
while inserting a control non-
functional reporter construct  
p∆HSP101/IBIS::IBIS-Myc Plasmid see above 
pLISP2::HSP101-Myc Plasmid HSP101 overexpression 
pEXP2::HSP101-Myc Plasmid HSP101 overexpression 
pHSP70::HSP101-mCh Plasmid HSP101 overexpression 
